Radiation protection of patients undergoing high-dose-rate brachytherapy: peripheral dose estimation, review of radiation risks and implant shielding design by Candela Juan, Cristian
  
 
 
Departamento de física atómica, molecular y nuclear 
Facultad de física 
 
 
RADIATION PROTECTION OF PATIENTS 
UNDERGOING HIGH-DOSE-RATE BRACHYTHERAPY: 
PERIPHERAL DOSE ESTIMATION, REVIEW OF 
RADIATION RISKS AND IMPLANT SHIELDING DESIGN 
 
Cristian Candela Juan 
 
Valencia, 2015
      i 
 
RADIATION PROTECTION OF PATIENTS UNDERGOING 
HIGH-DOSE-RATE BRACHYTHERAPY: PERIPHERAL DOSE 
ESTIMATION, REVIEW OF RADIATION RISKS AND IMPLANT 
SHIELDING DESIGN  
 
Thesis presented by 
Cristian Candela Juan 
to obtain the degree of Doctor of Philosophy in the subject of Physics  
at Universitat de València. 
 
Valencia, February 2015 
 
Supervisor: 
Facundo Ballester Pallarés 
 
Co-supervisor: 
José Pérez Calatayud 
 
Co-supervisor: 
Mark J. Rivard 
  
 ii 
 
  
      iii 
DECLARATION 
 
Dr. Facundo Ballester Pallarés, professor from the Atomic, Molecular and 
Nuclear Physics Department of the University of Valencia,  
Dr. José Pérez Calatayud, head of the physics section of the Radiation 
Oncology Department of La Fe University and Polytechnic Hospital from 
Valencia, and 
Dr. Mark J. Rivard, Professor of Radiation Oncology in the Department of 
Radiation Oncology of the Tufts University School of Medicine from Boston, 
Massachusetts, 
 
CERTIFY:  
That the thesis entitled “RADIATION PROTECTION OF PATIENTS 
UNDERGOING HIGH-DOSE-RATE BRACHYTHERAPY: PERIPHERAL DOSE 
ESTIMATION, REVIEW OF RADIATION RISKS AND IMPLANT SHIELDING 
DESIGN” has been developed under their direction by Cristian Candela 
Juan. 
 
And for the record, in compliance with the current legislation of the 
University of Valencia, this memory is signed and presented to the 
Department of Atomic, Molecular and Nuclear Physics of the University of 
Valencia. 
 
Signed: 
 
Dr. Facundo Ballester 
Pallarés 
 
Dr. José Pérez 
Calatayud 
 
 
 
 
Dr. Mark J. Rivard 
 
Date: February 2015 Date: February 2015 Date: February 2015 
 
 iv 
  
      v 
AGRADECIMIENTOS / ACKNOWLEDGEMENTS 
  
 En primer lugar, mis más sinceros agradecimientos a mis directores de tesis: 
el Dr. Facundo Ballester, el Dr. José Pérez-Calatayud y el Dr. Mark Rivard. 
Facundo, Pepe, muchísimas gracias por aceptarme en vuestro grupo como a uno 
más desde el primer día, por vuestra gran dedicación y ayuda durante estos tres 
años, y por ser como mi familia aquí en Valencia. Gracias también por la 
oportunidad de asistir con vosotros a todos los grandes congresos y a tantos 
comités científicos donde tanto he aprendido de los mejores, sin olvidar las 
excelentes comidas y catas de vino. Mark, muchas gracias a ti también por toda tu 
ayuda y tu apoyo incluso en la distancia. Sabes que me divertía mucho en esos 
intercambios rápidos de versiones que, como tú dijiste, hacía que la situación se 
asemejara a un partido de tenis. Serás muy bien recibido cuando quieras visitarnos 
de nuevo en Valencia y, por supuesto, habrá que repetir fiesta. Muchas gracias a 
los tres por vuestra gran humildad a pesar de ser los mejores. Seguro que me 
quedo corto de palabras para expresar estos agradecimientos. 
 Muchas gracias también a los otros miembros del grupo, los doctores 
Domingo Granero, Mª Carmen Pujades y Javier Vijande, por vuestra valiosa 
ayuda, ya sea en Monte Carlo o en medidas experimentales, y por esas 
maravillosas cenas esporádicas.  
 Quiero agradecer también a todas las personas que granito a granito tanto 
han contribuido a mi formación científica, por orden cronológico: el grupo del Dr. 
J. M. Benlloch Baviera (Valencia), el Dr. M. Aslaninejad (Londres) y M. Crispín 
(Valencia), el grupo de la Dra. M. Rafecas (Valencia) y el grupo del Dr. D. Ros y 
del Dr. J. Pavía (Barcelona). Quiero agradecer también a M. Karlsson, M. Lundell 
y A. Carlsson Tedgren (Suecia) por compartir con nosotros el proyecto de la 
dosimetría del radio que forma parte de esta tesis, y por su confianza a lo largo de 
todo ese estudio.  
 Muchas gracias también al Servicio de Protección Radiológica, al Servicio 
de Medicina Nuclear y al Servicio de Oncología Radioterápica del Hospital 
 vi 
Universitario y Politécnico La Fe, que tanto apoyo y ayuda me han dedicado en 
estos tres años de mi residencia para contribuir a mi formación como radiofísico 
hospitalario, como investigador y como persona. Gracias también al Dr. Luis 
Martí-Bonmatí (Valencia), a la Dra. Alegría Montoro (Valencia) y a sus grupos, 
por su confianza en mí, su apoyo y sus valiosos consejos. Aprovecho para 
agradecer también al Servicio de Docencia del hospital y al IIS La Fe por fomentar 
la investigación y el desarrollo de la tesis durante nuestra residencia. 
 Muchas gracias también a mis compañeros y buenos amigos de la facultad, 
con quienes tantas experiencias he compartido. En muchos casos el destino nos ha 
llevado por caminos diferentes, pero espero que nos podamos seguir reuniendo. 
Gracias también a mis nuevos y tan buenos amigos del ámbito hospitalario, por 
todas las fiestas y experiencias vividas y por vivir, y especialmente a mi amigo Juan 
por todas esas risas, cervezas, historias y aventuras ciclistas, y a Carolina, por 
animarme, quererme y hacerme reír tanto en estos últimos meses.  
 Gracias a todos mis amigos del pueblo, a esos que han estado ahí toda mi 
vida, casi desde que empecé a hablar. Ya sabéis quienes sois y todo lo que os 
aprecio. 
 Por último, muchas gracias a toda mi familia sin excepción, por ser la mejor 
y la más unida, y por apoyarme siempre en todas mis decisiones, aunque fueran 
arriesgadas o me llevaran lejos de vosotros. En especial me gustaría agradecer a 
mis padres y a mi hermano, sabéis que no hay palabras para expresar todo lo que 
me importáis. 
_____________________________________________________________ 
 
 First, my sincere thanks to my thesis supervisors: Dr. Facundo Ballester, Dr. 
José Pérez-Calatayud and Dr. Mark Rivard. Facundo, Pepe, thank you for accepting 
me in your group as one more since the first day, for your dedication and support 
during these three years, and to be like my family here in Valencia. Thanks also for 
the opportunity to attend with you at all major conferences and many scientific 
committees where I learned so much from the best, not to mention the excellent 
      vii 
food and wine tastings. Mark, you too thank you very much for all your help and 
your support even in the distance. I had a lot of fun in those fast exchanges of 
versions, like you said, it was like a tennis match. You will be very welcome 
anytime you visit us again in Valencia and, of course, we must repeat partying. 
Thank you very much to all you three for your great humility despite being the best. 
Sure I fall short of words to express these acknowledgments. 
 Thank you very much also to the other group members, doctors Domingo 
Granero, Mª Carmen Pujades and Javier Vijande, for your valuable support in either 
Monte Carlo simulations or experimental measures, and for those wonderful casual 
dinner. 
 I want to thank also everyone who has contributed to my scientific training, 
in chronological order: the group of Dr. JM Benlloch Baviera (Valencia), Dr. M. 
Aslaninejad (London) and M. Crispín (Valencia), the group of Dr. M. Rafecas 
(Valencia) and the group of Dr. D. Ros and Dr. J. Pavia (Barcelona). I would also 
like to thank M. Karlsson, M. Lundell and A. Carlsson Tedgren (Sweden) for 
sharing with us the dosimetric study of radium sources that has contributed to this, 
and their confidence throughout that study. 
 Thank you very much also to the Radiological Protection Service, the 
Department of Nuclear Medicine and the Department of Radiation Oncology from 
La Fe University and Polytechnic Hospital, which dedicated me support and help in 
these three years to allow me improving my skills as a medical physicist, as 
researcher and as a person. Thanks also to Dr. Luis Martí-Bonmatí (Valencia), Dr. 
Alegría Montoro (Valencia) and their groups for their confidence, their support and 
valuable advices. I take this opportunity to also thank the Teaching Department 
form La Fe Hospital and to the IIS La Fe for promoting research and development 
of the thesis during our residency program. 
 Thank you very much also to my colleagues and good friends of the faculty 
with whom I shared many experiences. Thanks also to my new and such good 
friends from the hospital, for all those parties and life experiences, and especially to 
my friend Juan for all those laughs, beers, stories and cycling adventures, and to 
 viii 
Carolina, for encouraging, loving and making me laugh so much during the last 
months. 
 Thanks to all my friends from the town, those who have been there for all my 
life, almost since I started talking. You know who you are and all that I appreciate 
you. 
 Finally, thanks very much to all my family without exception, being the best 
and most united, and for always supporting me in all my decisions, even if they 
were risky or took me away from you. I would especially like to thank my parents 
and my brother, you know there are no words to express all I love you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
      ix 
TABLE OF CONTENTS 
DECLARATION ........................................................................................................................ III 
AGRADECIMIENTOS / ACKNOWLEDGEMENTS .............................................................. V 
TABLE OF CONTENTS ............................................................................................................ IX 
LIST OF TABLES .................................................................................................................... XII 
LIST OF FIGURES .................................................................................................................. XIV 
LIST OF ABBREVIATIONS AND ACRONYMS ............................................................ XVIII 
CHAPTER 1. INTRODUCTION ............................................................................................. 1 
1.1 HIGH-DOSE-RATE BRACHYTHERAPY ............................................................................................. 2 
1.2 PERIPHERAL DOSE AND SECONDARY RADIATION RISKS ............................................................. 4 
1.3 REVIEW OF MONTE CARLO METHODS .......................................................................................... 5 
1.4 OBJECTIVES AND OUTLINE OF THIS THESIS .................................................................................. 7 
CHAPTER 2. PERIPHERAL DOSE IN HDR BRACHYHTERAPY .................................. 9 
2.1 INTRODUCTION .............................................................................................................................. 10 
2.2 MATERIALS AND METHODS ......................................................................................................... 12 
2.2.1 Geometry definition ......................................................................................................... 12 
2.2.2 Brachytherapy sources .................................................................................................. 13 
2.2.3 MC simulation setup and organ equivalent dose calculation ......................... 14 
2.3 RESULTS ......................................................................................................................................... 16 
2.3.1 Organ equivalent dose .................................................................................................... 16 
2.3.2 Influence of prostate size .............................................................................................. 20 
2.3.3 60Co vs. 192Ir ......................................................................................................................... 20 
2.3.4 Heterogeneous vs. water phantom ............................................................................ 21 
2.4 DISCUSSION .................................................................................................................................... 24 
2.5 CONCLUSIONS ................................................................................................................................ 31 
CHAPTER 3. TUMOR INDUCTION BY RADIATION DOSES ...................................... 32 
3.1 INTRODUCTION .............................................................................................................................. 33 
3.2 FACTORS THAT AFFECT THE PROBABILITY OF CANCER INDUCTION ...................................... 36 
 x 
3.3 ESTIMATION OF CANCER RISK AT HIGH RADIATION DOSES ..................................................... 37 
3.4 ESTIMATION OF CANCER RISK AT LOW RADIATION DOSES ..................................................... 39 
3.4.1 Risk coefficients ................................................................................................................. 39 
3.4.2 Recent epidemiological data ....................................................................................... 41 
3.4.3 Analysis of the situation ................................................................................................. 43 
3.5 CONCLUSIONS ................................................................................................................................ 47 
CHAPTER 4. DOSIMETRIC CHARACTERIZATION OF 226RA SOURCES................ 48 
4.1 INTRODUCTION .............................................................................................................................. 49 
4.2 MATERIALS AND METHODS ......................................................................................................... 51 
4.2.1 Description of sources .................................................................................................... 51 
4.2.2 Decay scheme of the radioactive source ................................................................. 53 
4.2.3 AAPM Task group 43 dosimetry formalism ........................................................... 54 
4.2.4 Monte Carlo methodology for the derivation of TG-43 parameters ............ 54 
4.2.5 Monte Carlo simulation of a superficial mould mesh......................................... 58 
4.2.6 Absorbed dose at large distances ............................................................................... 59 
4.3 RESULTS ......................................................................................................................................... 60 
4.3.1 Contribution from each radionuclide to the overall absorbed dose ............ 60 
4.3.2 Time dependence of absorbed dose ........................................................................... 61 
4.3.3 Absorbed dose distributions ......................................................................................... 63 
4.3.4 TG-43U1 parameters ...................................................................................................... 64 
4.3.5 Superficial mould mesh .................................................................................................. 65 
4.3.6 Absorbed dose at large distances ............................................................................... 67 
4.3.7 Uncertainty analysis ....................................................................................................... 68 
4.4 DISCUSSION .................................................................................................................................... 69 
4.4.1 Comparison with older dosimetry data ................................................................... 69 
4.4.2 Applicability and limitations of this study .............................................................. 72 
4.5 CONCLUSIONS ................................................................................................................................ 73 
CHAPTER 5. LEAD SHIELD FOR SURFACE HDR BRACHYTHERAPY ................... 75 
5.1 INTRODUCTION .............................................................................................................................. 76 
5.2 METHODS AND MATERIALS ......................................................................................................... 77 
5.3 RESULTS ......................................................................................................................................... 81 
5.3.1 Energy spectra ................................................................................................................... 81 
      xi 
5.3.2 Backscattered dose perturbation .............................................................................. 85 
5.3.3 Transmission ...................................................................................................................... 91 
5.4 DISCUSSION .................................................................................................................................... 93 
5.4.1 Backscattered dose perturbation .............................................................................. 93 
5.4.2 Transmission ...................................................................................................................... 94 
5.5 CONCLUSIONS ................................................................................................................................ 96 
CHAPTER 6. FETAL DOSE REDUCTION IN PREGNANT PATIENT WITH BREAST 
CANCER 97 
6.1 INTRODUCTION .............................................................................................................................. 98 
6.2 MATERIALS AND METHODS ....................................................................................................... 101 
6.2.1 Case report ....................................................................................................................... 101 
6.2.2 Treatment planning ..................................................................................................... 101 
6.2.3 Shielding design ............................................................................................................. 103 
6.2.4 Fetal dose evaluation ................................................................................................... 104 
6.3 RESULTS ....................................................................................................................................... 108 
6.3.1 Dose distribution in the central region ................................................................. 108 
6.3.2 Dose homogeneity on an axial plane ..................................................................... 110 
6.3.3 Case report ....................................................................................................................... 110 
6.4 DISCUSSION .................................................................................................................................. 111 
6.4.1 Clinical considerations ................................................................................................ 111 
6.4.2 Analysis of the dose as a function of depth .......................................................... 111 
6.4.3 HDR 192Ir BT vs. EBRT .................................................................................................. 112 
6.4.4 Comparison of 192Ir with other HDR-BT sources ............................................... 116 
6.4.5 Applicability of the current study to other setups ............................................ 117 
6.5 CONCLUSIONS .............................................................................................................................. 118 
CHAPTER 7. GENERAL DISCUSSION ............................................................................ 119 
SUMMARY ............................................................................................................................. 125 
SUMMARY IN SPANISH / RESUMEN EN ESPAÑOL .................................................... 134 
REFERENCES ........................................................................................................................ 146 
LIST OF PUBLICATIONS .................................................................................................... 165 
 xii 
LIST OF TABLES 
Table 2-1. Organ equivalent dose per therapeutic absorbed dose to the prostate, 
(HT/DP), given to the heterogeneous voxelized phantom by the 60Co source 
and by the 192Ir source. Distances correspond to those between the prostate 
and the organ center of masses. The statistical uncertainty (Type A) 
percentage (k=2), ε, is also shown (but for those with ε < 0.05%), as well as 
the effective dose. The last column corresponds to the relative variation of 
absorbed dose between the water and the heterogeneous phantom, Δ, being 
positive if absorbed dose in water is higher than in a tissue. ............................... 18 
Table 2-2. Equivalent dose per therapeutic absorbed dose (HT/DP) for some body 
organs, comparing brachytherapy results from this work in a heterogeneous 
phantom and previously reported data for 3D-CRT (ref. (Bednarz et al., 2009; 
Bednarz et al., 2010)), IMRT (ref. (Fontenot et al., 2008; Bednarz et al., 
2009)) and protontherapy (Fontenot et al., 2008; Fontenot et al., 2009). 
Relative uncertainties ε (type A for brachytherapy (but for those with ε < 
0.05%) and the ones published for EBRT) are given in brackets (%) with one 
decimal unit. ................................................................................................................................ 27 
Table 4-1. Elemental compositions and mass densities for the materials used. ..... 52 
Table 4-2. Relative differences between dose rates around a 226Ra needle 
calculated with the Sievert integral (as provided by Young and Batho (1962)) 
for a needle with 0.56 mm overall filtration (the platinum filter was 0.5 mm) 
and the TG-43 formalism. ...................................................................................................... 70 
Table 5-1. Mean energy of source photons and electrons that go back from the 
lead shield to the water phantom, and that traverse the lead shield, as a 
function of source depth ds and lead thickness tPb. .................................................... 84 
Table 5-2. Transmission through the lead shield for 60Co, 192Ir, and 169Yb, as a 
function of lead thickness tPb and source depth ds. Transmission is evaluated 
in the x-z plane, in the range 20 100z   mm and 25 25x    mm. The 
reference point is ( 0, 0, 50)P x y z    mm. ...................................................... 92 
      xiii 
Table 6-1. Absorbed dose after a complete (36 Gy) brachytherapy treatment, 
measured with EBT3 radiochromic films placed between slices of the 
phantom, at 15 cm from the phantom’s back. Distance dz was measured from 
the axial slice at the lower edge of the breast. Estimated uncertainties (with 
coverage factor 1k  ) are given in parentheses.................................................... 109 
Table 6-2. Relative difference between absorbed dose at a given point on the axial 
plane (see Figure 6-3b) and absorbed dose DC at the center C of the same 
axial plane (from Table 6-1), after a complete (36 Gy) brachytherapy 
treatment. ................................................................................................................................... 109 
  
 xiv 
LIST OF FIGURES 
Figure 2-1. Organ absorbed doses obtained in this work as a function of distance 
to the prostate for: a) 60Co source and b) 192Ir source. Distances are between 
the prostate and the organ center of masses. Absorbed doses are normalized 
such that D(1 cm)=1 (arbitrary units). The fitting curve obtained from 
Venselaar et al. (1996) is also shown and compared with depth dose 
distribution in the 1 m radius water sphere simulated in this work, with real 
spectra exiting the source capsules. ................................................................................. 19 
Figure 2-2 .60Co to 192Ir absorbed dose ratio for different body organs, using a 
heterogeneous and a water phantom. ............................................................................. 21 
Figure 2-3. Equivalent dose per therapeutic absorbed dose in a coronal plane 
containing the 60Co source (left) and the 192Ir source (right). .............................. 22 
Figure 2-4. Heterogeneous to water absorbed dose ratio, using 60Co and 192Ir 
sources. .......................................................................................................................................... 23 
Figure 2-5. Muscle to water absorbed dose ratio for 60Co and 192Ir encapsulated 
sources at the center of 1 m radius spheres. Absorbed doses are averaged 
over shells of 5 mm width. .................................................................................................... 23 
Figure 2-6. Organ equivalent dose per therapeutic absorbed dose for different 
radiation treatments applied to the prostate: brachytherapy (from this work, 
with 60Co and 192Ir), IMRT (Bednarz et al., 2009; Fontenot et al., 2008), and 
proton therapy (Fontenot et al., 2008; Fontenot et al., 2009). ............................. 26 
Figure 3-1. Schematic representation of different possible models of radiation-
induced cancers at low radiation doses: a) adaptive response with threshold 
dose, b) hormesis, c) bystander effect and d) linear-no threshold. The 
horizontal line expresses no over or under risk. Data points and their 95% 
confidence intervals correspond to the relative risks of brain tumour 
induction as a function of brain dose, taken from recent epidemiological 
studies with paediatric CTs performed in the UK (Pearce et al., 2012) (in 
blue) and Australia (Mathews et al., 2013) (in red), considering a 5-year 
exclusion period. ....................................................................................................................... 35 
      xv 
Figure 4-1. Cross-sectional drawing of the 8 mg radium tube and the 10 mg 
radium needle. The white circle at the right side of both sources is a 
cylindrical air cavity. All distances are given in mm. ................................................ 52 
Figure 4-2. Decay scheme of a 226Ra source, adapted from a document by 
Laboratoire National Henri Becquerel, Le radium 226 et ses descendents: 
Tables et commentaries. The crossed radionuclides can be neglected due to 
their low yield (< 0.1%). Only the half-lives of those transitions considered in 
this study are included in the figure. ................................................................................ 53 
Figure 4-3. Collision kerma along 90º   and normalized at 
0 1r   cm for the 
226Ra needle in secular equilibrium and immersed in water. The contribution 
to the collision kerma from the decay of each radionuclide is plotted, 
neglecting energy released by 218Po, 210Pb and 210Po. .............................................. 60 
Figure 4-4. Ratio of the activity of the daughter product with symbol X (and atomic 
number Z) and the activity of the parent 226Ra, as a function of time, 
according to Bateman equations (Bateman, 1910). .................................................. 62 
Figure 4-5. Absorbed dose to collision kerma ratio (left-half part of the figure), and 
normalized dose distribution (right-half part of the figure) around the 226Ra 
tube. The tube location is also represented. ................................................................. 63 
Figure 4-6. a) Superficial mould mesh consisting of 5 needles inside a glass casing. 
In the MC simulations, this was placed over a 20 cm cubic water phantom. 
The origin of coordinates is placed at the interface between glass and water, 
just below the center of the central needle. b) Relative differences between 
absorbed doses to water calculated with TG-43 formalism and with a realistic 
MC simulation, in a coronal plane (plane perpendicular to the mould, at z = 0 
cm) (left) and in a tangential plane (plane parallel to the mould, at y = -0.2 cm 
depth) (right). ............................................................................................................................. 66 
Figure 4-7. Absorbed dose rate as a function of the radial distance from a 10 mg 
226Ra point-like source. In red it is shown the relative difference between the 
dose rate calculated with GEANT4 and with expression (4-3) with the fitting 
parameters obtained in this study. ................................................................................... 67 
 xvi 
Figure 4-8. Absorbed dose rate on the transverse axis of the radium needle and 
radium tube calculated in this study, in comparison with experimental data 
from TLD measurements for the same radium needle. For comparison 
purposes, the dose rate shown by Johns and Cunnigham (1983) (J&C in the 
legend) for a given filtration thickness d and source active length L has been 
plotted. ........................................................................................................................................... 71 
Figure 5-1. Scheme of the longitudinal section of the simulation setup, indicating 
some relevant parameters and the coordinate system used for a) surface 
brachytherapy, and b) interstitial brachytherapy. The figure is not to scale. 79 
Figure 5-2. Energy spectra of a) photons and b) electrons that are backscattered 
from the lead shield to the water phantom, and energy spectra of c) photons 
and d) electrons that traverse the lead shield. Spectra correspond to the 
simulations with dPb = 5 mm and ts = 3 mm, for all three HDR sources 
considered. ................................................................................................................................... 83 
Figure 5-3. Shielded to unshielded absorbed dose ratio in the z-axis (radial 
distance 0  ) for all sources and for the three configurations used 
according to source location: surface BT, and interstitial BT with ds=5 mm 
and 10 mm. .................................................................................................................................. 87 
Figure 5-4. Percentage excess dose (%) in the water phantom (y = 0) due to the 
lead shielding for a) surface (ds = 0) and b) interstitial (ds = 5 mm) HDR 
brachytherapy with 192Ir. This corresponds to a real configuration with the 
source having multiple dwell positions. Grooves appear at the different dwell 
positions. The bin widths are 0.2 mm and 0.5 mm for z and x, respectively.. 89 
Figure 5-5. Shielded to unshielded absorbed dose ratio in the z-axis for all three 
sources, using ds=5 mm and tPb=6 mm, with contribution from backscattered 
photons and electrons. ........................................................................................................... 90 
Figure 5-6. Shielded to unshielded absorbed dose ratio in the X-Z plane of the air 
volume due to the tPb=6 mm lead shielding for interstitial (ds=5 mm) HDR 
brachytherapy with multiple dwell positions of a 60Co source. ........................... 91 
Figure 5-7. Transmission dose through the lead shield calculated in this work at 
the reference point, for 60Co, 192Ir, and 169Yb sources in the surface 
      xvii 
brachytherapy case. Error bars show the range of transmissions given in 
Table 5-2. Data are compared with the fitting curve by Papagiannis et al. 
(2008) (solid lines). ................................................................................................................. 96 
Figure 6-1. Simulation of the proposed patient set-up in the HDR brachytherapy 
treatment room. The patient is seated in a chair, placing the breast to be 
treated over the lead shielding, which has a hole in the lateral wall to allow 
connecting the transfer tubes to the catheters. With this position, the fetus is 
maximally located beneath the shielded table........................................................... 102 
Figure 6-2. Representation of the HDR 192Ir brachytherapy treatment set-up, 
showing a) the implant within the breast phantom, and b) the assembled lead 
shielding arrangement. ........................................................................................................ 104 
Figure 6-3. a) Lateral view of the Rando phantom showing vertical distances dz 
from the caudal edge of the breast. b) Axial plane of the Rando phantom 
showing the location of the dosimeters and the distance between them. The 
location of each film is identified according to the notation: central C, anterior 
A, posterior P, right R and left L. ...................................................................................... 106 
Figure 6-4. Calibration data and calibration function for all three channels (R, G, B) 
of the Gafchromic EBT3 films used in this study to convert pixel values to 
absorbed dose. ......................................................................................................................... 107 
Figure 6-5. Comparison of accumulated absorbed doses in the central region of a 
phantom after 50 Gy whole breast treatment using external-beam 
radiotherapy (EBRT) 6 MV X-rays without any wedges or shielding (from 
Martín Rincón et al. (2002)), and 36 Gy interstitial brachytherapy (BT) 
without and with shielding (from the current study). Dose values have been 
fitted by exponential curves. The curve by Venselaar et al. (1996) has also 
been plotted. The 5 cGy constraint presumed in this study is depicted with a 
red horizontal line. ................................................................................................................. 114 
 
 
  
 xviii 
LIST OF ABBREVIATIONS AND ACRONYMS 
AAPM  American Association of Physicists in Medicine 
ABS   American Brachytherapy Society 
ALARA As Low As Reasonably Achievable 
APBI    Accelerated Partial Breast Irradiation 
ASTRO  American Society for Radiation Oncology 
BEIR   Biological Effects of Ionizing Radiation 
BT   Brachytherapy 
CGE   Cobalt Gray Equivalent 
CRT   Conformal RadioTherapy 
CT   Computed Tomography 
DDREF  Dose and Dose-Rate REduction Factor 
EBRT   External Beam RadioTherapy 
ERR    Excess Relative Risk 
ESTRO  European Society for Therapeutic Radiology and Oncology 
GEC   Groupe Européen de Curiethérapie 
HDR   High-Dose-Rate 
HEBD  High Energy Brachytherapy Source Dosimetry 
ICRP    International Commission on Radiological Protection 
ICRU   International Commission on Radiation Units and measurements 
IMRT   Intensity Modulated Radiation Therapy 
IORT   IntraOperative Radiation Therapy 
LAR    Lifetime Attributable Risks 
LDR   Low-Dose-Rate 
LNT    Linear No-Threshold 
MC   Monte Carlo 
MDR   Medium-Dose-Rate 
NCRP   National Council on Radiation Protection and Measurements 
      xix 
OAR   Organ At Risk 
PD   Peripheral Dose 
PDR   Pulsed-Dose-Rate 
RBE   RadioBiological Effectiveness 
TLD   ThermoLuminiscent Dosimeter 
UNSCEAR United Nations Scientific Committee on the Effects of Atomic 
Radiation 
VMAT  Volumetric Modulated Arc Therapy 
WBI   Whole Breast Irradiation  
 xx 
 
 
 
 Chapter 1. INTRODUCTION 
 
  
Chapter 1 
_____________________________________________________________________________________________________________________________________________ 
2  
1.1 High-dose-rate brachytherapy  
 Brachytherapy (BT) is a radiation treatment modality in which a sealed 
radioactive source is placed near, in contact or inside the tumor volume. The 
disintegration of this source produces the emission of energy, which may give place 
to cell death. A very high dose (absorbed dose is defined as energy absorbed per 
unit mass) is delivered in a short time period and a small number of fractions. It 
requires the treatment volume to be accessible and well limited in size and shape. 
BT is commonly used as an effective treatment modality for cancers of cervix, 
prostate, breast, and skin. It has been also shown to be effective to treat tumors of 
the brain, head and neck region (e.g. lip, tongue or floor of mouth), eye, trachea and 
bronchi, the digestive and urinary tract (e.g. bladder, rectum, anus, urethra, penis), 
female reproductive tract (uterus, vagina and vulva), and other soft tissues 
(Gerbaulet et al., 2002). BT plays today a fundamental therapeutic tool. For 
example, for prostate carcinomas the cancer cure rates are either comparable to 
those of external beam radiotherapy (EBRT) and surgery, or even improved when 
used in combination with them (Viswanathan et al., 2007; Pickles et al., 2009; 
Haie-Meder et al., 2009; Pieters et al., 2009).  
 Compared to EBRT, in which collimated photon beams produced by a linear 
accelerator are generated outside the patient, BT has the advantages of a rapid fall 
off of dose around the sources due to the inverse distance square law. This implies 
less adverse side effects, and shorter overall treatment duration, thus reducing the 
risk of tumor repopulation. However, the dose distribution is not homogeneous and 
accuracy in source positioning is critical (Gerbaulet et al., 2002). The use of BT has 
increased substantially since the 1990s and it is expected to grow even more in the 
near future (Guedea, 2014).  
 Depending on the dose rate D of the radioactive BT source employed, either 
high-dose-rate (HDR) (D>12 Gy/h), medium-dose-rate (MDR) (D=2 to 12 Gy/h), 
pulsed-dose-rate (PDR) (short pulses of radiation, usually once an hour) or low-
dose-rate (LDR) (D<2 Gy/h) can be distinguished. In detriment of LDR, HDR is 
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becoming nowadays the most extended BT modality worldwide (Guedea, 2014). 
Advantages of HDR over LDR BT include reduced radiation exposure to personnel, 
reduced overall treatment time, treatment delivery in the outpatient setting, and 
potential cost savings (Bastin et al., 1993). In addition, for the particular case of 
prostate brachytherapy, common problems related to permanent seeds implants 
such as inability to correct seeds position, inability to optimize the dose delivered 
once the seeds are in place, and discrepancy between planned and actual seeds 
distribution are relatively infrequent in HDR brachytherapy (Demanes et al., 2014). 
Nevertheless, with HDR BT an increased risk of late tissue effects has been 
estimated (Dale, 1985), and so more efforts are needed in this field. For these 
reasons, HDR therapy is the BT technique considered in this study.  
 In HDR BT one single source is placed at several dwell positions in order to 
cover the whole extension of the tumor, staying in each position a planned dwell 
time. The delivery of the treatment is performed by an afterloader system controlled 
from outside the treatment room. The overall treatment time is just a few minutes. 
A high specific activity (radioactivity per unit mass) of a radionuclide is necessary 
to produce miniaturized sources of just a few mm as those used in HDR BT. 
60
Co 
and 
192
Ir sources are nowadays the only commercially-available radionuclides for 
HDR BT. The characteristics of these sources are presented in detail in Chapter 2. 
The reasons why 
60
Co is an alternative option to the traditional 
192
Ir sources have 
already been reported (Righter et al., 2008; Strohmaier et al., 2011; Andrássy et al., 
2012; Palmer et al., 2012). Relative dosimetric differences around 
60
Co and 
192
Ir 
sources are less significant than prescription technique and the optimization 
parameters, given that they have a similar radial dose distribution governed by the 
inverse distance square law, 1/r
2
. This results in no clinically significant differences. 
Advantage of 
60
Co over 
192
Ir is the significant cost savings, due to the fact that this 
source has to be replaced every 4 to 5 years, whereas 
192
Ir sources need to be 
changed every 3 to 4 months. Thus, in comparison to 
192
Ir, with 
60
Co equipment 
down-time and physics support time is also reduced by around 40%. However the 
irradiation time is on average a factor 1.7 longer with 
60
Co. The 
60
Co source activity 
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required to produce the same absorbed dose rate in air is a factor 2.8 lower. In 
addition, due to its higher mean energy, 
60
Co needs a higher room shielding.  
 
1.2 Peripheral dose and secondary radiation risks 
 During radiation therapy not only does the tumor volume absorbs dose, but 
also all the remaining tissues of the body, even though they are out of the beam path 
in the case of EBRT or far from a brachytherapy source. The latter is known as 
peripheral dose (PD). This may result in some cases in acute, sub-acute and/or long-
term side-effects, which depend on the location of the target volume, the type of BT 
that is used and also the amount of absorbed dose. Due to improved long term 
survival rates, long-term side-effects are becoming increasingly important. Thus, 
reducing the PD helps to improve the treatment success.  
 The hazard effects of ionizing radiation in the human health can be classified 
in deterministic and stochastic. Deterministic effects are those for which a threshold 
dose exists, below which the hazard effect is not produced. If the dose to healthy 
organs at risk (OAR) is reduced, then the possibility to overcome that threshold 
decreases. On the other hand, stochastic effects are those in which the probability of 
having the effect generally increases with absorbed dose, with no threshold dose. 
The severity of these effects is independent on dose.  
 Among the stochastic effects is the induction of a secondary tumor not 
related to the initial one. The scientific community tries to establish a relationship 
between organ equivalent dose and the probability that a specific tumor is induced. 
If the relationship were known, the secondary cancer induction from a typical 
brachytherapy treatment could be obtained and compared with the probability from 
other radiation therapies. However, this requires the knowledge of both the dose-
response relationship and the peripheral dose. A deep review of the literature is 
necessary to evaluate the knowledge on this dose curve. In addition, the PD is 
necessary. This can be already estimated in EBRT using the software program 
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Peridose (Van der Giessen, 2001). However, according to a summary on second 
cancer induction done by Xu et al. (2008), the American Association of Physicists 
in Medicine (AAPM) Task Group 158 and the National Council on Radiation 
Protection and Measurements (NCRP) Scientific Committee have excluded 
brachytherapy from their studies due to lack of data, which confirms the necessity 
to make a complete study regarding equivalent doses to all organs when applying 
brachytherapy (NCRP, 2001). Furthermore, a major European collaboration 
involving 13 organizations across Europe, the ALLEGRO project 
(http://www.allegroproject.org), whose aim is to address many issues of damage 
produced to normal healthy tissues after treatment with conventional and emerging 
radiotherapy techniques, has not yet considered brachytherapy, which again 
confirms the need for greater knowledge in this treatment technique.  
 
1.3 Review of Monte Carlo methods 
 Most part of the research work of this study is based on the results of Monte 
Carlo (MC) simulation techniques. MC simulations have become an essential tool 
to improve the calculation of absorbed doses in brachytherapy. The basic principle 
of the MC method is the use of random numbers and probability density 
distributions programmed into computers to find the solution to a physical or 
mathematical problem. 
 For BT with its pertinent laws of radiological physics, the MC method 
enables accurate calculation of absorbed doses in regions with a high dose gradient. 
This allows enhancing and complementing the dose calculations obtained 
experimentally since the latter has a large uncertainty due to small errors in the 
position of the detector. In addition, with MC there are no experimental problems 
such as energy and sensitivity dependence of the detectors. Another advantage of 
the MC method compared to experimental measurements is the possibility to 
separate the different components of absorbed dose: the primary radiation, scattered 
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radiation and multiple scattering components. This is useful in modeling dose 
deposition. Also, the MC method can provide additional information of interest 
such as the energy spectra from radioactive sources at any distance in any medium.  
 In MC simulations, absorbed dose can be calculated directly or from 
collision kerma. In the direct method, the absorbed dose in a given cell is computed 
as the sum of the energies deposited in the cell divided by the cell mass. When there 
is electronic equilibrium, then absorbed dose equals collision kerma, which is given 
by the sum of the initial kinetic energies of charged particles released in the cell by 
non-charged particles. The calculation of absorbed dose from kerma significantly 
reduces the variance (Williamson, 1987), i.e., the simulation time necessary to 
achieve a given statistical noise. This is achieved by using the linear track-length 
estimator, which is based on the equivalence between particle fluence and the total 
length of the photon path per unit volume (Carlsson, 1985). The variance is 
significantly reduced because all the paths of the photons passing through a given 
cell contribute to the calculation of the linear track-length estimator. 
 Currently there are multiple MC codes available for medical physics 
applications. The main ones are: MCNP (X-5 Monte Carlo Team, 2003; Goorley et 
al., 2012), EGS (Nelson et al., 1985), PENELOPE (Salvat et al., 2011), FLUKA 
(Ferrari et al., 2005) and GEANT4 (Agostinelli et al., 2003; Allison et al., 2006). 
 For the development of this study, I specialized in the MC code GEANT4, a 
general purpose code written in C++ that allows simulating the passage of particles 
through matter. GEANT4 allows creating complex geometries using predefined 
shapes or importing CAD geometries and voxelized phantoms. In addition, all kind 
of “particles” (including leptons, hadrons, ions or even new particles created by the 
user) can be initiated. GEANT4 provides the user with a large set of physical 
processes including electromagnetic, hadronic and optical physics. In addition, the 
user can "communicate" with the code by choosing various interfaces and visualize 
the geometry and particle tracking using multiple display systems. The code 
functions are designed in a compact and reusable way such that the user can extend 
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or modify the services provided by these to be used in their own applications. 
GEANT4 has been widely validated for its use in brachytherapy dosimetry (Rivard 
et al., 2010; Granero et al., 2011; Vijande et al., 2012). 
 
1.4 Objectives and outline of this thesis 
 The goal of this thesis was threefold. Firstly, to evaluate the peripheral dose 
in a typical brachytherapy scenario and discern which HDR radioactive source is 
more advantageous from a patient radiation protection point of view, i.e., which 
source deposits less dose to the nearest and the furthest tissues. Secondly, the risk of 
secondary malignancies induced by the BT treatment was reviewed. Because old 
epidemiological studies are needed with higher accuracy in dose calculation, we 
provide a more accurate dosimetry based on the current formalism for old radium 
brachytherapy sources, for which a lot of patient follow-up exists, allowing 
performing retrospective studies. Thirdly, we aimed to reduce the peripheral dose 
received by organs and tissues near the implant using specifically designed implant 
shielding.  
 Chapter 1 has covered the principles behind HDR brachytherapy and 
secondary risks associated with this treatment modality. It also presents the 
objectives and outline of the present thesis. Chapter 2 to Chapter 6 are based on 
papers which have been published in international peer-reviewed journals. Chapter 
2 evaluates through MC simulations the peripheral dose in the treatment of a 
prostate carcinoma when using 
60
Co and 
192
Ir sources. Results of this study are 
compared with the peripheral dose in other radiotherapy modalities such as EBRT 
and proton therapy. Chapter 3 assesses the probability that the radiation doses 
absorbed by the healthy organs can induce a secondary tumor. Following a 
thorough literature review of current knowledge in this field, a critical analysis is 
presented. Chapter 4 aids epidemiologists with accurate dose estimations, which 
can be linked to secondary risks for a BT treatment. For this purpose, a radium 
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(
226
Ra) tube and needle, widely used from 1920s to the 1970s, and for which there 
exists a wide medical record with clinical follow-up, are dosimetrically 
characterized using MC simulations and the formalism employed in clinical 
practice. Chapter 5 is the first chapter aimed to reduce the peripheral dose. The use 
of lead shielding in certain surface treatments is considered, and the optimum 
shielding thickness is evaluated. Because the shield may increase the dose near the 
patient surface that is in contact with the shield, the use of a layer of material 
equivalent to water (bolus) placed between the shield and the patient surface is 
proposed, and its effect is evaluated, as well as the required bolus thickness as a 
function of the radionuclide used. Results of this study are applied in Chapter 6 to 
a case of great interest: dose reduction to the fetus of a pregnant patient having 
breast cancer. For this particular case, a novel breast shield is designed and 
absorbed dose to the fetus is measured, with and without shielding. These data are 
compared to the fetal dose delivered by other radiotherapy techniques. Finally, 
Chapter 7 presents a general discussion of all previous studies. 
  
 Chapter 2. PERIPHERAL DOSE IN HDR 
BRACHYHTERAPY 
 
 
 
Most of the content of this chapter was published in the original research paper: 
Candela-Juan C, Perez-Calatayud J, Ballester F, Rivard MJ. Calculated organ 
doses using Monte Carlo simulations in a reference male phantom undergoing 
HDR brachytherapy applied to localized prostate carcinoma. Medical Physics. 40: 
033901 (2013). 
Kind permission was granted by the journal to reprint this article as a chapter of this 
dissertation. 
  
Chapter 2 
_____________________________________________________________________________________________________________________________________________ 
10  
2.1 Introduction 
 Prostate carcinoma is the second most frequently diagnosed tumor among 
men in economically developed countries (14% of cancer cases in 2008), being the 
sixth leading cause of cancer death (6% of cancer deaths in males in 2008) (Jemal et 
al., 2011), although there are variations amongst countries (IARC, 2001). If 
increasing life expectancy is also considered, an even higher death rate due to 
prostate cancer is expected and it is thus worth directing efforts to improve 
treatment options for this disease. 
 The American Brachytherapy Society (ABS) has shown the success of HDR 
brachytherapy applied to localized prostate cancer (Yamada et al., 2012). In 
addition to low toxicities (<5% for Grade 3 or higher), biochemical control rates of 
85% to 100%, 81% to 100%, and 43% to 93% have been reported for low-, 
intermediate-, and high-risk prostate tumors, respectively. In addition, it has been 
shown that HDR brachytherapy achieves complete prostate target coverage and 
doses to urethra, bladder and rectum below the dose constraints for these OARs 
(White et al., 2013). From a population-based analysis, it is also shown that 
mortality rates are reduced when applying brachytherapy alone or in combination 
with EBRT, even for high-risk cancers. In fact, besides HDR monotherapy being a 
treatment technique for this disease, it also plays a fundamental tool as a boost (9 
Gy or 15 Gy) after 60 Gy or 46 Gy intensity modulated radiation therapy (IMRT), 
respectively. 
 Several manufacturers have traditionally offered HDR 
192
Ir as a 
brachytherapy source. The new Eckert & Ziegler BEBIG GmbH MultiSource 
remote afterloader permits HDR 
60
Co brachytherapy.  
 Tumor control is the main concern in a radiotherapy treatment plan. 
However, production of secondary cancers becomes a criterion that can be used to 
establish the treatment choice when target coverage and dose sparing are 
comparable for different radiotherapy modalities. As stated by Schneider et al. 
(2006), new radiation treatment techniques such as IMRT or hadron therapy may 
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increase cancer cure rates, although it is expected they can also increase secondary 
tumor incidence. This is because of the relatively high equivalent dose deposition in 
OARs that are within the primary beam trajectory. In addition, a considerable 
increase in beam-on time for IMRT gives to organs out of field a higher absorbed 
dose, mainly from leakage radiation, since contribution from scatter is equal or less 
than in 3D-conformal radiotherapy (3D-CRT) if proper collimation is used. In the 
case of proton therapy or radiation therapy with high energy photons, neutrons are 
created in the accelerator which, due to their higher radiobiological effectiveness 
than photons, may also lead to an increase of secondary cancers. 
 Given the successful clinical results when using brachytherapy, IMRT, or 
proton therapy (Schneider et al., 2006; Shen et al., 2012), it is of interest to discern 
the treatment modalities and compare probabilities for secondary cancer 
occurrence. The peripheral dose has been obtained for 3D-CRT, IMRT, and proton 
therapy (Schneider et al., 2006; Stathakis et al., 2007; Fontenot et al., 2009; 
Bednarz et al., 2009; Bednarz et al., 2010). This has also been done for 
brachytherapy applied to the breast, using HDR 
192
Ir and electronic sources (Mille 
et al., 2010). However, it does not appear to have been done for HDR 
brachytherapy with 
60
Co and 
192
Ir sources applied to prostate cancer, nor with 
comparison to EBRT techniques. As previously stated, according to a summary on 
the topic done by Xu et al. (2008), the AAPM Task Group 158 and the NCRP 
Scientific Committee excluded brachytherapy from their studies due to lack of data. 
This exclusion supports the study of equivalent doses in a similar context to include 
brachytherapy. 
 Consequently, the aim of this study was to obtain equivalent doses to a 
variety of organs when applying HDR brachytherapy to the prostate using 
60
Co or 
192
Ir sources, and to provide EBRT comparisons. Given that absorbed doses to the 
bladder and rectum are dependent on patient-specific treatment plans and are 
already estimated during the planning process, the focus is on farther organs. Due to 
the intrinsic difficulties and limitations of absorbed dose measurements to organs, 
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MC simulated radiation transport has been selected as the calculation method to 
estimate the needed data. 
 
2.2 Materials and methods 
2.2.1 Geometry definition 
 In order to reproduce a prostate brachytherapy treatment, a representative 
adult male phantom is needed. Since the 1960s, more than one hundred phantoms 
have been reported in the literature (Caon, 2004; Zaidi et al., 2007; Zhang et al., 
2009; Xu et al., 2010), going from stylized phantoms formed by mathematical 
shapes, to voxelized phantoms, and finally to mesh phantoms, where their postures 
can be adjusted and the body organs deformed. A recent and complete analysis of 
all these body phantoms was presented by Xu et al. (2010). 
 In its Publication 110 (ICRP, 2009), the International Commission on 
Radiological Protection (ICRP), jointly with the International Commission on 
Radiation Units and Measurements (ICRU), defines an official voxelized phantom 
that reproduces reference organ and tissue values given in ICRP Publication 89 
(ICRP, 2002). For design of the ICRP/ICRU 110 phantom, tomographic datasets 
from a real individual with physical characteristics close to those from the reference 
phantom (176 cm tall and 73 kg mass) were selected, and voxel scaling was applied 
to adjust the body height and the skeletal mass. Individual organs were then 
segmented and adjusted to reproduce reference masses within 0.01 g. The final 
phantom consists of over 140 organs and tissues, formed by almost 1.95 million 
voxels (7.16 million voxels if exterior air is considered). For the male phantom, the 
voxel height is 8 mm, whereas the voxel in-plane resolution is 2.137 mm with a 
voxel volume of 36.54 mm
3
. Since the physical posture of a patient with prostate 
carcinoma who is being treated with HDR brachytherapy is not very different from 
the ICRP/ICRU 110 phantom, this voxelized phantom was used in this work. 
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 Some tissues/organs such as lymphatic nodes, blood, and bone marrow, 
among others, could not be perfectly segmented due to the limited voxel resolution 
(ICRP, 2009). Lymphatic nodes were included manually at specific locations, 
whereas a blood portion was incorporated in the elemental tissue composition of 
each organ. In addition, the mass percentage of bone marrow in the spongiosa part 
of skeletal targets is given in ICRP Publication 110 (ICRP, 2009), which allows an 
estimation of absorbed dose to red bone marrow and endosteum tissue (bone 
surface), which are part of the radiosensitive organs needed to obtain effective dose. 
This is, however, an overestimation of absorbed dose in these two tissues given that 
secondary equilibrium between the mineral bone and soft tissue components of the 
spongiosa does not exist (ICRP, 2009). Despite this, the voxelized phantom is 
considered adequate for the purpose of this study given that variation of absorbed 
doses due to exact organs resolutions is expected to be small compared to variations 
between different patients. In addition, dealing with relatively high energy photons, 
this voxel resolution should not be a concern. 
 In order to assess the adequacy of a homogeneous phantom for HDR 
absorbed dose calculations, and to permit model validation against measurements 
by others, simulations were repeated with the entire phantom composition replaced 
as liquid water. In addition, an extra simulation with the heterogeneous voxelized 
phantom immersed in water was later performed in order to explain the behavior of 
organ doses as a function of distance when compared to an ‘infinite’ medium. 
Additional simulations were performed in 1 m radii spheres of water (ρ = 1.00 
g/cm
3
) and muscle (ρ = 1.05 g/cm
3
). 
2.2.2 Brachytherapy sources 
 Energy spectra used in the MC simulations and their probabilities are the 
ones obtained by our group in previous studies (Ballester et al., 2009; Rivard et al., 
2010), which provide spectra exiting real encapsulated HDR 
60
Co and 
192
Ir sources. 
The photons were generated at the prostate center of the voxelized phantom (i.e., 
point sources) emitting photons isotropically. Source capsule effects have been 
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included in the simulations using those spectra. These spectra were also used for 
simulations at the center of the spheres of water and muscle as explained above. 
2.2.3 MC simulation setup and organ equivalent dose 
calculation 
 The simulation toolkit GEANT4 version 9.4 (Agostinelli et al., 2003) was 
used to read ASCII data provided in ICRP/ICRU 110 (ICRP, 2009) and to simulate 
the human phantom and the HDR brachytherapy treatment. The low-energy 
electromagnetic models of the Livermore physics package, which use detailed 
handling, were employed. Standard multiple scattering cross-sections were also 
utilized, with specialized processes for each particle type. Detailed information 
about these models can be found in  the GEANT4 User Documentation webpage 
(http://geant4.cern.ch/supports/userdocuments.shtml). This code has been widely 
validated for its use in brachytherapy dosimetry (Rivard et al., 2010; Granero et al., 
2011; Vijande et al., 2012). Secondary electrons were also tracked. For electrons 
and photons, the cutoff range was set to 0.1 mm, so secondary particles having a 
smaller range were not generated. 
 In order to hasten simulation time without extra memory requirement, the 
G4RegulatorNavigation algorithm was used, as implemented in the DICOM 
example of GEANT4. It is based on removing voxel frontiers when two voxels 
share the same material. An iterative algorithm is later applied to determine 
absorbed dose in each individual voxel of a cluster. More details about this 
technique, which has already been validated, can be found on the cited example of 
GEANT4.  
 A text file with absorbed dose in each voxel was obtained as an output of the 
simulation. In-house developed software was then used to convert this output to 
absorbed dose DT in each organ or tissue T, by summing all voxel absorbed doses in 
an organ and dividing by the number of voxels that form it. This is a mass weighted 
average considering that all voxels of the same tissue have the same mass. DT was 
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then converted to mean absorbed dose per released photon by dividing by the 
number of events per simulation, N. Finally, equivalent dose per photon, HT/N, was 
obtained from absorbed dose through a radiation weighting factor wR: 
,T RT
R
R
DH
w
N N

 
(2-1) 
 According to ICRP Publication 103 (ICRP, 2007), wR equals 1 for photons 
and electrons. Since these are the only particle types in the simulation environment, 
the equivalent dose HT in an organ was numerically equal to absorbed dose in that 
organ. Effective dose E was also obtained through a tissue weighting factor wT: 
T
T
T
HE
w
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(2-2) 
 The point source was located at the prostate center. For each source and 
phantom composition (heterogeneities or water), 10
9
 initial photons were used, 
which provided statistical (Type A) uncertainties < 1% for most of the organs 
considered. As recommended in the joint AAPM Task Group No. 138 report 
(DeWerd et al., 2011), a coverage factor of k=2 (confidence level of 95%) was used 
to express uncertainties in brachytherapy dose. 
 The procedure by Pujades et al. (2011) was used to correlate the MC 
simulations of the source at a single position at the prostate center with a realistic 
therapeutic absorbed dose to the prostate for the source at various locations and 
with different dwell times. They derived the relationship between prostate volume 
V, therapeutic absorbed dose DP, air-kerma strength SK, and total irradiation time t 
for 127 clinical cases. The correlation was presented as a nomogram fitted to a 
linear function and allowed estimation of t for the source at the center of the 
prostate to deliver the required absorbed dose: 
Chapter 2 
_____________________________________________________________________________________________________________________________________________ 
16  
( )K Pt S D a V b     
(2-3) 
where a and b are fitting parameters obtained experimentally (Pujades et al., 2011). 
From previous Monte Carlo studies (Ballester et al., 2009; Rivard et al., 2010; 
Granero et al., 2011; Vijande et al., 2012), the air-kerma strength per Bq, SK/A, was 
derived for both HDR 
60
Co and 
192
Ir sources. From all these clinical data, the 
number of events N1 Gy necessary to provide a therapeutic absorbed dose of DP = 1 
Gy to the prostate, as a function of V was obtained: 
1 Gy ( )
KP
N a V b
SD
A
 

 
(2-4) 
 Using N1 Gy with Eq. (2-1), equivalent dose per therapeutic absorbed dose to 
the prostate, HT/DP, was determined. Data correspond to those from a typical 
prostate volume of V=30 cm
3
, although variations with V were also analyzed. 
 
2.3 Results 
2.3.1 Organ equivalent dose 
 N1 Gy = 8.4×10
12
 and N1 Gy = 3.0×10
13
 photon histories for 
60
Co and 
192
Ir, 
respectively, were needed to deliver 1 Gy of therapeutic absorbed dose to a 30 cm
3
 
prostate. If the method by Pujades et al. (2011) had not been used, for that number 
of initial events, absorbed dose in the prostate would be 3.9 Sv/Gy and 4.9 Sv/Gy 
instead of 1 Sv/Gy for 
60
Co and 
192
Ir, respectively. They are larger than 1 Sv/Gy, 
which was expected given that N1 Gy is used to account for a real case where the 
source is located at various points inside the prostate. This source distribution 
reduces overall absorbed dose in the prostate in exchange for uniform dose 
deposition in the target volume. This methodology might underestimate absorbed 
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doses to the nearest organs (mainly the ones which are in contact with the prostate), 
due to proximity of a specific source position. For the rest of the organs, the 
variations were expected to be negligible. 
 Table 2-1 shows mean equivalent doses (per therapeutic absorbed dose to a 
30 cm
3
 prostate), HT/DP, in several radiosensitive organs in the heterogeneous 
phantom, for both the 
60
Co and 
192
Ir sources, all together with the Type A statistical 
uncertainties. Effective dose is also included. In addition, the relative variation of 
organ absorbed doses for the water phantom in comparison to the heterogeneous 
phantom is shown. For completeness, organ masses and distances, r, from their 
center of mass to the center of mass of the prostate are also given. 
 Figure 2-1 shows organ absorbed doses as a function of r. The depth dose 
distribution in the 1 m radius water sphere and fitted curves obtained by Venselaar 
et al. (1996) from measurements of point sources (
60
Co and 
192
Ir) in water are 
plotted (see Figure 2-1a and Figure 2-1b, respectively) for comparison. Similarity 
of the curves validates the simulations and physics package used. 
 There is reasonable agreement between organ data and the fitted curves. 
There are three organs that received an absorbed dose higher than predicted by 
simulations in water: spinal cord, small intestine wall, and the colon. The latter two 
are close to the prostate, and all three subtend volumes over a large range of 
distances from the prostate. For organs with d > 30 cm, organ absorbed dose is 
smaller than expected in water by 50% to 125% for 
192
Ir, and by 17% to 60% for 
60
Co. These discrepancies are also present for organ absorbed doses in the 
homogeneous water phantom. There are two known radiological effects that 
contribute to these differences. First, there is dosimetric difference between water 
and soft tissue for d > 30 cm, as shown later. Second, there is lack of backscatter at 
the phantom skin compared to an infinite medium. This was demonstrated by 
immersing the heterogeneous voxelized phantom in water. With this configuration, 
organ absorbed doses increased up to ~25% with variations between different 
organs. 
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Table 2-1. Organ equivalent dose per therapeutic absorbed dose to the prostate, 
(HT/DP), given to the heterogeneous voxelized phantom by the 
60
Co source and by 
the 
192
Ir source. Distances correspond to those between the prostate and the organ 
center of masses. The statistical uncertainty (Type A) percentage (k=2), ε, is also 
shown (but for those with ε < 0.05%), as well as the effective dose. The last column 
corresponds to the relative variation of absorbed dose between the water and the 
heterogeneous phantom, Δ, being positive if absorbed dose in water is higher than 
in a tissue. 
 
 1 
 HT / DP (Sv/Gy) 
Δ (%) 
Organ name 
Mass 
(g) 
Distance 
(cm) 
60
Co 
192
Ir 
Mean ε (%) Mean ε (%) 60Co 192Ir 
Urinary bladder wall 50.0 5.0 1.30x10
-1
 0.1 1.60x10
-1
 0.1 0.6 -0.4 
Rectum wall 30.0 5.3 1.51x10
-1
 0.1 1.83x10
-1
 0.1 0.6 0.5 
Testis, right 17.5 11.2 2.51x10
-2
 0.3 2.94x10
-2
 0.3 -0.1 0.2 
Testis, left 17.5 11.3 2.42x10
-2
 0.2 2.82x10
-2
 0.2 0.2 0.2 
Small intestine wall 650.0 20.3 9.24x10
-3
 0.1 1.05x10
-2
 0.1 1.2 2.7 
Colon 340.0 24.0 6.21x10
-3
 0.1 6.78x10
-3
 0.1 0.9 2.7 
Kidney, right 157.0 29.9 1.75x10
-3
 0.3 1.40x10
-3
 0.3 5.1 11.5 
Kidney, left 153.0 31.1 1.56x10
-3
 0.5 1.20x10
-3
 0.3 4.9 10.8 
Pancreas 140.0 31.2 1.53x10
-3
 0.3 1.21x10
-3
 0.4 4.9 9.5 
Gall bladder wall 13.9 32.9 1.26x10
-3
 1.2 9.33x10
-4
 1.3 4.2 7.5 
Adrenal, right 7.0 33.6 1.11x10
-3
 1.9 7.63x10
-4
 1.4 10.5 19.5 
Adrenal, left 7.0 34.8 9.79x10
-4
 1.7 6.50x10
-4
 2.3 9.4 17.6 
Stomach wall 150.0 35.8 9.50x10
-4
 0.5 6.40x10
-4
 0.4 2.4 6.9 
Liver 1800.0 36.2 8.88x10
-4
 0.1 5.88x10
-4
 0.2 4.2 9.3 
Spleen 150.0 38.1 7.15x10
-4
 0.6 4.32x10
-4
 0.3 6.2 13.1 
Heart contents 510.0 44.3 4.03x10
-4
 0.3 2.09x10
-4
 0.7 9.3 17.9 
Heart wall 330.0 44.7 3.97x10
-4
 0.2 2.08x10
-4
 0.3 9.0 15.1 
Lung, right 471.7 47.3 3.37x10
-4
 0.4 1.60x10
-4
 0.4 1.0 8.8 
Lung, left 376.8 47.9 3.27x10
-4
 0.3 1.56x10
-4
 0.6 0.1 5.7 
Esophagus 40.0 50.0 3.01x10
-4
 1.8 1.55x10
-4
 1.9 14.7 23.3 
Spinal cord 36.6 50.9 4.35x10
-4
 1.3 2.51x10
-4
 1.7 13.1 34.4 
Thymus 25.0 54.6 1.53x10
-4
 2.5 6.16x10
-5
 4.5 13.6 6.3 
Trachea 10.0 57.0 1.28x10
-4
 4.1 4.74x10
-5
 6.1 11.4 18.5 
Thyroid 20.0 59.1 1.04x10
-4
 3.7 3.46x10
-5
 4.6 5.9 6.2 
Tongue (inner part) 42.3 70.0 5.62x10
-5
 1.8 1.50x10
-5
 6.7 0.6 0.8 
Salivary gland, right 42.5 70.3 5.88x10
-5
 2.3 1.45x10
-5
 6.7 -16.7 -14.1 
Salivary gland, left 42.5 70.3 4.71x10
-5
 2.5 1.20x10
-5
 6.3 -0.9 -4.0 
Brain 1450.0 79.5 2.08x10
-5
 1.1 4.17x10
-6
 2.0 2.6 4.3 
Active bone marrow - - 1.26x10
-2
 - 1.62x10
-2
 - 0.4 -6.2 
Skin - - 3.21x10
-3
 - 3.23x10
-3
 0.1 2.5 4.7 
Lymphatic nodes - - 2.69x10
-2
 0.1 3.13x10
-2
 0.1 1.5 1.3 
Effective dose - - 1.11x10
-2
 - 1.32x10
-2
 - - - 
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Figure 2-1. Organ absorbed doses obtained in this work as a function of distance 
to the prostate for: a) 
60
Co source and b) 
192
Ir source. Distances are between the 
prostate and the organ center of masses. Absorbed doses are normalized such that 
D(1 cm)=1 (arbitrary units). The fitting curve obtained from Venselaar et al. (1996) 
is also shown and compared with depth dose distribution in the 1 m radius water 
sphere simulated in this work, with real spectra exiting the source capsules. 
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2.3.2 Influence of prostate size 
 Mean equivalent dose in each organ is proportional to the number of photons 
emitted by the source, N1 Gy. In addition, according to Eq. (2-4), N1 Gy is linear with 
V. Hence, if D0 is the absorbed dose in a specific organ when the prostate volume is 
V0=30 cm
3
, when V=V0 (1+X), i.e., when the volume is X % higher or lower, then 
the relative variation of organ absorbed dose is: 
0 0
0 0
XD D a VX
D a V b
 

 
 
(2-5) 
 Using real clinical values obtained by Pujades et al. (2011) (a=0.0605 cm
-1
, 
b=1.7 cm
2
), then the relative variation is 0.52 times X. Therefore, if prostate volume 
increases (decreases) 10% respect to the reference volume, equivalent dose in each 
organ increases (decreases) by ~5.2%. 
 
2.3.3 60Co vs. 192Ir 
 Figure 2-2 represents the 
60
Co to 
192
Ir absorbed dose ratio for each organ, for 
the heterogeneous and the water phantom. Presented error bars are statistical (Type 
A) uncertainties from MC simulations. Absorbed doses have been normalized such 
that the prostate receives the same absorbed dose from both sources. It can be 
observed that absorbed doses in those organs near the treated prostate, such as the 
bladder, rectum, testes, small intestine, and colon are roughly 10% smaller when 
using 
60
Co. This can be rationalized considering that in a real treatment, as shown 
above, to give the same absorbed dose at 1 cm from the source, the required activity 
of 
60
Co is smaller and so is the number of emitted photons. This is not the case for 
distant organs. As the distance between the prostate and the organ increases, so does 
the relative contribution of 
60
Co absorbed dose in comparison to 
192
Ir. This can be 
understood from the mean energy of emitted photons for each radionuclide, which 
is higher for 
60
Co and has greater penetration within the body. This trend can be 
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also observed in Figure 2-3, where it is plotted the dose distribution in a coronal 
plane containing the sources.  
 Given that the same therapeutic absorbed dose is prescribed with both 
radionuclides, and that estimated effective doses were 11.1 mSv/Gy for 
60
Co and 
13.2 mSv/Gy for 
192
Ir, an overall advantage of 
60
Co seems to exist when organ 
doses are considered. 
 
2.3.4 Heterogeneous vs. water phantom 
 Currently, brachytherapy treatment planning systems consider the body to be 
composed of water. In this section, validity of this assumption when obtaining 
organ absorbed dose in the whole body is analyzed. Figure 2-4 shows the organ 
absorbed dose ratio of heterogeneous media to water for the two sources. For the 
closest organs considered, absorbed dose was the same for all organs having near-
unity mass density. 
 
Figure 2-2 .
60
Co to 
192
Ir absorbed dose ratio for different body organs, using a 
heterogeneous and a water phantom. 
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Figure 2-3. Equivalent dose per therapeutic absorbed dose in a coronal plane 
containing the 
60
Co source (left) and the 
192
Ir source (right). 
 
  However, as the distance increases the absorbed dose ratio decreases, 
reaching differences of almost 25% (but for the spinal cord, which is surrounded by 
bone and so the absorbed dose ratio is even lower), being lower for 
192
Ir than for 
60
Co (but for the thymus and the left salivary gland, where uncertainties are 
relatively high and so no conclusions can be extracted). The reason for the absorbed 
dose rate reduction is in the material composition. In order to prove this, absorbed 
dose as a function of distance was obtained in water and muscle spheres with the 
sources placed at the centers. The absorbed dose ratios when using both 
60
Co and 
192
Ir, with their real spectra exiting the sources, are shown in Figure 2-5. 
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Figure 2-5. Muscle to water absorbed dose ratio for 
60
Co and 
192
Ir encapsulated 
sources at the center of 1 m radius spheres. Absorbed doses are averaged over 
shells of 5 mm width. 
 
Figure 2-4. Heterogeneous to water absorbed dose ratio, using 
60
Co and 
192
Ir 
sources. 
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 As an example, at 30 cm from the source, the muscle to water absorbed dose 
ratio for 
192
Ir is 0.92, being the difference between the kidneys and its 
corresponding water volume of around 10%, in agreement. Hence, the general 
decrease of the heterogeneous to water absorbed dose ratio can be explained 
considering the differences between real tissue and water, which are negligible for 
distances below 10 cm, but not after that. With 
60
Co, which has higher mean photon 
energy, photoelectric effect is not dominant and so the difference between water 
and soft tissue is smaller than for 
192
Ir. The other factor which influences the curve 
from Figure 2-4 is the presence of different materials like air inside some organs, 
bone, or the lungs. An interesting case is the salivary glands, where the 
heterogeneous to water absorbed dose ratio between the left and the right gland 
might seem consistent for the 
192
Ir source considering their uncertainties, but not for 
the 
60
Co source. This difference can be explained taking into account that the 
prostate center of mass of the voxelized phantom is almost 1 cm at right from our 
geometrical center, and so it traverses more lung to reach the right salivary gland 
than to reach the left one. In addition, the right lung is more superior than the left 
one due to the presence of the heart, and so the effect is even larger. 
 
2.4 Discussion 
 It is interesting to compare organ equivalent doses that result from different 
radiation modalities (brachytherapy, 3D-conformal radiotherapy, IMRT, and proton 
therapy). There are some studies regarding organ equivalent doses from proton 
therapy applied to prostate. Fontenot et al. (2008) estimated equivalent doses from 
stray radiation, i.e., neutrons and photons generated (either inside or outside the 
body) in a passively scattered proton treatment to radiosensitive organs. The 
prescribed equivalent dose was 75.6 CGE (Cobalt Gray Equivalent), i.e., 68.7 
Gy×1.1 RBE (radiobiological effectiveness of protons), to the clinical treatment 
volume. Simulations were run in the MCNPX code, using an anatomically realistic 
male phantom developed by Billings and Yucker (1973). In their first work, they 
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did not consider absorbed dose from the therapeutic beam, which mainly concerns 
additional absorbed dose to the bladder and rectum. In a follow-up paper (Fontenot 
et al., 2010) they considered primary absorbed dose calculated using a commercial 
treatment planning system applied to three patients. Summing the contributions 
from secondary particles, they obtained total equivalent dose and estimated the 
probability of secondary tumor induction using recommendations by the Biological 
Effects of Ionising Radiation (BEIR) committee (BEIR, 2006). Given that some 
data were not explicitly written in the paper (Fontenot et al., 2010), the authors 
were contacted and kindly provided the needed details. The three patients were of 
different sizes (small, medium, and large). Their medium sized data are compared 
in the current study. In their work, equivalent dose to the colon was obtained as a 
mass-weighted average of the equivalent doses to the colon and rectum: 
total colon colon colon rectum rectumD w D w D    
(2-6) 
where the colon wcolon and rectum wrectum mass weights were 20% and 80%, 
respectively, according to ICRP 89 (2002).  
 On the other hand, Bednarz et al. (2009, 2010) estimated organ equivalent 
doses and risk probabilities from two 3D-CRT (a 4-field box and a 4-field box + 6-
field boost), and a 7-field IMRT treatment applied to the prostate. Absorbed doses 
were estimated through MCNPX using a voxelized male phantom also in agreement 
with the male reference phantom from ICRP Publication 89, and a previously 
validated Varian Clinac 2100C linear accelerator (Bednarz et al., 2009). Their 
results are within an order of magnitude of those obtained by Kry et al. (2005) and 
Howell et al. (2006). Study discrepancies are due in part to the different organ 
locations and methods used to obtain absorbed doses. Organs within the therapeutic 
beam (testes, bladder, skin, and prostate) were not yet considered in those papers 
(Bednarz et al., 2009; Bednarz et al., 2010). However, this was evaluated by 
Fontenot et al. (2009), who considered primary radiation for IMRT to colon, 
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bladder, and testes. Eq. (2-6) was also used to obtain equivalent dose to colon from 
the IMRT treatment. 
 Figure 2-6 shows organ equivalent doses per therapeutic absorbed dose for 
three radiation modalities: brachytherapy, IMRT, and proton therapy, whereas 
numerical data in Table 2-2 also include 3D-CRT. First, HT/DP in organs near the 
prostate (e.g. testes, urinary bladder, and colon) are about a factor of two larger 
when using IMRT than when using proton therapy. A higher amount of beam time 
is needed for IMRT to conform absorbed dose to the prostate. In fact, besides 
results from Fontenot et al. for protons, which are based on a passive scanning 
system, there are other studies by Schneider et al. (2006, 2007) that have shown that 
the probability of secondary cancers could be decreased by a factor of two when 
using spot-scanned proton therapy instead of IMRT. A spot-scanned system 
requires fewer beam conformal elements and results in a lower secondary neutron 
flux than in a passive system. 
 
Figure 2-6. Organ equivalent dose per therapeutic absorbed dose for different 
radiation treatments applied to the prostate: brachytherapy (from this work, with 
60
Co and 
192
Ir), IMRT (Bednarz et al., 2009; Fontenot et al., 2008), and proton 
therapy (Fontenot et al., 2008; Fontenot et al., 2009).  
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Table 2-2. Equivalent dose per therapeutic absorbed dose (HT/DP) for some body 
organs, comparing brachytherapy results from this work in a heterogeneous 
phantom and previously reported data for 3D-CRT (ref. (Bednarz et al., 2009; 
Bednarz et al., 2010)), IMRT (ref. (Fontenot et al., 2008; Bednarz et al., 2009)) and 
protontherapy (Fontenot et al., 2008; Fontenot et al., 2009). Relative uncertainties ε 
(type A for brachytherapy (but for those with ε < 0.05%) and the ones published for 
EBRT) are given in brackets (%) with one decimal unit. 
 
 
 When considering HDR brachytherapy with 
60
Co and 
192
Ir, equivalent doses 
(per prescribed absorbed dose) to organs up to the stomach (around 35 cm from the 
prostate) are the same within an order of magnitude when compared to IMRT and 
proton therapy. This is consistent with results published more recently by Georg et 
al. (2014), who considered the dose distribution in OARs near the prostate for ten 
patients planned with: volumetric modulated arc therapy, intensity-modulated 
proton therapy, intensity-modulated carbon-ion therapy, and LDR and HDR 
brachytherapy. This study showed that, despite the different EBRT prescription and 
 1 
 Organ HT/DP 
(Sv/Gy) 
 Organ name 
60
Co 
192
Ir Box+boost IMRT Protons 
 Bladder 1.30x10
-1
 (0.1) 1.60x10
-1
 (0.1) -  2.57x10
-1
  1.87x10
-1
 (14.5) 
 Rectum 1.51x10
-1
 (0.1) 1.83x10
-1
 (0.1) -  3.65x10
-1
  2.75x10
-1
 (3.4) 
 Testes 2.51x10
-2
 (0.3) 2.94x10
-2
 (0.3) -  1.26x10
-2
  7.60x10
-3
  
 Small intestine 9.24x10
-3
 (0.1) 1.05x10
-2
 (0.1) 2.36x10
-2
 (0.4) 1.16x10
-2
 (0.8) -  
 Colon 6.21x10
-3
 (0.1) 6.78x10
-3
 (0.1) 9.07x10
-3
 (1.4) 6.01x10
-3
 (3.2) 7.80x10
-3
  
 Kidneys 1.75x10
-3
 (0.3) 1.40x10
-3
 (0.3) 5.88x10
-3
 (2.3) 3.14x10
-3
 (3.7) -  
 Pancreas 1.53x10
-3
 (0.3) 1.21x10
-3
 (0.4) 3.43x10
-3
 (3.8) 2.27x10
-3
 (3.5) -  
 Gall bladder 1.26x10
-3
 (1.0) 9.33x10
-4
 (1.3) 3.02x10
-3
 (3.4) 2.55x10
-3
 (2.5)  -  
 Stomach 9.50x10
-4
 (0.5) 6.40x10
-4
 (0.4) 3.50x10
-3
 (1.5) 2.87x10
-3
 (2.9) 3.40x10
-3
  
 Liver 8.88x10
-4
 (0.1) 5.88x10
-4
 (0.2) 3.68x10
-3
 (1.1) 2.65x10
-3
 (2.0) 3.40x10
-3
  
 Spleen 7.15x10
-4
 (0.6) 4.32x10
-4
 (0.3) 4.15x10
-3
 (2.3) 2.33x10
-3
 (3.6)  -  
 Heart 3.97x10
-4
 (0.2) 2.08x10
-4
 (0.3) 2.14x10
-3
 (2.0) 1.95x10
-3
 (3.6)  -  
 Lungs 3.37x10
-4
 (0.4) 1.60x10
-4
 (0.4) 2.76x10
-3
 (1.5) 1.57x10
-3
 (2.0) 2.50x10
-3
  
 Oesophagus 3.01x10
-4
 (1.8) 1.55x10
-4
 (1.9) 1.60x10
-3
 (10.4) 9.75x10
-4
 (3.2) 1.90x10
-3
  
 Thyroid 1.04x10
-4
 (3.7) 3.46x10
-5
 (4.6) 2.12x10
-3
 (17.5) 8.67x10
-4
 (10.8) 1.90x10
-3
  
 Brain 2.08x10
-5
 (1.1) 4.17x10
-6
 (2.0) 1.21x10
-3
 (2.4) 6.50x10
-4
 (3.6)  -  
 Active bone marrow 1.26x10
-2
 - 1.62x10
-2
 - 2.28x10
-3
 (1.9) 2.00x10
-3
 (4.3) 6.40x10
-3
  
 Skin 3.21x10
-3
 - 3.23x10
-3
 (0.1)  -  -   6.40x10
-3
  
 2 
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fractionation schemes, the high-dose regions of bladder wall and rectal wall were on 
the same order of magnitude for all radiation modalities, and that BT were clearly 
superior in terms of bladder wall, rectal wall, and normal tissue sparing, with better 
values for HDR-BT. 
 The high doses to organs near the prostate dominate in the calculation of 
effective doses from the different radiation modalities. Results from Table 2-2 
provide an effective dose of 12 mSv/CGE for proton therapy and 13 mSv/Gy for 
IMRT, similar to 11.1 mSv/Gy and 13.2 mSv/Gy obtained for both brachytherapy 
sources. Nevertheless, in the previous figure, only stray radiation is considered for 
the testes when using IMRT, and so real equivalent dose there is expected to be 
higher. For all these near organs, there might be variations between patients within 
an order of magnitude. As an example, Fontenot et al. (2009) estimates an 
HT/DP=0.07 Sv/Gy for the colon when using IMRT, a factor ten higher from what it 
is shown here. In addition, estimation done by Fontenot et al. of equivalent doses to 
skin and bone marrow, which contributes considerably to effective dose, are 
average values from equivalent dose in the other organs they considered. 
Furthermore, in our study equivalent dose to bone marrow was overestimated, as 
explained above, although equivalent doses to rectum and bladder might be under 
estimated. As a result, effective doses per therapeutic absorbed dose might be 
similar between all radiation modalities considered in this comparison. These 
results are estimations for the considered cases and exact conclusions for the nearest 
organs are patient and equipment dependent.  
 For the furthest organs, this study has shown that equivalent doses were 
approximately the same (within an order of magnitude) throughout the whole body 
(see Figure 2-6) for 3D-CRT, proton therapy, and IMRT. For these three 
modalities, although equivalent doses were smaller for larger distances, given a 
smaller contribution from scattering radiation, they were within the same order of 
magnitude. This was not the case when using brachytherapy. As the distance 
increased, equivalent dose decreased rapidly, going from approximately 1 mSv/Gy 
in the stomach to 10 μSv/Gy in the brain. For the furthest organs, equivalent doses 
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given by brachytherapy are between one and two orders of magnitude smaller to 
those delivered by other radiation modalities. This gives brachytherapy a clear 
advantage if, for a given prostate absorbed dose, equivalent dose for distant organs 
needs to be minimized. 
 HDR monotherapy has been shown to be an excellent treatment modality for 
prostate carcinoma, although there seems to be no consensus on the optimal dose 
and fractionation schedule for this radiation technique (Demanes et al., 2014). The 
longest follow-up for outcomes is with moderate-hypofractionation (4 to 9 
fractions), although excellent results are also being reported with ultra-
hypofractionation (1 to 3 fractions). Based on a recent literature review performed 
by Demanes and Ghilezan (2014), one of the most extended protocols for HDR 
monotherapy is based on 4 fractions, with 9.5 Gy per fraction, thus totaling 38 Gy. 
Considering this prescribed dose, beyond roughly 25 cm, i.e., beyond the colon, all 
organs absorb doses below 100 mSv after the complete BT treatment. Therefore, 
most of the organs of the patients are exposed to low radiation doses. 
 In this work, probabilities for secondary cancer induction have not been 
estimated given the low equivalent doses received by organs far from the prostate 
and given the dose-risk model uncertainties in this dose range (Hall et al., 2004; 
Candela-Juan et al., 2014). This will be discussed in more detail in Chapter 3.  
 Although this work provides results concerning radiation protection 
applications in radiotherapy, the presented conclusions are based on certain 
assumptions. First, the point source was placed in the prostate center. Although it 
was corrected from empirical clinical data (nomogram) to account for a clinical 
source with varying dwell positions within the prostate, the source would be closer 
to an OAR at some positions and would cause some discrepancies with results 
presented herein for the nearest organs. This variation, however, is lower than an 
order of magnitude and would only apply to the nearest organs, being negligible for 
the rest, beyond roughly 10 cm. The aim of this work was to provide a general 
organ equivalent dose database for this particular treatment, comparing 
60
Co and 
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192
Ir sources in the same circumstances, bearing in mind that equivalent dose to the 
closest organs is patient and facility dependent, and so general values for these 
tissues cannot be established. Hence, the first assumption was not a limitation of the 
proposed aim. Second, the different radiation treatments have been compared 
according to equivalent dose per therapeutic absorbed dose. It has not been taken 
into account that the therapeutic course is generally given in several fractions to 
take advantage of biological effects like cell repair. The hypothesis made is that cell 
damage is proportional to overall absorbed dose, without considering some 
biological effects which are dependent on parameters that could be modality 
dependent. If this hypothesis is correct, then this work shows an advantage of 
brachytherapy in comparison to IMRT and proton therapy when considering 
equivalent doses to the farthest organs. If not, a biological model should be 
included. However, given that several possible fractionating plans can be applied 
for the different radiation treatments, with different total prostate absorbed dose in 
each case, no general conclusions can be extracted. As stated above, comparison 
herein between the different radiation modalities cannot be considered as 
representative of all particular cases. Next, when comparing 
60
Co and 
192
Ir sources, 
the same amount of absorbed dose was assumed in both cases to produce the same 
biological effects, i.e., dependence of biological effects was assumed to be 
independent of source energy. A more precise estimation would account for 
radiobiological effectiveness (it was considered as unity in this work) as a function 
of energy (Reniers et al., 2008). However, this is expected to be a proportionately 
small correction for these high energy sources that would not change the overall 
findings. Therefore, after all these considerations, data presented in Table 2-1 can 
be considered as representative equivalent doses received by a patient with a body 
height similar to the reference male phantom, considering however a 30 cm
3
 
prostate instead of 16.5 cm
3
, the latter corresponding to the prostate size of the 
reference male phantom, which has many variations among people and age. 
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2.5 Conclusions 
 A database of organ equivalent doses when applying HDR brachytherapy to 
the prostate with either 
60
Co or 
192
Ir is provided. Making only physical 
considerations, 
192
Ir seems to be a better choice than 
60
Co when considering damage 
to distant organs, which have to be also considered because of their radiosensitivity, 
but not to the farthest ones, which are the ones which receive a considerably higher 
equivalent dose.  
 Up to around 30 cm, organ variations due to differences between water and 
soft tissue are negligible. However, for larger distances this is not the case. More 
variations with an infinite water medium are due to the lack of back-scattering after 
the skin, which depends on organ positions. Both effects together make that an 
infinite water volume can be used to obtain organ absorbed doses all over the body 
considering, however, a higher uncertainty. The latter will be discussed in more 
detail in Chapter 4. Finally, the radiation treatment (considering HDR 
brachytherapy, IMRT, and proton therapy) to be used if considering organ 
equivalent doses are patient, treatment, and facility dependent. In any case, as the 
distance increases, brachytherapy shows a radiation protection advantage over all 
EBRT techniques. 
 Chapter 3. TUMOR INDUCTION BY 
RADIATION DOSES 
 
 
 
Most of the content of this chapter was published in the review paper: 
Candela-Juan C, Montoro A, Ruiz-Martínez E, Villaescusa JI, Martí-Bonmatí L. 
Current knowledge on tumour induction by Computed Tomography should be used 
carefully. European Radiology. 24: 649-656 (2014).  
Kind permission was granted by the journal to reprint this article as a chapter of this 
dissertation. 
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3.1 Introduction 
 Data on population radiation exposure and advances in the field of 
radiobiology showed that ionizing radiation could be associated to secondary risks 
for an individual subject (ICRP, 2007). In particular, cell damage may give place to 
genetic mutations and even the induction of a tumor.  
 The dose–effect curve represents the likelihood of inducing a tumor as a 
function of organ-equivalent dose or effective dose. Graphically, three main areas 
can be identified in this dose–effect curve (Hall et al., 2004). In the central zone 
(between around 0.1 Sv and 2.5 Sv) there seems to be a clear linear relationship in 
which, as the effective dose increases so does the probability of tumor induction, 
which has been confirmed by numerous studies (Xu et al., 2008). In particular, the 
Life Span Study of the Japanese atomic bomb survivors of Hiroshima and Nagasaki 
was the first large enough group used to conduct an epidemiological dose 
relationship, being the clearest evidence of the linear relationship at intermediate 
doses. Part of the Japanese population was exposed to this dose range, generally 
uniform throughout the body and involving different types of radiation particles 
such as neutrons, alpha particles, and gamma rays.  
 However, uncertainties in the dose–effect curve do exist at the high and low 
extreme doses. At high organ equivalent doses (>2.5 Sv), radiation induced cell 
sterilization, cell repopulation, and proliferation may cause a deviation from a linear 
dose response (Nguyen et al., 2015). Several studies show that the higher 
probability of cell death decreases the possibility of inducing a tumor in comparison 
with the linear extrapolation, although the rate of decline appears to vary between 
different published data (Hall et al., 2004). Most of the second cancers from 
radiation therapy appear within the volume irradiated by the primary radiation field 
(Nguyen et al., 2015), i.e., at high radiation doses. While Boice et al. (1985) 
estimated that 43% of second cancers are developed near the primary field, Dorr 
and Herrmann (2002) increased this percentage to between 60% and 90%. This 
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chapter reviews recent estimates of cancer induction from high radiation doses, and 
their associated uncertainties. 
 On the other part, at low radiation doses (less than 0.1 Sv) different models 
have been proposed and observed, as summarized in Figure 3-1. One of them is the 
adaptive response (curve a), in which there is a threshold dose below which no extra 
risk exists (NCRP, 2001; UNSCEAR, 1994). Uncertainties in past epidemiological 
data of irradiation exposures within the diagnostic dose range did not rule out a 
possible threshold dose, which might be within the range of 10 to 60 mSv (Pierce et 
al., 2000; Hall et al., 2004; Pauwels et al., 2011). Even more, some researchers 
have indicated that very low doses may produce hormesis (Cuttler et al., 2009), i.e. 
they stimulate our immunological system such that they inhibit effects of higher 
doses later received (curve b). This effect has also been questioned (Wall et al., 
2006). Other experiments have shown the so-called bystander effect, in which not 
only the irradiated cells are affected but also others near them, hence increasing the 
probability of cancer induction (curve c). Based on theoretical studies, the bystander 
effect is also predicted to be present at higher doses (Nikjoo et al., 2003; 
Rzeszowska-Wolny et al., 2009). Finally, because of its simplicity, reasonability, 
and conservative approach, international committees such as the ICRP and the 
NCRP, among others, recommended extrapolating the linear relationship to the 
lowest dose range (curve d in Figure 3-1). The latter term is known as the linear no-
threshold (LNT) model and its assumption implies that even the least amount of 
absorbed dose can lead to an induced tumor or, put in another way, a radiation-
induced tumor may develop from a single hit to a single cell (microdosimetric 
argument (Rossi et al., 1972; Brenner et al., 2006). Brenner and Sachs (2006) 
argued that, if the action in a single cell dominates over intercellular effects, then 
the linear model is appropriate. However, the microdosimetric argument has also 
been criticized (Tubiana, 2005; Tubiana et al., 2006). 
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Figure 3-1. Schematic representation of different possible models of radiation-
induced cancers at low radiation doses: a) adaptive response with threshold dose, 
b) hormesis, c) bystander effect and d) linear-no threshold. The horizontal line 
expresses no over or under risk. Data points and their 95% confidence intervals 
correspond to the relative risks of brain tumour induction as a function of brain 
dose, taken from recent epidemiological studies with paediatric CTs performed in 
the UK (Pearce et al., 2012) (in blue) and Australia (Mathews et al., 2013) (in red), 
considering a 5-year exclusion period. 
 
 Chapter 2 has shown that most of the organs exposed during a 
brachytherapy treatment receive low radiation doses (< 0.1 Sv). For this reason, and 
because diagnostic medical exposures, which contribute significantly to the overall 
collective dose, give doses to patients within this low dose range, we will focus a 
notable part of this chapter to risks due to radiation exposures which imply less than 
0.1 Sv. Current knowledge on the probability that such absorbed doses can induce 
tumor is under discussion among the scientific community. This chapter reviews the 
methods used in the literature to estimate the likelihood that low radiation doses 
induce cancer and summarizes the current quantitative estimates. It is also intended 
to highlight their main sources of uncertainty. Based on all information reported, it 
is discussed whether the linear model that relates probability of cancer induction 
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and dose can be considered to be validated. Finally, some recommendations about 
the appropriate use of current knowledge on this topic are stated.  
  
3.2 Factors that affect the probability of cancer induction 
 Although the probability that ionizing radiation may induce a tumor has been 
shown to be dose-dependent (see Figure 3-1), there are some other factors that also 
affect the “intensity” of the dose–effect curve:   
1) Different biological effects appear when the same amount of energy is either 
deposited in several fractions or continuously during a long or short period of time. 
In order to take this into account, the dose and dose–rate reduction factor (DDREF) 
were defined. International committees recommended extrapolation of known data 
at intermediate doses (and with a high-dose-rate irradiation) to the low-dose range 
by dividing the linear estimations by a DDREF within the range of 1.1–2.3 (BEIR, 
2006).  
2) Different organs/tissues have different sensitivity to ionizing radiation. Hence, 
the probability of inducing a tumor is dependent on the organs that are irradiated. 
As a quantitative example, for a male patient receiving a single dose of 0.1 Sv to the 
colon and the liver, the lifetime attributable risk (LAR) of cancer incidence 
(probability that an individual develops a cancer because of the exposure) is 0.125% 
and 0.022%, respectively (BEIR, 2006). It is reasonable to think that this organ-
dependency can be extrapolated to an even lower dose. 
3) The gender of the irradiated person has also been observed to influence the 
“intensity” of the dose–effect curve. The male to female LAR ratio depends on each 
specific organ and ranges between around 0.2 (female more sensitive in the case of 
the thyroid) and 2.2 (male more sensitive in the case of the liver) (BEIR, 2006).  
4) Significant variations are also associated with age at exposure. Particularly, 
children have been a group considered to be of greatest concern. First, they are 
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more radiosensitive than adults (Pierce et al., 1996; Brenner, 2002) as they have a 
higher fraction of cells in full division processes where genetic changes may lead to 
tumor induction. Second, they will have more time to express any stochastic effect 
in relation to older persons. The excess relative risk (ERR) of cancer incidence (rate 
of disease in an exposed population divided by the rate of disease in an unexposed 
population minus 1) after 40 years of a 1 Sv exposure is around a factor of 3 higher 
when the age at exposure is 10 compared with a person older than 30 years-old 
(BEIR, 2006). The ERR ratio progressively increases as the age at exposure 
decreases. A variation of cancer induction with age at exposure is also expected in 
the low dose range used in medical imaging.  
5) As in a brachytherapy treatment, medical imaging examinations involve a 
heterogeneous dose distribution. Differences of a factor of 2 between the mean and 
maximum dose received by the lung in chest computed tomography (CT) 
examination have been reported using Monte Carlo methods (Samei et al., 2013). 
This underscores the need for a systematic study with a risk model that takes into 
account dose heterogeneities in the excess relative risk and whether the mean or 
maximum dose value should be used. 
6) Finally, given that many cancers have different baseline risks in different 
countries, it might be possible that the ERR is also dependent on environmental or 
sociological factors, and so data from the Japanese population cannot be 
extrapolated worldwide (BEIR, 2006). 
 
3.3 Estimation of cancer risk at high radiation doses 
 In general, two different procedures are being used nowadays to estimate the 
probability that a given radiation exposure in excess of 2.5 Gy may induce a tumor: 
phenomenological risk models and epidemiological studies. 
 Phenomenological risk models based on fitting parameters have been applied 
to estimate the risk of inducing a tumor in organs inside the primary radiation field, 
Chapter 3 
_____________________________________________________________________________________________________________________________________________ 
38  
i.e., at doses in excess of 2.5 Gy. Recent studies have applied a model developed by 
Schneider (2009), which is based on the linear-quadratic formula, to estimate the 
outcome of different treatment modalities (Nguyen et al., 2015). Linear, linear-
exponential and plateau models have been also used (Abo-Madyan et al., 2014). As 
an example, Paganetti et al. (2012) evaluated the dose distribution to OARs located 
inside the primary radiation field, for pediatric phantoms planned to be irradiated 
with IMRT and proton therapy. LARs were then evaluated using risk models, and it 
was found to be up to 2.7% for a 4 year old optic glioma patient treated with IMRT, 
decreasing a factor of 2 for a 14 year old patient. In all cases considered in that 
study, the estimated risk from proton therapy was up to a factor of 10 lower. Similar 
results have been published in other studies (Moteabbed et al., 2014). A review 
study by Xu et al. (2008) showed that the cumulative risk for the development of 
second cancers has been estimated as ranging from 5% to 12% over a 25 year 
follow-up interval, although there exists a high dispersion of data. 
 The model parameters have been determined with limited data and, therefore, 
uncertainties will limit the model predictions. Nguyen et al. (2015) have recently 
estimated that the uncertainties associated with model predictions are higher than 
100%. This is a lower limit to the overall uncertainty because the uncertainty 
introduced by different fractionations was not considered, neither the uncertainty in 
dose delivered to OAR. As concluded in this uncertainty study, the large magnitude 
of the uncertainty implies that, currently, it might not be feasible to reliably predict 
cancer risks based on treatment plan information and phenomenological risk 
models. 
 On the other hand, many epidemiological studies have been also performed 
on second cancer induction after radiation therapy. However, they focused on a 
typically narrow dose range, making the transfer of the reported risk to other doses 
difficult (Nguyen et al., 2015). 
 In relation with Chapter 2, Murray et al. (2014) have recently performed a 
literature review on second primary cancers after radiation for prostate cancer. It 
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was concluded that the risk was below 0.5% over all durations of follow-up when 
considering older radiation techniques. About more modern RT techniques such as 
HDR BT, it was faced that there are not enough clinical data to extract firm 
conclusions. Limited evidence is encouraging as no excess risks have been found, 
although it may be likely that long follow-up might show a small increase. 
 
3.4 Estimation of cancer risk at low radiation doses 
 Two methodological procedures are being used nowadays to estimate the 
probability that a given radiation exposure may induce a tumor: a) risk coefficients 
that linearly relate equivalent dose to probability of tumor induction, and b) 
epidemiological data assessing the ratio of tumor incidence between population 
exposed and unexposed to ionizing radiation.  
3.4.1 Risk coefficients 
 Radiation risk models have been developed in the last decade by 
international bodies such as the BEIR VII committee (BEIR, 2006). They are 
extrapolations of the LNT model for all doses lower than 2.5 Sv, based on data from 
the atomic bomb survivors and other medical studies in animals and in vitro. This 
committee provides for several organs the risk coefficients for estimating lifetime 
risks of cancer incidence and mortality, which depend on the dose rate, gender and 
age of the exposed person. If multiplied by the organ-equivalent dose, these 
coefficients provide the probability of cancer induction. Of relevance, risk 
estimations based on effective doses are clearly obsolete (Brenner et al., 2008; 
HPA, 2011; Calandrino et al., 2012; Ivanov et al., 2012; Ivanov et al., 2013). 
Effective dose is the sum of organ equivalent doses weighted by tissue-specific 
factors (ICRP, 2007). These age-independent factors are based on a subjective mix 
of different endpoints of cancer mortality and incidence, life shortening, and 
hereditary risk. In addition, those endpoints have different significant age 
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dependencies not considered by the weighting factors and, thus, effective dose has 
high associated uncertainties when applied to a specific patient different than the 
reference male or female phantoms (Martin, 2007).  
 Other international organizations that review radiation risks are the United 
Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), the 
NCRP, and the ICRP (ICRP, 2007). Risks from CTs were already estimated in 
children through risk coefficients more than a decade ago (Brenner et al., 2001), 
and are still used nowadays with the same aim (Berrington et al., 2012; Perisinakis 
et al., 2012; Miglioretti et al., 2013). The BEIR VII model has been also applied to 
estimate cancer risks from radiotherapy. Bednarz et al. (2010) used the linear 
relationship to estimate the risk of second primary cancer in out-of-field organs 
receiving less than 0.1 Sv after 3D-CRT and IMRT applied to the prostate. They 
concluded that the probabilities for secondary cancer induction for the considered 
organs were about an order of magnitude lower than the baseline risks for those 
organs. On another study, Mazonaquis et al. (2014) evaluated through MC 
simulations the radiation dose to all organs that were out of the primary beam of a 
testicular seminoma treatment, and used gender- and organ-specific risk coefficients 
to estimate the risk of second primary cancer induction. It was concluded that the 
lifetime intrinsic risk of developing thyroid, lung, bladder, prostate, and esophageal 
cancer was increased by (0.1-1.4)%, (0.4-1.1)%, (2.5-5.4)%, (0.2-0.4)%, and (6.4-
9.2)%, respectively, depending upon the patient age at exposure and the field size 
employed. For the other organs considered the increased risk was nearly negligible. 
Similar studies were performed by Berris et al. (2014) and by Kourinou et al. 
(2013) considering the treatment of heterotopic ossification and head and neck 
lesions, respectively.  
 As noted by Fletcher et al. (2013), it can be concluded from the BEIR VII 
report that the available evidence for the use of the LNT model at low radiation 
doses has not been statistically significantly better for predicting cancer than other 
methods based on a threshold dose owing to high background incidence cases 
(ICRP, 2007; Wall et al., 2006). Even international committees were critical with 
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their own coefficients and pointed out several sources of uncertainty related to: 
limitations in the epidemiological data; extrapolating the data to low doses and dose 
rates (appropriate choice of DDREF); and transporting results from Japanese 
survivors to any other country (BEIR, 2006). Of importance, there are large and 
clear differences between atomic bomb survivors and people exposed to 
radiotherapy treatments. The first ones were exposed to a uniform radiation dosage 
throughout the whole body, with several types of radiation particles (including 
neutrons), whereas patients exposed to brachytherapy receive a heterogeneous and 
lower dose throughout most of his body. Thus, current methods used to estimate 
probabilities within the low dose range may be scientifically questionable (Pauwels 
et al., 2011). This is why the Health Physics Society recommended that, below 
effective doses of 50 mSv, no quantitative estimations of health risks should be 
made with risk coefficients (HPS, 2004; Fletcher et al., 2013). 
3.4.2 Recent epidemiological data 
 Computed tomography (CT), which was invented in 1972, makes nowadays 
the biggest contribution to the collective dose (being from 46% up to 80% (Aroua et 
al., 2013)) of a population exposed to x-rays imaging techniques. Typical median 
effective doses from CT examinations are 1.2 mSv for a head CT, 4.1 mSv for a 
chest CT and 7.7 mSv for an abdominal CT (Teeuwisse et al., 2007), although 
variations within the same order of magnitude might be found between different x-
ray acquisition techniques and equipment models. Thus, CT exposure provides the 
most complete database that can be used to relate cancer induction and organ 
equivalent dose at low radiation doses, and so it was been analyzed in detail in this 
chapter. 
 Two independent epidemiological studies that used data from a large sample 
of children exposed to CT have recently been published. The first one was 
conducted in the United Kingdom by Pearce and colleagues (Pearce et al., 2012; 
Kim et al., 2012), taking data from nearly 180,000 teenagers under age 22 at the 
time of the examination (between 1985 and 2002). Doses to brain and red bone 
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marrow were roughly estimated with typical x-ray acquisition techniques combined 
with MC simulations. In addition, given that up to 2001 protocols used for children 
were usually the same than for adults, the authors of the study considered that 
before that year the dose children received was approximately 2–3 times higher. 
Exclusion periods of 2 years for leukemia and 5 years for brain tumor were 
considered, meaning that cancers diagnosed up to that exclusion period since the 
CT was undertaken were considered not to be due to the CT. Results suggest a LNT 
relationship between the absorbed dose in the brain (see Figure 3-1) or bone 
marrow, and the probability of inducing a brain tumor or leukemia, respectively. 
These are the two types of tumors that are expected to appear earlier in irradiated 
children, given the higher sensitivity of bone marrow and brain (UNSCEAR, 2010).  
 From the previous epidemiological study, it was concluded that for children 
in their first decade of life one brain tumor and one case of leukemia would be 
induced every 10,000 CTs with a dose close to 10 mSv per CT in the first decade 
after the study (Pearce et al., 2012). Even more, 10 years after the CT exposure, 
30% and 90% of final cases of leukemia and brain tumor, respectively, have yet not 
appeared (Ron et al., 1988; Preston et al., 1994). Therefore, the risk of inducing 
leukemia over a lifetime is 1 in every 7500 CTs in children explored in their first 
decade of life, and to infer a brain tumor is 1 per 1,000 CTs (Brenner et al., 2012b). 
These values, from epidemiological studies, are roughly similar in magnitude to 
those inferred (Brenner et al., 2001) from a linear extrapolation of the LNT model. 
 On the other hand, the most recent and massive study conducted in Australia 
by Mathews and colleagues (Mathews et al., 2013) evaluated the cancer incidence 
in over 680,000 young people (0 to 19 years) exposed to CT and compared with the 
baseline risk for the same age range of a cohort of over 10 million unexposed 
persons. Radiation exposures were carried out between 1985 and 2005, and exposed 
children were followed for at least 10 years, up to 2007. In this case, not only 
leukemia and brain tumors were considered, but also all other solid tumors. 
Average effective doses and average organ absorbed doses were estimated for each 
CT category, each site and year of CT, and each age. As in the previous study by 
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Pearce et al, doses before 2001 were rescaled. The Australian epidemiological study 
detected an increase in cancer incidence of 24% in young people exposed to a 
single CT, considering a 1-year exclusion period. If the exclusion period is 
considered to be 5 years, the increase would be 21%. Average effective doses of 
around 4.5 mSv were considered. If, instead, 2 mSv are given (as usually happens 
with current equipment and imaging techniques), 1 excess cancer per 4000 head 
CTs would be radiation-induced (Sodickson, 2013). This study “generally” supports 
the linear-no-threshold dose-response model, and roughly matches attributable risks 
predicted by the BEIR report (BEIR, 2006) and by the epidemiological study by 
Pearce et al. (2012) (see Figure 3-1).  
 
3.4.3 Analysis of the situation 
 Epidemiological data taken by Pearce and colleagues in the United Kingdom 
and, more recently, by Mathews and colleagues in Australia, constitute important 
steps in the difficult path of modeling the development of radiation-induced tumors 
at low doses. It is important to note that results from cancer risk coefficients (with 
high uncertainties already discussed earlier) and from both studies roughly agree for 
pediatric patients. Can we then consider the linear model at low radiation doses to 
be validated with no threshold dose? Some authors have answered yes (Brenner et 
al., 2012b), but precautions should be taken given the following arguments:  
1) Acquisition protocols and, consequently, doses assigned to individual 
exposures were estimations based on national surveys, but did not consider the 
exact techniques used in different hospitals from which data were taken, neither 
physical constitution of each patient. The Smith–Bindman group (2009) found a 
mean 13-fold variation between the highest and lowest dose given by different 
hospitals that performed the same study. In addition, no registries of repeated 
exposures exist for the people considered in the recent epidemiological studies 
(Mathews et al., 2013), which also increase uncertainty in dose estimation. The low 
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magnitude of cancer induction makes necessary a more accurate evaluation of organ 
doses, which is still lacked. Guidance for developing a harmonized system that 
allows intercomparability has been provided (ECRP, 2008) and the capture of 
patient-specific dosimetry in future epidemiological studies will surely improve the 
validation of the model (Sodickson, 2013; Smith-Bindman et al., 2009). With this 
aim, the IAEA launched in 2006 a Smart Card project, which would allow personal 
recording of all expositions to ionizing radiation in medical imaging (Rehani et al., 
2009; 2011). 
2) It is difficult to know whether a tumor has been radiation-induced or, on the 
contrary, the CT was performed because there already was a suspicion of its 
presence. If the second option applies, at least partially, risk estimations from 
epidemiological studies would be reduced (Pearce et al., 2012; Mathews et al., 
2013), although reverse causation cannot explain all the cancer excess observed 
(Sodickson, 2013). The appropriate choice of the exclusion period might be 
considered as an intrinsic uncertainty of epidemiological studies on this difficult 
task. 
3) Relative uncertainties in the risks derived from the epidemiological studies 
are still large (statistical uncertainty) (see Figure 3-1), making feasible other 
adjustments of the values aside from the linear fitting (AAPM, 2013).  
 Thus, there are several biases that make us to be cautious before definitely 
accepting the LNT model within the CT dose-range. Independently of the last two 
arguments, the linear fit has been shown to be preferable according to a statistical 
analysis of the epidemiological data (Mathews et al., 2013). However, as far as we 
know, it has not been studied how the high dose uncertainty in each individual 
patient may influence this analysis. 
 Also, a deep literature review of studies concerning radiation therapy and 
cancer risks for organs receiving low radiation doses was published by Xu et al. 
(2008). It was concluded that many of the past dosimetry studies were based on 
inconsistent and sometimes confusing dose quantities. Thus, a systematic dosimetry 
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methodology for quantifying secondary organ absorbed doses needs to be 
developed in the future based on MC simulations.  
 If current estimations of radiation-induced tumors by medical imaging 
exposures are correct, should they really be a concern? The probability of inducing 
a brain tumor after a single 10 mSv exposure has been estimated to be ~0.1%, 
which is clearly within the background level produced by environmental and 
physiological aspects (Fletcher et al., 2013). As an example, in some situations the 
increase in cancer risk due to a higher concentration of radioactive radon is 
estimated to be 0.3%. If all cancer types and CT protocols were considered, a single 
CT in children would increase their baseline risk probability (~0.2% in children up 
to 14 years old (Stiller, 2007)) by around 20% according to the latest 
epidemiological study. This relative number may seem large, but it has to be noted 
that the baseline incidence of cancer in children and teenagers is very small, and so 
this increase just makes it slightly less small (Sodickson, 2013). In addition, doses 
are continuously reduced and they can now be up to 2–5 times lower than those 
considered in the epidemiological studies (AAPM, 2012). In adults, who represent 
the largest proportion of patients with CT examinations, the probability of inducing 
a tumor is even smaller. Thus, data provided in this work corresponds to the worst 
scenario in medical imaging. 
 Based on the reviewed information of this work, some recommendations 
may be useful for CT examinations (some of these may be applied to brachytherapy 
treatments as well), as stated by different authors: 
1) Prediction of the absolute number of tumors that will be induced in a large 
amount of the population exposed to ionizing radiation should be avoided as it 
would have a great and unknown absolute uncertainty (UNSCEAR, 2012). In 
addition, it has been estimated that about 10% of the total effective dose given in 
medical imaging is received by cancer patients (Brix et al., 2009), who have a 
reduced life expectancy. Therefore, a considerable fraction of the dose is ineffective 
from a radiobiological point of view (Eschner et al., 2010). 
Chapter 3 
_____________________________________________________________________________________________________________________________________________ 
46  
2) Always reemphasize the great benefits that a CT examination or a brachytherapy 
treatment may provide to an individual patient in personalized medicine (AAPM, 
2012). In a quite timely fashion, the International Organization for Medical Physics 
states that predictions of radiation-induced cancers should be accompanied by 
estimates of reductions in mortality and patient morbidity (Hendee, 2013). 
3) For CTs, because the estimated cancer risks are near the background level, no 
attempts at reducing the radiation dose should be made if image quality is likely to 
be reduced to a point where accurate diagnosis is compromised or not performing a 
CT examination if its information may be relevant for the patient’s condition 
(Eisenberg et al., 2012).  
4) The scientific and popular press has to avoid exploiting the sensational nature of 
this topic without a critical analysis (Hendee et al., 2012), and medical specialists 
should be careful and not worry patients at the time of the exposure. Appropriate 
information should be given to patients to improve autonomy (Recchia et al., 2013).  
5) Despite the extremely low magnitude of the risk, the increased incidence could 
be real according to the latest epidemiological studies. Pediatric CT protocols 
should be always standardized and acquired with dose reduction algorithms. The As 
Low As Reasonably Achievable (ALARA) principle must be considered when 
performing a CT examination and radiologists should understand dosimetric 
magnitudes (Durand et al., 2012) and be consistent when approving a CT 
examination (Pandharipande et al., 2013). It has been shown that around 30% of all 
CT examinations conducted on patients younger than 35 years were not properly 
justified, being unnecessary or replaceable by other imaging procedures like 
magnetic resonance imaging (Oikarinen et al., 2009). In another study of Brenner, it 
was estimated that 20 to 40% of CT scans could have been avoided if decision 
guidelines for mild traumatic brain injury were followed (Brenner et al., 2012a).  
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3.5 Conclusions 
 Several estimations of the probability that high and low radiation doses 
induce cancer have been made in the past, either through risk models and fitting 
parameters or through epidemiological studies. The uncertainties associated with 
model predictions at radiation doses above 2.5 Sv are higher than 100%, and it 
might not be feasible to reliably predict cancer risks based on treatment plan 
information. For the low dose range (<0.1 Sv), recent epidemiological studies 
undergone in United Kingdom and Australia are roughly consistent with each other 
and with risk coefficients. Some authors have considered this to be the ultimate 
prove of the validity of the LNT model at low radiation doses. However, because of 
some dosimetric uncertainties and the proximity of the risk estimates to the 
background level, we should still be cautious and wait for possible incoming new 
results, with even higher and more accurate data. The latter is addressed in more 
detail in Chapter 4. Estimated risks of a low radiation exposure, if existent, are 
very low even for pediatric patients.  
 Therefore, based on many reviewed papers on this topic, several 
recommendations may be synthesized. Prediction of the number of tumors that will 
be induced in population exposed to ionizing radiation should be avoided or, if 
given, it should be accompanied by a realistic evaluation of its uncertainty and of 
the advantages of the medical exposures. Otherwise they may be used 
inappropriately and have a negative impact. For the particular case of CTs, it is not 
justified that society panics, neither the medical or scientific community has to 
obsess on reducing doses even more if that compromises clinical image quality, as 
long as we are all consistent with ALARA’s principle. 
 Chapter 4. DOSIMETRIC 
CHARACTERIZATION OF 226RA SOURCES 
 
 
 
Most of the content of this chapter is included in the original research paper: 
Candela-Juan C, Karlsson M, Lundell M, Ballester F, Carlsson Tedgren A. 
Dosimetric characterization of two radium sources for retrospective dosimetry 
studies. (Under review by Medical Physics)  
Kind permission was granted by the journal to reprint this article (if accepted) as a 
chapter of this dissertation. 
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4.1 Introduction 
 From the discovery of radium in the late 19th century and well into the 20th 
century, 
226
Ra was the most used radionuclide for brachytherapy (Gerbaulet et al., 
1998; Williamson, 2006). Radium pioneers investigated the therapeutic use of this 
radionuclide in numerous diseases, with various clinical outcomes and sometimes 
leading to tissue necrosis or infections due to overdosage (Dutreix et al., 1998). The 
source filtration with gold or platinum improved radium therapy by effectively 
stopping the β-rays and low-energy photons, preventing tissue complications 
(Aronowitz, 2002). When radium became more accessible, methodologies were 
developed that propagated the spread of radium therapy. Radium sources for 
brachytherapy have been reported in many different models, often as tubes or 
needles, containing 0.5 to 20 mg of radium and filtrated with 0.5 to 2.0 mm of Pt 
(with possible addition of silver or gold) (Fitzwilliams, 1930; Smocovitis, 1966). In 
general, the tubes were wider and longer than needles.  
 The use of radium was associated with radiation protection problems due to 
the relative high-energy photons emitted (mean energy approximately 800 keV). In 
addition, helium and 
222
Rn produced by α-decay increased the pressure in the sealed 
sources, eventually leading to gaseous 
222
Rn-leaks (Villforth, 1964; Hilaris, 1975), 
causing a wide contamination. These drawbacks made the use of radium to 
gradually be replaced with artificially produced radionuclides, such as 
60
Co and 
137
Cs (Myers, 1948; Brucer, 1952). 
226
Ra remained the most used radionuclide for 
brachytherapy into the late 20th century (Hilaris, 1975; Boice et al., 1988). 
Experiences from radium therapy have left a legacy which has effectively 
influenced methods of modern brachytherapy.  
 Radium was used extensively in intracavitary, gynecological applications 
and was also commonly applied to treat many other types of cancer. Other fields of 
application include treatment of skin hemangioma in early childhood, using tubes 
and needles of 
226
Ra, which was performed between 1920 and 1959 at 
Radiumhemmet (Stockholm, Sweden) (Lundell et al., 1994; 1995; 1999), between 
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1930 and 1965 at Sahlgrenska University Hospital (Gothenburg, Sweden) 
(Lindberg et al., 1995) and between 1940 and 1973 at Institut Gustave-Roussy 
(Paris, France) (Dondon et al., 2004). As recently noted by the UNSCEAR (2013) 
committee, the hemangioma cohort is of current interest in the search for improved 
knowledge on dose-response relationships for cancer induction and other late 
effects due to exposure to ionizing radiation in early childhood. Sweden has long 
held a complete registry on cancer incidence coupled to unique citizen ID numbers. 
Together with detailed knowledge about the children that underwent 
226
Ra 
treatment, these data are of interest to use in research on late effects due to radiation 
exposure in early childhood.  
 Retrospective risk assessments of ionizing radiation demand, among other 
information, high-quality dosimetry data. Previous dose estimations for the 
hemangioma cohort at Karolinska University Hospital were based on measurements 
with thermoluminescent dosimeters (TLD) in an anthropomorphic phantom using 
the original sources, and by Sidos (Operating Instructions 
SIDOS/EVADOS/SOMADOS, SIDOS-BRACHY, Siemens, 1984) (Visser, 1989; 
Feroldi et al., 1992), an early computerized dose planning system (Lundell et al., 
1990; 1994). Today, the original sources have been decommissioned, leaving only 
drawings and specifications of the sources. Having the dosimetry data in a modern 
format would enable its use with modern planning systems and open up for further 
individualization of patient doses and improved uncertainty estimations.  
 The aim of this study was to facilitate and investigate ways to allow flexible 
and as accurate as possible recalculation of absorbed doses from old, 
decommissioned radiation sources for retrospective studies. Having data in the 
format recommended by AAPM Task group 43 (TG-43) (Nath et al., 1995; Rivard 
et al., 2004) opens for implementation in modern planning systems and hence for 
effective recalculation and further individualization of absorbed doses for various 
scenarios of interest. The absorbed dose distribution around two of the most used 
radium sources at Radiumhemmet was characterized using MC simulations. The 
accuracy of TG-43 dosimetry parameters for surface brachytherapy with several 
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needles is evaluated, as well as compared with previously reported dose 
measurements with TLDs. Finally, because absorbed doses to organs far from the 
treatment volume are also required by epidemiologists, and because TG-43 
parameters are calculated up to about 15 cm from the implant, the fitting parameters 
of an analytical function valid up to about 60 cm, which was previously used for 
60
Co, 
192
Ir and 
137
Cs sources (Venselaar et al., 1996), are provided here for a 
226
Ra 
source.   
 
4.2 Materials and methods 
4.2.1 Description of sources  
 The radium sources used at the Radiumhemmet were constructed in 1925. 
The sources were of two types, the tube and the needle, containing 8 mg and 10 mg 
of 
226
Ra, respectively. Both source types consisted of an active volume of radium 
sulphate and barium sulphate, surrounded by an internal capsule of gold and an 
external capsule of platinum. The radioactivity is assumed to have been 
homogeneously distributed in the radium compound. Both sources were 
cylindrically symmetric and the needle had a conical tip. Cross-sectional drawings 
of the radium tube and the needle are shown in Figure 4-1. Values for the elemental 
compositions denoted in this figure are presented in Table 4-1. Geometries and 
material compositions were based on preserved drawings and commissioning 
protocols of the sources from 1925. For liquid water and air, elemental 
compositions were taken from the updated recommendations by the AAPM Task 
Group 43 (Rivard et al., 2004). 
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Figure 4-1. Cross-sectional drawing of the 8 mg radium tube and the 10 mg 
radium needle. The white circle at the right side of both sources is a cylindrical 
air cavity. All distances are given in mm. 
 
Table 4-1. Elemental compositions and mass densities for the materials used. 
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4.2.2 Decay scheme of the radioactive source 
 The sources contain 
226
Ra and its radioactive daughter nuclides, as observed 
in the decay scheme shown in Figure 4-2. 
226
Ra is the sixth member of the uranium 
series. With its decay, a chain of daughter radionuclides will follow to the stable 
206
Pb. In total, the decay chain comprises emission of α-, β- and γ-rays, internal 
conversion electrons, Auger electrons and characteristic x-rays. 
 
 
Figure 4-2. Decay scheme of a 
226
Ra source, adapted from a document by 
Laboratoire National Henri Becquerel, Le radium 226 et ses descendents: Tables et 
commentaries. The crossed radionuclides can be neglected due to their low yield (< 
0.1%). Only the half-lives of those transitions considered in this study are included 
in the figure. 
 
 The contribution of 
218
At, 
218
Rn, 
210
Tl, 
206
Hg and 
206
Tl to the overall absorbed 
dose can be neglected due to their very low yield (< 0.1%). Thus, the considered 
decay scheme includes nine radionuclides, with their half-lives differing in orders 
of magnitude. In order to determine the overall absorbed dose, it is necessary to 
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know the activity of each radionuclide at the treatment time. Bateman equations 
(Bateman, 1910) provide the solution to this problem. These were programmed in 
MATLAB 7.10.0 (R2010a) (The MathWorks Inc., Massachusetts, US) such that the 
number of radionuclides present in the source and the activity of each one was 
known as a function of elapsed time.  
 
4.2.3 AAPM Task group 43 dosimetry formalism 
 The absorbed dose calculation formalism recommended in the updated report 
of AAPM Task Group 43 (TG-43U1) (Rivard et al., 2004) is based on the 
parameters air-kerma strength SK, dose-rate constant Λ, radial dose function gL(r), 
geometry function GL(r,θ) and anisotropy function F(r,θ). In the general 2D TG-43 
formalism, using the line source approximation, the absorbed dose rate in a point at 
the radial distance r and polar angle θ relative to the longitudinal axis of the source, 
can be expressed as: 
 
 
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(4-1) 
where the reference distance is r0 = 1 cm and reference polar angle is θ0 = π/2. The 
TG-43 formalism models the dose distribution in water around a single source. 
Further discussion on the formalism can be found in the reports of AAPM Task 
Group 43 (Nath et al., 1995; Rivard et al., 2004). 
 
4.2.4 Monte Carlo methodology for the derivation of TG-43 
parameters 
 The tube and the needle were modeled with GEANT4 (Agostinelli et al., 
2003) and MCNP5 (Briesmeister et al., 2004). This study adheres to the latest 
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recommendations from the High Energy Brachytherapy Source Dosimetry (HEBD) 
working group (Perez-Calatayud et al., 2012). The relatively high mean energy of 
photons involved in the decay scheme of 
226
Ra made it necessary to consider in 
detail the secondary electrons that exit the source (Ballester et al., 2009).  
 Absorbed dose in water was obtained with the sources immersed in the 
center of a water sphere R=50 cm in radius, with the origin of coordinates at the 
center of the radioactive pellet, with the z-axis being the longitudinal axis of the 
source and the y-axis the transversal one (see Figure 4-1). It was scored in D(y,z) 
and D(r,) coordinates, 0   corresponding to the needle tip. This scoring 
allowed obtaining the radial dose and the anisotropy functions, as required in TG-43 
formalism. Doses were scored in histograms, with a bin width of 0.5 mm for 
coordinates y, z, and r, and 1° for . 
 The air-kerma strength per unit activity, /K KS A s , was estimated with 
the sources positioned in vacuum scoring collisional kerma over a cylindrical cell 
filled with air of height and thickness 0.10 cm at a distance of  r=10 cm in a plane 
perpendicular to the source axis passing by the origin of coordinates. The 
recommended air composition for dry air from the HEBD report was used (Perez-
Calatayud et al., 2012).  
 The default cutoff energy of 1 keV was used for both photons and electrons 
in all simulations except for SK estimation, where the cutoff was 10 keV for both of 
them (Perez-Calatayud et al., 2012). 
 
4.2.4.1 GEANT4 
 The low energy package PENELOPE included in GEANT4 v.9.4.p02 was 
used to track electromagnetic processes. All radioactive ions can be simulated in 
GEANT4 using the G4Physics package G4RadioactiveDecay v.0.b.4. By default, 
once a 
226
Ra nuclide is released, it decays until 
206
Pb. Hence, for each 
226
Ra atom, 
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approximately one radioactive daughter of each of the considered types would be 
created. However, given the different half-lives, each daughter product has a 
different number of disintegrations per unit of time, at different time periods. 
Therefore, each radioactive nuclide was decided to be simulated separately. For 
example, when a 
226
Ra nuclide was created, it automatically disintegrated via alpha 
emission to 
222
Rn. When the daughter nuclide (in this example, the 
222
Rn) had zero 
excitation energy, it was halted. Then, another independent simulation starting with 
222
Rn was performed, saving the results in a different file. This was done for each of 
the nine radionuclides considered in the decay chain of 
226
Ra, and after that, results 
were weighted and summed according to the activities given by Bateman equations, 
which are time dependent, i.e.:  
   
9
1
, , ( ) ,i i
i
D r t A t D r 


 
(4-2) 
where 1i   corresponds to 226Ra, 2i   to 222Rn, 3i   to 218Po, 4i   to 214Pb, 5i   
to 
214
Bi, 6i   to 214Po, 7i   to 210Pb, 8i   to 210Bi, and 9i   to 210Po. This enabled 
that dosimetric data could be obtained either in secular equilibrium or at any 
previous state. 
 All secondary particles generated by the G4RadioactiveDecay package 
(recoil nuclei, gammas, electrons, and alphas) were tracked, except neutrinos 
coming from beta decays, which were removed at their generating point. Energy 
spectra of generated alphas, betas, and gammas were saved, as well as spectra of 
particles leaving the platinum shield. 
 Given the photon energies involved in the decay scheme, a build-up region 
of a few mm in water around the source was expected. Thus, absorbed dose was 
scored as energy deposited per unit mass and disintegration. For each radioactive 
nuclide of the decay chain, 95 10  initial radioactive atoms were released and their 
disintegration was simulated until the next daughter product. Collision kerma was 
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also scored. Since collision kerma equals absorbed dose where electronic 
equilibrium exists, data from absorbed dose was used where there is not such 
equilibrium, whereas data from collision kerma was used in the rest of the space. 
810  atoms of each radioactive nuclide of the decay chain were released to estimate 
SK/A. Track-length kerma estimator was used in both water and air. 
 
4.2.4.2 MCNP5 
 To validate results from GEANT4, independent simulations were performed 
with “Monte Carlo N-particle transport code, version 5” (MCNP5 v.1.51) 
(Briesmeister et al., 2004), to derive SK/A, Λ and gL(r). The daughter nuclei were 
considered to be in secular equilibrium with 
226
Ra. Default MCNP5 photon cross-
section library MCPLIB04 was used, based upon “Evaluated Nuclear Data File/B 
Version VI” (ENDF/B-VI) release 8, which in turn is derived from “Evaluated 
Photon Data Library ’97” (EPDL97). In this case, decay data were taken from ICRP 
Publication 107 (Cullen et al., 1997) to validate energy spectra generated by 
GEANT4.  
 Since MCNP5 does not allow photons and electrons to be started in the same 
run, two separate runs were needed to estimate each parameter. First, the 
contribution from primary photons were scored and then the contribution from β-
particles, internal conversion electrons and Auger electrons (including 
bremsstrahlung). Simulations of absorbed dose to water were run using tally *F8, 
starting 2×10
9 
 particles in each run and detailed electron transport (mode PE). SK 
was estimated with the track length collision kerma estimator tally F6, starting 
5×10
8
 particles in each run. 
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4.2.5 Monte Carlo simulation of a superficial mould mesh 
 One of the limitations in accuracy of the TG-43 formalism arises when 
scattering properties are altered from that of an extended phantom, such as when 
sources are positioned close to patient surfaces and at low photon energies (<50 
keV) where differences between water and soft tissues are large due to high 
influence of photoelectric effect (Beaulieu et al., 2012). In the presence of several 
sources, source-to-source attenuation may also produce dose variations.  
 In order to test the influence of these effects in surface treatments with 
226
Ra 
sources, a typical clinical case consisting of a superficial mould mesh with 5 radium 
needles of 10 mg·Ra each was studied. During treatment, each needle was inside a 
rectangular glass casing that held the sources. Each glass casing was 4.5 mm wide, 
9 mm in height and 17 mm in length, with a glass density of 2.23 g·cm
-3
 (see 
composition in Table 4-1). Each needle fitted perfectly the inner hole of the glass 
casing. Each casing was next to each other, with the longitudinal axes of the sources 
(z-axis) in parallel. This clinical setup was used to prevent the sources to be in 
direct contact with the skin, which resulted in severe skin damage. In addition, the 
glass kept a fixed geometry, which allowed determining treatment times from 
tabulated curves valid for this particular configuration (Strandqvist, 1939a; 1939b).  
 The superficial mould was placed on top of a 20 cm cubic liquid water 
phantom that mimics the patient. The centers of the needles were at the mid-plane 
of the casing, i.e. 4.5 mm above the water surface (along the y-axis). Center-to-
center distance between the needles was 4.5 mm (along the x-axis). The geometrical 
setup described in this section is illustrated in the results section. With GEANT4, 
absorbed dose was scored in the water phantom and results were compared with 
those of the TG-43 formalism applying the principle of dose superposition. 
Independent simulations were performed for each radionuclide, totaling an 
equivalent of 92 10  radium atoms per needle. 
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4.2.6 Absorbed dose at large distances 
 Another set of simulations was run with GEANT4 in order to evaluate the 
absorbed dose at large distances (>10 cm) from a 
226
Ra source. Due to the reduced 
dimensions of the sources, beyond 10 cm these can be considered to be point 
sources. Thus, a point-like source emitting photons with the energy spectrum of the 
photons exiting the needle previously simulated was placed in the center of a 100 
cm radius water sphere. 92.4 10  photons were released and absorbed dose was 
scored in spherical shells of 1 mm thickness.  
 Absorbed dose rate D [cGy·h
-1
] as a function of radial distance r [cm] was 
then fitted using the following expression: 
 
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(4-3) 
where the average mass energy absorption coefficient  / 1.112
w
en a
    was 
used (Venselaar et al., 1996).
 
The coefficients a, b and μ are the fitting parameters 
to be obtained. The activity of radium sources A was generally given in terms of the 
quantity mg·Ra. The SK [U] value of the source can be calculated from A [mg·Ra] 
and the air-kerma strength per unit activity SK/A [U·Bq
-1
] calculated in this study, 
considering that 1 mg·Ra equals 37 MBq, i.e.: 
73.7 10 KK
S
S A
A
 
    
   
(4-4) 
 Expression (4-3) was used by Kornelsen and Young (1981) for 
226
Ra sources 
in the range up to 18 cm. Venselaar et al. (1996) showed that the same expression 
could be used with 
60
Co, 
192
Ir and 
137
Cs sources for distances up to 60 cm, so this 
study aims to provide the required fitting parameters needed to use expression (4-3) 
between 10 cm and 60 cm for a 
226
Ra source. 
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4.3 Results 
4.3.1 Contribution from each radionuclide to the overall 
absorbed dose 
 Figure 4-3 shows collision kerma along the transversal axis of the 
226
Ra 
needle immersed in water. Contribution from the decay of each radionuclide to the 
overall collision kerma is plotted. 
218
Po, 
210
Pb and 
210
Po have not been included in 
Figure 4-3 because of their negligible contribution (< 0.001%) and high statistical 
noise in the curves. As observed, only the decay of 
214
Pb and, mainly, 
214
Bi 
contribute; the collision kerma contribution by the others is < 0.2%. 
 
Figure 4-3. Collision kerma along 90º   and normalized at 
0 1r   cm for the 
226
Ra needle in secular equilibrium and immersed in water. The contribution to the 
collision kerma from the decay of each radionuclide is plotted, neglecting energy 
released by 
218
Po, 
210
Pb and 
210
Po. 
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 Simulations with GEANT4 were performed to assess the influence of high-
energetic α- and β-rays emitted in the decay chain to absorbed dose and collision 
kerma. It was found that α-rays were completely stopped in the source 
encapsulation. However, some high energetic β-rays and mono energetic electrons, 
with associated bremsstrahlung, contributed to approximately 1% of absorbed dose 
to water. Therefore, the electrons generated during the decay should be also 
considered for any MC simulation with 
226
Ra sources.  
 
4.3.2 Time dependence of absorbed dose 
 Figure 4-4 shows the activity of each daughter product considered in the 
decay chain of 
226
Ra as a function of elapsed time, normalized by the activity of 
226
Ra. These curves are given by the Bateman equations.  
 Some of the radionuclides reached secular equilibrium after about 50 days. 
However, 
210
Pb, with a half-life higher than 22 years, and its daughter products 
210
Bi and 
210
Po reached transient equilibrium after about 200 years since the 
226
Ra 
source was sealed. Therefore, this is the time required for the source to be 
considered in secular equilibrium. 
 Given that calculations with GEANT4 provided the independent contribution 
of each radionuclide to the overall absorbed dose (as a function of the activity of the 
radionuclides), the absorbed dose at each point around the source was known as a 
function of time. For the reference point given by r0 = 1 cm and θ0 = π/2, the 
variation in absorbed dose (in comparison with the complete equilibrium) was 
undetectable (variation < 0.01%) after 120 years. However, after 55 days the dose 
variation was below 0.2%, and after 27 days it was below 1%, which is considered 
to be negligible. Therefore, even though secular equilibrium was not reached until 
200 years after the source was made, after 1 month the absorbed dose around the 
source could be considered to decrease only due to the radioactive decay of 
226
Ra. If 
the sources were used before one month, some corrections to the overall absorbed 
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dose should be done. For example, if the source was used after 11 days, the dose 
was 14% smaller than in the secular equilibrium, whereas after 7 days it was 27% 
smaller.  
 From now on, all results presented correspond to the secular equilibrium 
state, which from a practical point of view, was considered to be reached after 1 
month since the source was sealed. 
 
 
Figure 4-4. Ratio of the activity of the daughter product with symbol X (and atomic 
number Z) and the activity of the parent 
226
Ra, as a function of time, according to 
Bateman equations (Bateman, 1910).  
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4.3.3 Absorbed dose distributions 
 Absorbed dose and collision kerma distributions in water were obtained in 
(y,z) and (r,) coordinates. The left part of Figure 4-5 shows the absorbed dose to 
collision kerma ratio around the 
226
Ra tube, which illustrates the area around the 
source where there is not electronic equilibrium (ratio different than 1). In the right 
part, the absorbed dose distribution is plotted, showing a build-up region of 2 to 3 
mm. For this reason D(y,z) and D(r,) were derived taking collision kerma results 
for distances where there is electronic equilibrium (beyond 1.1 cm from the source 
approximately) and absorbed dose results (i.e. tracking electrons) for shorter 
distances. The procedure to choose the limit between collision kerma and absorbed 
dose was as follows: a table was calculated with the ratio of absorbed dose and 
collision kerma, and collision kerma was used when ratios became smaller than 
1.01 (see the left part of Figure 4-5). 
 
Figure 4-5. Absorbed dose to collision kerma ratio (left-half part of the figure), 
and normalized dose distribution (right-half part of the figure) around the 226Ra 
tube. The tube location is also represented.  
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 Differences between GEANT4 and MCNP5 results beyond 5 mm were 
below 1% along the transversal axis ( 90º  ) of the source. Roughly 1 to 2% 
differences exist for other   values, except at the longitudinal axis, where there 
exist differences up to 4%. Furthermore, the energy spectra of photons and 
electrons generated within the source with both MC codes were compared. Relative 
differences in intensity were at most 3% for a few energy lines, but below 1% for 
most of them. Higher discrepancies appear for very low energies (<10 keV). 
However, those low energy photons are stopped in the source shielding and so they 
do not contribute to the absorbed dose.  
 
4.3.4 TG-43U1 parameters 
 The absorbed dose rate distributions D(r,) derived with GEANT4 were used 
to derive the TG-43 dosimetry parameters for both, the tube and the needle. For 
each source being in secular equilibrium, the radial dose function, the anisotropy 
function, the air-kerma strength per unit activity, the dose rate constant and an 
along-and-away table for QA purposes (extracted from D(y,z)) were obtained. All 
these data have been uploaded in an Excel spreadsheet as additional material 
together with published paper. 
 gL(r) and F(r,θ) were obtained using collision kerma for 1.1r   cm 
approximately (except for angles θ near the longitudinal axis of the source, where a 
higher r value was used), whereas absorbed dose was used for shorter distances (see 
section 3.C.).  
 GEANT4 yielded an air-kerma strength per unit activity SK/A value of 
1.892×10
-7
 U Bq
-1
 for the tube, and 1.948×10
-7
 U Bq
-1
 for the needle. Results from 
both MC codes for SK/A agreed within 0.2%. For comparison purposes, the 
exposure rate constant stated in previous works for a 
226
Ra source filtrated by 0.5 
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mm Pt was Γ( 
226
Ra) = 8.25 R cm
2
 h
-1
 mCi
-1
 (Attix et al., 1957; Williamson et al., 
1983; ICRP, 2008), which corresponds to 1.955×10
-7
 U Bq
-1
 in dry air.  
 The dose rate constant, Λ, obtained with GEANT4 was 0.952 cGy h
-1
 U
-1
 for 
the tube and 1.062 cGy h
-1
 U
-1
 for the needle. Both values have roughly 1.7% 
uncertainty with k=1 coverage factor (see uncertainty analysis in section 3.G.). The 
relative deviations of these values compared to those of MCNP5 were 0.7% and 
0.08% for the tube and the needle, respectively. 
 
4.3.5 Superficial mould mesh 
 The validity of the TG-43 parameters for surface treatments was evaluated 
by comparing the dose distribution obtained from TG-43 tables and the principle of 
dose superposition, with results from a MC simulation with 5 needles immersed in 
glass casing, and placed over a water phantom. Figure 4-6a shows geometry of the 
mould mesh described in section 2.E., whereas Figure 4-6b shows the ratio of these 
two dose distributions in a coronal plane that crosses the active center of the 
radioactive needles (left) and a tangential plane parallel to the mould, corresponding 
to a depth in water of 2 mm (right). Because of the symmetry of the dose ratio (the 
central needle is placed at x=0, whereas the others are placed at x=±4.5 mm and 
±9.0 mm), only the right part of the plane has been shown. Results agree within 5% 
inside the volume covered by the implant, and within 10% up to at least 6 cm from 
the implant center, except within y=1 cm from the surface, where large differences 
appear mainly due to the higher attenuation in the glass casing and the lack of 
backscattering. These results are consistent with those obtained by Granero et al. 
(2014) for 
60
Co, 
192
Ir and 
169
Yb sources.  
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Figure 4-6. a) Superficial mould mesh consisting of 5 needles inside a glass 
casing. In the MC simulations, this was placed over a 20 cm cubic water phantom. 
The origin of coordinates is placed at the interface between glass and water, just 
below the center of the central needle. b) Relative differences between absorbed 
doses to water calculated with TG-43 formalism and with a realistic MC 
simulation, in a coronal plane (plane perpendicular to the mould, at z = 0 cm) 
(left) and in a tangential plane (plane parallel to the mould, at y = -0.2 cm depth) 
(right).  
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4.3.6 Absorbed dose at large distances 
 The absorbed dose rate at large distances can be determined using 
expressions (4-3) and (4-4). The coefficients obtained from the fitting of the MC 
results are: 0.968a  , 1.205b   and 0.0641   cm
-1
. When these values 
are used together with expression (4-3), the dose rate thus calculated differs from 
the MC calculation by less than 1.5% in the range 10 cm to 60 cm. Between 60 cm 
and 90 cm differences increase continuously up to 10%. The dose rates obtained 
from MC simulations and from expression (4-3) are shown in Figure 4-7, together 
with the relative difference between both data sets. Beyond roughly 95 cm the 
relative difference becomes quickly negative due to the lack of backscattering in the 
MC simulation beyond 100 cm.  
 
Figure 4-7. Absorbed dose rate as a function of the radial distance from a 10 mg 
226Ra point-like source. In red it is shown the relative difference between the dose 
rate calculated with GEANT4 and with expression (4-3) with the fitting 
parameters obtained in this study.    
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4.3.7 Uncertainty analysis 
 As recommended by AAPM TG-138 (DeWerd et al., 2011) and HEBD 
(Perez-Calatayud et al., 2012) reports, an uncertainty analysis should be performed 
for the dosimetric data provided in this study. This was computed based on the 
method used by Rivard et al. (2004) and Granero et al. (2011). The type A 
statistical uncertainty of the absorbed dose rate calculated with GEANT4 was 
around 0.3%, increasing up to almost 1% near the longitudinal axis of the sources. 
On the other hand, the type B uncertainty components are roughly similar to the 
ones calculated by Granero et al. (2011). The overall uncertainty thus estimated 
(with coverage factor 1k  ) is roughly 1.2% for the absorbed dose rates at 1 and 5 
cm, as well as for SK. The Λ uncertainty is about 1.1% ( 1)k  . These are the 
uncertainties that may be attributed to the MC calculations, since they include the 
influence of the uncertainties due to: 
226
Ra spectrum, MC physics, phantom 
composition, phantom cross-sections, tally volume averaging and tally statistics. 
However, these uncertainties are negligible in comparison with the uncertainty that 
should be assigned to the dose estimates made retrospectively. The reason is that 
any dose estimate requires the activity of the radium sources. Nevertheless, one of 
the drawbacks of old dosimetry is the lack of a measurable source strength; in fact, 
the uncertainty in source strength specified in terms of quantities like mg·Ra can be 
considered one of the largest sources of dosimetric uncertainty before measureable 
quantities were established (see, e.g., Ref. (Visser, 1989; ICWG, 1990; Williamson, 
2006)). Because the old sources are no longer available, the quantity mg·Ra needs 
to be used also with the data provided in this study, and so this drawback is present 
for both, the old and the new dosimetry. As reported in the literature reviewed, the 
size of the radium mass enclosed in the sources had an uncertainty of 10% to 15% 
(Dutreix et al., 1982). Therefore, this can be the uncertainty assigned to each dose 
estimation at a given point, for the radium tube and the radium needle studied here.   
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4.4 Discussion 
4.4.1 Comparison with older dosimetry data 
 The dosimetric formalisms used to calculate absorbed doses around radium 
sources changed considerably throughout the last century. The very first ones only 
considered primary radiation and the inverse square law for air (Mould, 2007). 
Later on, the dosimetric calculations based on the Sievert Integral became widely 
used. This model partitioned the line source into point sources, considering also the 
inverse square law and filtration corrections. In 1970, Goodwin et al. (1970) 
published tables of dose rate in tissue as a function of the platinum filtration 
thickness, source active length and the distances along-and-away. Tabulated data 
existed as a function of area or volume to be treated. Computerized treatment 
planning based on Sievert integration became available after that, and the Siemens 
Sidos system used at Radiumhemmet in Sweden was one of these (Feroldi et al., 
1992). A comparison of such systems showed differences among them in particular 
along the source long axis (Visser, 1989).  
 In order to test the accuracy of existing dose tables based on the Sievert 
Integral, the along-and-away table calculated by Young and Batho (1962) with an 
electronic computer for a needle similar to the one considered in this study is 
compared with data evaluated with the TG-43 formalism. Table 4-2 shows the 
relative difference between both data sets. It is shown that at large distances (y >1 
cm) and in the regions not bounded by the ends of the active source (z >0.77 cm), 
the difference increases, i.e. the dose calculated with TG-43 data is smaller. This is 
due to the fact that the other data set did not consider absorption and scattering in 
tissue. This result is consistent with the findings by Williamson et al., who showed 
that the calculations based on the Sievert Integral overestimated the exposure rate 
per unit activity (Williamson et al., 1983).  
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Table 4-2. Relative differences between dose rates around a 
226
Ra needle calculated 
with the Sievert integral (as provided by Young and Batho (1962)) for a needle with 
0.56 mm overall filtration (the platinum filter was 0.5 mm) and the TG-43 
formalism. 
 
 
 In a previous study by Lundell (1994), absorbed dose rates were measured 
with TLDs in an anthropomorphic child phantom and calculated using the Sidos 
treatment planning system with simplified input regarding source filtration. In 
conjunction with that study, a radial dose profile was measured close to the 10 mg 
radium needle considered in this work with lithium fluoride TL dosimeters in full 
scatter conditions in PMMA (up to r=1 cm) and polystyrene (for r 1 cm). Figure 
4-8 shows those data in comparison with MC results from the current study in 
water. For the TLD measurements, distances in PMMA were expressed in 
equivalent distances in liquid water (Lundell, 1994). For distances greater than r=1 
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cm, experimental and calculated results for the same 
226
Ra needle agree within 13% 
and -10%. At distances shorter than r=1 cm, differences are between 4% and -13%. 
These differences are reasonable considering the experimental uncertainties in this 
steep dose-gradient area, but limit the accuracy of experimental dosimetric values 
near the sources, which have a high dose uncertainty even without considering the 
uncertainty in the mass of radium. 
 
 
Figure 4-8. Absorbed dose rate on the transverse axis of the radium needle and 
radium tube calculated in this study, in comparison with experimental data from 
TLD measurements for the same radium needle. For comparison purposes, the dose 
rate shown by Johns and Cunnigham (1983) (J&C in the legend) for a given 
filtration thickness d and source active length L has been plotted.  
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4.4.2 Applicability and limitations of this study 
 Retrospective risk assessments of ionizing radiation require dosimetric data 
as reliable as possible, as well as an estimate of its uncertainty. The dosimetric data 
provided in this study is important particularly in following up the large cohort of 
children treated for hemangioma through the Swedish cancer registry (Eidemüller et 
al., 2009). Like survivors of the atomic bombs, those children data may be very 
helpful to determine the relationship between a specific late hazard effect and the 
absorbed dose (UNSCEAR, 2013), especially it will contribute to provide 
information on radiation sensitivity in early childhood, a topic of current interest 
(Candela-Juan et al., 2014a). Earlier dosimetric data was restricted, e.g., regards the 
number of source configurations and difficult to use when further individualization 
of absorbed doses was desired. Data provided here are the most accurate available 
for these sources and may be easily incorporated into current planning systems or 
home-made spreadsheets in order to perform retrospective studies of any source 
configuration.  
 In addition, for those epidemiologic studies in which absorbed doses to 
distant sensitive organs such as breasts, thyroid, brain or gonads are needed, the 
fitting parameters of a mathematical expression have been determined and 
provided. Candela-Juan et al. (2013) calculated organ equivalent doses in a 
voxelized phantom using 
60
Co and 
192
Ir sources applied to the prostate. Differences 
up to 20% were found between the simulations when the phantom was 
heterogeneous and when it is made just of water. Because the 
226
Ra source has a 
mean photon energy spectrum between that of 
60
Co and that of 
192
Ir, those results 
are of reasonable applicability in this case. This 20% uncertainty, together in 
quadrature with the 10 to 15% uncertainty previously stated due to the generally 
unknown exact mass of radium, is assumed to give the best dose range estimation of 
absorbed doses. It is out of the scope of this study to evaluate if that uncertainty is 
acceptable for epidemiological studies since that may depend on each particular 
case and the amount of data available. It is surely important for the epidemiologic 
studies to be aware of this uncertainty before extracting their conclusions. 
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 The sources considered in this study were a radium tube and a radium needle 
commonly used in Sweden and requested for ongoing epidemiologic studies. The 
TG-43 formalism has been shown to provide consistent results in comparison with 
MC simulations of a superficial mould implant within the regions bounded by the 
ends of the sources and a few cm extra margin, i.e., these results are well suited to 
determine the absorbed dose in the treatment area. However, it is possible to 
estimate the influence of the source design on these results. Figure 4-8 shows, 
besides the dose rate along the transversal axis of these Swedish sources, the dose 
rate along the transversal axis of two radium sources of the same active length than 
the needle and the tube, but with different platinum thicknesses. These data were 
obtained from the book by Johns and Cunningham (1983), and were evaluated 
through the Sievert Integral. Beyond 3 cm approximately, the dose rate becomes 
nearly independent of the active length of the source, an expected result. In 
addition, the difference due to the different platinum shielding used in each case is 
roughly 11%. The two platinum thicknesses considered (0.5 mm Pt and 1.0 mm Pt) 
represent the platinum range used by most of the radium sources. Thus, it is 
reasonable to consider that the TG-43 data and the dose rate at large distances that 
have been provided in this work may be applied to other sources similar in active 
length with an increased dose uncertainty of at most 11%.  
 
4.5 Conclusions 
 Two independent Monte Carlo investigations have been performed to derive 
TG-43 parameters for a 8 mg 
226
Ra tube and a 10 mg 
226
Ra needle, previously used 
for brachytherapy at Radiumhemmet (Karolinska University Hospital, Stockholm, 
Sweden). The radial dose function, the 2D anisotropy function, the air-kerma 
strength per unit activity and dose rate constant are provided and can be used for 
these and similarly designed sources. Results from the TG-43 formalism have been 
shown to be accurate in cases with surface treatments and several sources inside 
glass casing. Thus, all these parameters can be put into a modern brachytherapy 
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treatment planning system in order to derive high quality dose estimations for 
retrospective dosimetry. In addition, the fitting parameters of a mathematical curve 
have been calculated in order to assess the absorbed dose to organs placed between 
10 cm and 60 cm from the radium implant. This will allow improving the current 
knowledge that relates absorbed dose with long term radiation effects. Throughout a 
critical analysis of uncertainties it was estimates that absorbed doses assigned to 
organs in retrospective studies have an uncertainty of 20% to 25%.  
 Chapter 5. LEAD SHIELD FOR SURFACE 
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5.1 Introduction 
 Skin brachytherapy with HDR sources is widely used. Based on tumor depth, 
superficial or interstitial modalities may be applied (Gerbaulet et al., 2002). In order 
to attenuate radiation that can reach radiosensitive organs in the patient, lead shields 
could be used to cover the implants on the body surface. For example, shields might 
be placed on the nose surface to attenuate radiation to the eye lens from a nasal 
implant, or around the breast to protect the thyroid from direct radiation coming 
from a breast treatment or even to protect the fetus in a hypothetical pregnant 
patient. This approach has two main dosimetric consequences. 
1)  Backscattering produces a dose enhancement in the patient in the vicinity of 
the shielding (Das et al., 1989; Das et al., 1995; Li et al., 1999; Nath et al., 
1999; Das et al., 2001; Das et al., 2002; Lliso et al., 2011). This overdose 
could be minimized by placing bolus with an appropriate thickness 
between lead and tissue. The backscatter dose enhancement has been 
reported for both kilovoltage and megavoltage photon beams, as well as for 
60
Co equipment (Das et al., 1989) and the Valencia applicators with HDR 
192
Ir brachytherapy sources (Lliso et al., 2011). Some reported data are 
based on experimental measurements with limitations related to the 
chamber size (e.g. volume averaging, effective measurement point, signal 
to noise ratio or chamber window for electrons), and so the need for 
additional Monte Carlo (MC) simulated radiation transport has been 
requested (Das et al., 1995). This is even more important when 
discrepancies between experimental results and MC simulations have been 
reported (Das et al., 2002). In addition, dose enhancement has not been 
evaluated in surface or interstitial BT with their corresponding boundary 
conditions. 
2)  Photon absorption reduces dose above the shield, downstream from the 
distal surface of the barrier. Radiation transmission data for radionuclides 
and materials relevant to BT facility shielding have been investigated for a 
point-like source placed in air, in broad-beam conditions typical of 
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radiation protection transmission studies (Papagiannis et al., 2008). 
However, radiation transmission has not been evaluated in surface or 
interstitial BT for a typical clinical scenario. 
 Consequently, this work aims to study the dosimetric perturbations produced 
by the use of a lead shield in surface or interstitial BT using 
60
Co, 
192
Ir, or 
169
Yb, 
and to provide the required bolus thicknesses that avoid overdose in the human 
tissue. This is examined for several shield thicknesses and for different source 
depths from the surface. 
 
5.2 Methods and materials 
 Three different HDR radionuclides were considered: 
60
Co (T1/2=5.27 yr, 
Eγ,mean=1253 keV), 
192
Ir (T1/2=73.8 days, Eγ,mean=350 keV), and 
169
Yb (T1/2=32.0 
days, Eγ,mean=93 keV). Both 
60
Co and 
192
Ir are commercially available for HDR BT, 
whereas 
169
Yb has potential (MacPherson et al., 1998) and might be available in the 
future. The corresponding source models were the Multisource HDR 
60
Co model 
GK60M21 (Eckert & Ziegler BEBIG GmbH) and the HDR 
192
Ir microSelectron 
mHDR-v2 (Nucletron BV, The Netherlands) source (Granero et al., 2007; 2011). 
For HDR 
169
Yb, since no commercial model is available and given that for the 
purpose of this work the exact geometry of the source has negligible effects, the 
source design has the same geometry as the microSelectron mHDR-v2. Results 
obtained herein for the studied source models should be generalizable to other 
commercially available models for the same radionuclides because energy spectra 
of photons that exit the different existent capsules are similar due to the energies 
involved. 
 Due to the intrinsic difficulties and limitations of absorbed dose 
measurements in very small depth intervals, MC simulated radiation transport has 
been used. The sources were radiologically characterized using the GEANT4 v.9.4 
MC code (Agostinelli et al., 2003), which has been used and validated extensively 
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in previous works in BT radiation transport simulations (Papagiannis et al., 2008; 
Granero et al., 2011; Vijande et al., 2012). This code has been benchmarked in 
dosimetric evaluations of internal shielding in HDR BT with experimental 
measurements using radiochromic films (Lliso et al., 2011). Instead of giving the 
energy spectra of emitted photons as an input to the MC code (Rivard et al., 2010), 
in this work either 
60
Co, 
192
Ir, or 
169
Yb radionuclides were placed inside the 
simulated sources, activating the GEANT4 radioactive decay module. This module 
generates all particles, including photons, electrons, recoil nucleus, and neutrinos 
(the latter are killed). Both photons and electrons were tracked, including secondary 
electrons generated by photons. The PENELOPE physics package included in the 
library of GEANT4 was used, although extra simulations were performed using the 
Livermore physics package of GEANT4, with no significant differences 
considering the statistical uncertainty of results shown in this work. Furthermore, 
results from GEANT4 were validated with the Monte Carlo code PENELOPE 
(Salvat et al., 2008), which was used for a single case, providing consistent results 
with those shown in this work. The cutoff range for both types of particles 
simulated was set to 10 μm in all materials (Ballester et al., 2009), considerably 
lower than the highest spatial resolution used in this work (100 μm). For photons, 
this range cutoff is roughly equivalent to an energy cutoff of 1 keV in air and water, 
and 6 keV in lead. For electrons, it is equivalent to 1 keV cutoff in air, 14 keV in 
water, and 58 keV in lead. 
 The geometry used in the simulations is shown in Figure 5-1. It mimics a 
typical clinical setup, although without catheters since the geometry reproduced 
here was considered to be the worst possible scenario from a radiation protection 
point of view. However, the catheter influence will be discussed later. The 
considered geometry is based on a 25×25×25 cm
3
 cubic water phantom (Granero et 
al., 2008) with a lead shield placed on its surface. While a large (25×25 cm
2
) lead 
shield was considered, it can be smaller under clinical circumstances as long as it 
covers the full implant. The lead thickness tPb {0, 3, 6, and 10 mm} was changed 
between simulations. Depending on the source depth ds, two cases were considered: 
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- Surface BT, with a single source placed on the surface  0sd  , i.e., 
between the water cube that represents the patient and the lead shield 
(Figure 5-1a). 
- Interstitial BT, with the single source placed at a depth ds {5, 10 mm} in the 
water cube (Figure 5-1b). A common width of the clinical target volume is 
10 mm, and ds = 5 mm is consequently a realistic value, which is the one 
used in these simulations. In order to further generalize these findings, 
simulations were repeated using ds = 10 mm. 
 Therefore, three different geometry setups were considered in this work and, 
for each of them, four different lead thicknesses and three different BT 
radionuclides. This resulted in 36 independent simulations. The number of 
disintegrations simulated (i.e. number of radioactive atoms in the sources) was 
9×10
8
 for 
60
Co, and 1.2×10
9
 for 
192
Ir and 
169
Yb. Three independent simulations 
were performed for each geometry setup and the statistical (type A) uncertainty of 
the results was calculated as the standard deviation of the three data sets. 
  
(a) (b) 
Figure 5-1. Scheme of the longitudinal section of the simulation setup, indicating 
some relevant parameters and the coordinate system used for a) surface 
brachytherapy, and b) interstitial brachytherapy. The figure is not to scale. 
Chapter 5 
_____________________________________________________________________________________________________________________________________________ 
80  
  For each considered simulation, total absorbed dose throughout the entire 
phantom volume was scored in 2D-histograms ( , )D z  , being 
2 2x y   . 
Overdose at water phantom surface due to radiation backscatter in the lead shield 
was then evaluated comparing water absorbed dose with and without the shield, as a 
function of z. In order to quantitatively evaluate which radiation particles are 
responsible for the overdose at water phantom surface, absorbed dose due to 
photons and electrons coming from the lead shield were assessed. In order to 
separate the fraction of dose deposited by both types of radiation particles, the 
following process was followed. When a photon interacted with the lead shield and 
came back to the water phantom, all energy deposited by this photon and/or by all 
its secondary particles (including electrons) was scored in the histogram of dose 
deposited by photons. The same was done for electrons interacting with the lead 
shield and coming back to the water phantom. For all these histograms, bin 
thicknesses of 0.1 mm and 0.5 mm were used for z and ρ, respectively. The small 
scoring thickness in the z-axis was selected to avoid volume averaging due to the 
high dose gradient. 
 On the other hand, the dose reduction above the shield was evaluated by 
comparing air absorbed dose with and without shield. For absorbed dose in air, the 
histogram has a bin width of 1 mm in both, z and ρ. A forward overdose up to a few 
millimeters in air was expected due to contribution from particles created within the 
lead shield (Li et al., 1999; Das et al., 2001; Lliso et al., 2011; Das, 1997). 
However, that overdose information is not relevant for the scope of this work due to 
their low range (Das, 1997) and given that no human tissue is expected to be 
located there. Hence, only attenuation in the above air volume is reported.  
 The geometry setup considered in the simulations represents a single source 
position. However, in a real clinical case the source has multiple dwell positions, 
remaining a specific time interval in each of them. In order to take this into account, 
the source configuration that allows irradiating uniformly a 50 50  mm2 area 
located at a depth 5z    mm and centered at 0x y   was obtained. This was 
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achieved by considering 4 catheters with 8 dwell positions each. The distance 
between consecutive catheters was 10 mm, with the catheters axes parallel to the y-
axis. Moving the source along the y-axis was done at 5 mm spatial intervals. For 
each particular dwell position, the required treatment time was calculated. Then, 
simulation results for a single source position were spatially displaced, weighted 
according to the dwell times, and superimposed, thus obtaining the dose 
distributions for a realistic clinical case with the phantom being water. This 
phantom material was chosen because planning systems in HDR brachytherapy 
make use of it and because our main aim was to obtain the required bolus thickness, 
being the bolus material equivalent to water. Despite these two reasons, the range of 
the dose perturbation was also evaluated in skin (density of 1.09 g/cm
3
), comparing 
it with the range obtained in water (density of 1.00 g/cm
3
). 
 In order to analyze and evaluate results, energy spectra of the simulated 
sources, of the back-scattered photons and electrons, and of the photons and 
electrons that cross the lead shield were assessed. Spectra correspond to those of 
photons and electrons emitted in all directions of the space, and not just in the 
transversal axis at a particular distance. All energy spectra were saved with a 1 keV 
bin width. 
 
5.3 Results 
5.3.1 Energy spectra 
 The GEANT4 radioactive decay module has been benchmarked comparing 
energy spectra of photons emitted by the simulated radionuclides with 
recommended data (Rivard et al., 2010; Perez-Calatayud et al., 2012) provided at  
http://www.nndc.bnl.gov/nudat2/indx_dec.jsp by the National Nuclear Data Center 
(NNDC). For 
60
Co, differences between both spectra are 1% for mean energy and 
overall intensity when considering photons > 15 keV. If lower energy photon 
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emissions are considered, there are higher differences (up to 16%). For 
192
Ir, 
differences are lower than 0.1% for both intensity and mean energy, whereas for 
169
Yb differences are 1.5% and 0.7%. Again, higher discrepancies are found for 
energies below 15 keV. Those low energy lines hardly exit the source capsule and 
so their influence in absorbed dose is neglected. As shown by Rivard et al. (2010), 
differences between various reported energy spectra result in a negligible effect 
when obtaining absorbed dose ratios, which is the case of this work. Furthermore, 
as previously reported, the physics models used in GEANT4 have already been 
validated in dosimetric evaluations of internal shielding in HDR BT with 
experimental measurements (Lliso et al., 2011). Therefore, the GEANT4 code used 
in this work can be considered to be validated for the scope of this study. 
 Figure 5-2 shows energy spectra of photons and electrons that go back from 
the lead shield to the water phantom, including backscattered photons and electrons, 
characteristic x-rays, and Auger electrons. The predominant energy lines in the 
backscattered photon spectra (Figure 5-2a) are those corresponding to 
characteristic x-rays coming from the deexcitation of lead atoms, with energies 
between 74 and 90 keV, in agreement with data reported by the Laboratoire 
National Henri Becquerel (LNHB) (http://www.nucleide.org/DDEP_WG/ 
/DDEPdata.htm). Figure 5-2 also shows energy spectra of photons and electrons 
that traverse the lead shield or are emitted by it, for the specific case tPb = 3 mm and 
ds = 5 mm. Characteristic x-rays from lead atoms are also observed in this case, 
although the predominant lines are still the ones associated with nuclear 
disintegration. 
 Table 5-1 shows, for all three HDR sources considered, mean energy of 
photons and electrons backscattered and that traverse the lead shield, as a function 
of source depth and lead thickness. The statistical uncertainty of the mean energy of 
both photons and electrons is generally lower than 2 keV. It is noted that: 
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(a) (b) 
  
(c) (d) 
Figure 5-2. Energy spectra of a) photons and b) electrons that are backscattered from 
the lead shield to the water phantom, and energy spectra of c) photons and d) electrons 
that traverse the lead shield. Spectra correspond to the simulations with dPb = 5 mm and 
ts = 3 mm, for all three HDR sources considered. 
 
Chapter 5 
_____________________________________________________________________________________________________________________________________________ 
84  
Table 5-1. Mean energy of source photons and electrons that go back from the lead 
shield to the water phantom, and that traverse the lead shield, as a function of 
source depth ds and lead thickness tPb. 
 
 
1) Mean energy of photons and electrons emitted in the backward direction 
(defined as the direction from shield to source) was lower than from the 
forward direction. 
2)  For a given lead thickness with 
60
Co and 
192
Ir, the mean energy of photons 
and electrons backscattered decreased when the source depth increases. For 
169
Yb, the same was valid for the mean energy of backscattered electrons, 
whereas for photons there was no variation within 1 keV. 
3)  For a given lead thickness with 
60
Co and 
192
Ir, the mean energy of photons 
and electrons that traverse the lead shield slightly decreased when the 
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source depth increased. For 
169
Yb, there was no variation within the 
relative uncertainty of these data. 
4)  For a given source depth and all three radionuclides, the mean energy of 
photons and electrons backscattered was independent of shield thickness 
(within the thickness range here considered), except for photons from 
60
Co, 
whose mean energy slightly increased with lead thickness. 
5)  For a given source depth, lower energy photons were attenuated more than 
higher energy photons as the lead thickness increased. Consequently, the 
mean energy of photons and electrons that traversed the lead shield 
increased with tPb for 
192
Ir. However for 
60
Co, given that the predominant 
lines are almost exclusively 1,173 keV and 1,332 keV, the beam hardening 
effect was not observed given the negligible influence of the more 
attenuated lower energy lines. For 
169
Yb, the mean energy of photons 
traversing the shield was also almost constant with tPb within the relative 
uncertainty of these data. 
 
5.3.2 Backscattered dose perturbation 
 Figure 5-3 shows the shielded to unshielded absorbed dose ratio in the water 
phantom (along the z-axis, for 0  ) for the 
60
Co, 
192
Ir, and 
169
Yb single dwell 
sources. For each z value, the statistical uncertainty was < 1.5% for 
60
Co and < 3% 
for 
192
Ir and 
169
Yb. The dose enhancement profile was the same if the phantom was 
made of skin or water. For each source, all three geometrical configurations 
(surface BT and interstitial BT with ds = 5 and ds = 10 mm) are shown for tPb = 6 
mm. For surface BT, the relative importance of backscattered dose in the z-axis is 
nearly negligible for all three HDR sources considered. This is due to the proximity 
of the source to the surface and to its high dose gradient. This is not the case with 
interstitial BT, where the backward dose perturbation reaches up to roughly 3 mm 
depth for 
60
Co and 1 mm depth for both 
192
Ir and 
169
Yb, with the perturbation being 
higher in magnitude as the mean energy of gammas emitted by the radionuclide 
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decreases. The depth of the perturbation and the perturbation ratio at 0.1z    mm 
(with 0  ) is independent of the lead thicknesses here considered (differences of 
perturbation ratios below 2% for all three sources). 
 For other ρ values, the dose enhancements due to the presence of the 
shielding are different than those reported in Figure 5-3: the dose enhancement 
generally increases with ρ for a single source position, although the range of the 
high dose perturbation remains nearly the same. The variation of the dose 
enhancement with ρ for a single dwell position is not considered to be relevant 
given that it is different than in a clinical case with multiple dwell positions. Figure 
5-4 shows the percentage excess dose (shielded to unshielded absorbed dose ratio 
minus 1, i.e.  0100% 1Pb Pbt tD D   ) throughout the water phantom (in the x-z 
plane) for a real clinical configuration with 
192
Ir. The excess dose plots for 
60
Co and 
169
Yb are equivalent to the ones shown in Figure 5-4, although with different 
excess dose values and ranges of the perturbations. The following is noted within t 
the 50 50  mm2 target region: 
- For 
60
Co, the range of the high dose enhancement reaches 3z    mm. For 
greater depths, there is an excess dose of 2 3%  and 0 1%  for surface and 
interstitial BT cases, respectively. This nearly constant excess dose reaches a depth 
of, at least, 30z    mm. 
- For 
192
Ir, the range of the high dose enhancement reaches 1z    mm. For 
greater depths, there is an excess dose of 2 3.5%  and 1 2%  for surface and 
interstitial BT cases, respectively. This nearly constant excess dose reaches a depth 
of, at least, 30z    mm. 
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(a) 
 
(b) 
 
(c) 
Figure 5-3. Shielded to unshielded absorbed dose ratio in the z-axis (radial 
distance 0  ) for all sources and for the three configurations used according to 
source location: surface BT, and interstitial BT with ds=5 mm and 10 mm. 
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- For 
169
Yb, the range of the high dose enhancement reaches almost 1z    mm. 
For greater depths, there is an excess dose of 4 5.5%  for surface BT, although 
variations up to 9%  are observed in planes without a dwell source position. For 
interstitial BT, the difference is 4 5%  up to 2z    mm and 3 4%  for 
greater depths. 
- For all three radionuclides, the excess dose in interstitial BT is negligible (<1%) at 
distances less than around 2 mm from the source (see grooves in Figure 5-4b). 
 Not only are the magnitude and depth of the backward dose perturbation 
important, but also is the type of ionizing radiation that produces it. Figure 5-5 
shows, for ds = 5 mm and tPb = 6 mm, the shielded to unshielded absorbed dose 
ratio in the z-axis for each considered source, showing contribution of photons and 
electrons that backscatter from the lead shield to the water phantom, which have the 
spectra shown in Figure 5-1. Contamination from backscattered photons is nearly 
constant with z, for the depths close to the phantom surface. This is not the case for 
electrons, which are the main source of contamination near the surface, as 
previously suggested in works about backscatter dose perturbations by kilovoltage 
and megavoltage photon beams (Das et al., 1989; Li et al., 1999). However, their 
influence decreases quickly with depth: their dose curves can be fitted by an 
exponential function, as previously proposed (Klevenhagen et al., 1982; Lambert et 
al., 1982; Perez-Calatayud et al., 2000). The current study confirms this behavior 
and quantifies it for the three HDR BT sources. 
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(a) 
 
(b) 
Figure 5-4. Percentage excess dose (%) in the water phantom (y = 0) due to the 
lead shielding for a) surface (ds = 0) and b) interstitial (ds = 5 mm) HDR 
brachytherapy with 192Ir. This corresponds to a real configuration with the source 
having multiple dwell positions. Grooves appear at the different dwell positions. 
The bin widths are 0.2 mm and 0.5 mm for z and x, respectively. 
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(a) 
 
(b) 
 
(c) 
Figure 5-5. Shielded to unshielded absorbed dose ratio in the z-axis for all three 
sources, using ds=5 mm and tPb=6 mm, with contribution from backscattered 
photons and electrons.  
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5.3.3 Transmission 
 Figure 5-6 shows the shielded to unshielded absorbed dose ratio above the 
lead shield for a 
60
Co source placed at 5 mm depth and with lead shield of 6 mm 
thickness, considering a clinical case with multiple dwell positions. Similar figures 
were obtained for 
192
Ir and 
169
Yb, as well as for the other source depths and lead 
thicknesses considered. Given the multiple and limited source positions, the dose 
reduction is not constant throughout the whole space, and so giving a single 
transmission value in a real case with multiple dwell positions seems not 
appropriate. Instead, a transmission range for each considered case is provided 
(Table 5-2). The forward dose enhancement near the surface is not considered, as 
previously argued. In addition, the treatment area has 50 mm thickness and is 
centered at 0x   mm. Thus, the transmission range is for the limits 
20 100z   mm and 25 25x    mm. Furthermore, an arbitrary reference 
point has been established at ( 0, 0, 50)x y z    mm, for which the 
transmission is also provided in Table 5-2. 
 
Figure 5-6. Shielded to unshielded absorbed dose ratio in the X-Z plane of the air 
volume due to the tPb=6 mm lead shielding for interstitial (ds=5 mm) HDR 
brachytherapy with multiple dwell positions of a 
60
Co source. 
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Table 5-2. Transmission through the lead shield for 
60
Co, 
192
Ir, and 
169
Yb, as a 
function of lead thickness tPb and source depth ds. Transmission is evaluated in the 
x-z plane, in the range 20 100z   mm and 25 25x    mm. The reference 
point is ( 0, 0, 50)P x y z    mm. 
 
 
  The statistical uncertainties of the transmission values reported are generally 
~10% for 
60
Co and 
192
Ir, and ~50% for 
192
Yb. Although these relative uncertainties 
may seem large, they are smaller or similar than the broad transmission range 
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shown in Table 5-2 for each configuration. As expected, the transmission decreases 
as the lead thickness increases. For 
60
Co, transmission data seem not sensitive to 
source depth, whereas for 
192
Ir and 
169
Yb, transmission is lower in surface BT than 
in interstitial BT, although with a large dose range. 
 
5.4 Discussion 
5.4.1 Backscattered dose perturbation 
 The range of the backscatter dose perturbation obtained in this work (along 
the z-axis) for 
60
Co (3 mm) is similar to experimental data by Das et al. (1989) and 
MC simulations by Li et al. (1999) (3 to 4 mm), both for an external collimated 
beam and a lead shield immersed in water equivalent tissue. 
 Results of this work for the single dwell position are also consistent with 
those published for the particular case of the Valencia applicator with 
192
Ir sources 
(Lliso et al., 2011), in which the backward perturbation was reported to be around 
0.5 mm (0.7 mm in this work, near 1 mm). The dose enhancement at the surface 
(within 0.1 mm depth) for the Valencia applicator configuration was a factor of 2. 
As shown in this work, this dose enhancement in the transversal axis depends on the 
distance between the source and the shielding, ranging between 2.7 for ds=10 mm 
and 1.1 for ds=0 (see Figure 5-3b). In addition, in the Valencia applicator 
configuration, the lead shield was immersed in water whereas it was only in contact 
with the upper surface in the current study. Due to backscattering in the water 
phantom, immersion in water increased absorbed dose when no shielding was 
placed. Scattered radiation is of lower energy and is more attenuated when the lead 
shield is used. This contributes to the fact that the ratio between the dose with and 
without the shield decreases in comparison to a shield placed between water and air. 
 The backscatter dose enhancements in water obtained in this work, observed 
to be equivalent to those for tissue, may be used to choose an appropriate bolus 
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thickness to be placed between the surface and the lead shield. As shown previously 
for a realistic clinical case, the high dose perturbation reaches 3 mm depth for 
60
Co 
and 1 mm for 
192
Ir and 
169
Yb, and equivalent or larger bolus thicknesses are needed 
for each radionuclide source. 
 Nowadays, plastic is used to flatten the surface and keep rigid the catheter 
geometry (Nag et al., 2001; Yang et al., 2009) and so it seems adequate to 
investigate whether its thickness is enough to negate backscatter overdose. With 
this aim, the backscatter dose perturbation was also obtained in polyethylene (
0.94   g/cm
3
) and the range of the perturbation was found to be equal to the 
range in water (within 0.1 mm) for 
192
Ir and 
169
Yb, whereas for 
60
Co the range in 
plastic was 0.4  0.1 mm larger, also negligibly different than water. Hence, 
polyethylene is equally valid to avoid surface overdose if it has the appropriate 
thickness previously obtained for water. 
 Bolus thicknesses determined in this work are required to avoid high 
overdoses produced by electrons, but there still remains a nearly constant 
contamination from photons which reaches at least a few centimeters depth. That 
contamination might be small taking into account that treatment planning systems 
currently used in HDR brachytherapy consider the source to be placed within an 
infinite water medium, thus not considering that there is air above the patient 
surface. Due to the negligible contribution of backscattering in air in comparison to 
backscattering in water, the calculated surface dose might be currently 
overestimated. The presence of the bolus and the lead shield could partly 
compensate this. 
 
5.4.2 Transmission 
 For all three radionuclides considered, Figure 5-7 plots the transmission at 
the reference point for the surface BT case, with error bars showing the range of 
transmissions given in Table 5-2. For comparison purposes, the transmission curve 
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fitted by Papagiannis et al. (2008) for brachytherapy facility shielding is also 
plotted. Discrepancies between both datasets appear as the energy of gammas 
emitted by the radionuclide increases. This is mainly due to the fact that in the work 
by Papagiannis et al. (2008) the source was placed in air and at a distance of 1 m of 
the lead shield, which covered the whole wall, and only photons emitted in the 
shield direction were considered. However, in this case the source was placed in 
contact with or near the lead shield and the water phantom, and there were several 
dwell positions. The water phantom in this work increased absorbed dose when no 
shield was used in comparison to an air phantom due to backscattering by air being 
negligible in comparison to water. Therefore, the shielded to unshielded absorbed 
dose ratio in the surface BT configuration is necessarily lower than that given by 
Papagiannis and colleagues. Since incoherent scattering is increasingly important as 
photon energies increase, the discrepancy is highest for 
60
Co and almost negligible 
for 
160
Yb. In addition, the transmission evaluated by Papagiannis et al. is the 
maximum one as it was obtained in the transversal axis of the wall and the source. 
When the source is displaced, its contribution along that axis is lower since their 
photons traverse a higher lead thickness. 
 Thus, the geometrical configuration can greatly influence the transmission 
values. It should be carefully evaluated for each particular case if a precise 
estimation of dose reduction is desired. For instance, data provided in this work can 
be used to estimate organ equivalent dose saving in a treatment with HDR surface 
or interstitial BT with lead shields. In addition, the dose reductions shown in this 
work justify the use of lead shields (with an appropriate bolus thickness) in some 
particular radiation treatments since they clearly compensate the small backscatter 
overdose. 
 
Chapter 5 
_____________________________________________________________________________________________________________________________________________ 
96  
  
Figure 5-7. Transmission dose through the lead shield calculated in this work at 
the reference point, for 
60
Co, 
192
Ir, and 
169
Yb sources in the surface brachytherapy 
case. Error bars show the range of transmissions given in Table 5-2. Data are 
compared with the fitting curve by Papagiannis et al. (2008) (solid lines). 
 
5.5 Conclusions 
 In surface and interstitial BT, the high backscatter dose enhancement in the 
body surface due to use of a lead shield can be avoided by using a bolus thickness   
3 mm for 
60
Co, and   1 mm for 192Ir and 169Yb. It is due mainly to backscattered 
electrons and characteristic x-rays to a lesser extent. 
 Transmission data as a function of lead thickness have been provided for the 
three radioactive sources. These have been shown to differ with radiation 
transmission data for facility shielding with high energy sources due to the 
environment geometry (presence of water and multiple dwell positions). These data 
can be used to estimate organ equivalent dose saving in a real treatment with HDR 
surface or interstitial BT with lead shields. 
 Chapter 6. FETAL DOSE REDUCTION IN 
PREGNANT PATIENT WITH BREAST 
CANCER 
 
 
 
Most of the content of this chapter is included in the original research paper: 
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Celada F, Ramírez-Coves JL, Ballester F, Tormo A, Pérez-Calatayud J. Fetal dose 
measurements and shielding efficiency assessment in a custom setup of 
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Ir 
brachytherapy for a pregnant woman with breast cancer. Physica Medica. (2015) 
doi: 10.1016/j.ejmp.2015.01.010. 
Kind permission was granted by the journal to reprint this article as a chapter of this 
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6.1 Introduction 
 Even though the incidence rate of cancer during pregnancy is low (roughly 
0.1% of pregnant women have cancer (ASCO, 2014; Filipov et al., 2013)), the 
magnitude of patients needing treatment is appreciable. In particular, many 
pregnant women are treated with radiation therapy. Given that ionizing radiation 
can also cause damage to the fetal cells, the possible risks to the developing baby 
should be carefully evaluated. 
 The effect of ionizing radiation to the fetus depends on the gestational age, 
equivalent dose and fractionation (Stovall et al., 1995; ICRP, 2000; Nuyttens et al., 
2002; NCRP, 2013). A summary of these radiation effects, classified by gestational 
age, can be found in reports by the AAPM (Stovall et al., 1995), the ICRP (2000) 
and, more recently, the NCRP (2013). Based on epidemiological data from atomic 
bomb survivors, from patients exposed to diagnostic X-rays, and from experiments 
with animals, it may be concluded that doses below 10 cGy do not produce 
observable deterministic effects in the fetus, although this dose threshold is reduced 
to 5 cGy in other studies (Kal et al., 2005). In addition, the possibility that such low 
doses may produce a radiation-induced tumor is under debate (Candela-Juan et al., 
2014a). A large uncertainty exists for this dose threshold, and so the main aim of 
any radiation treatment should be tumor control with absorbed doses to the fetus 
made as low as possible, trying not to exceed the stated dose constraint. It may be 
helpful to clarify at this point that even though the original data used to determine 
the existent dose constraints was expressed in mSv, the units of absorbed dose (i.e., 
cGy) are adopted in the current study for consistency with the reports by the AAPM 
(Stovall et al., 1995), ICRP (2000) and NCRP (2013). 
 Radiation therapy in pregnant patients has been widely reported for 
Hodgkin’s disease (Woo et al., 1992; Cygler et al., 1997; Antypas et al., 1998; 
Nuyttens et al., 2002; Mazonaquis et al., 2003), as well as for head and neck tumors 
or brain carcinomas (Wong et al., 1986; Sneed et al., 1995; Podgorsak et al., 1999; 
Haba et al., 2004; Lliso et al., 2004; Josipovic et al., 2009). There are also 
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publications on radiotherapy for pregnant patients with breast cancer (Ngu et al., 
1992; Van Der Giessen et al., 1997; Antypas et al., 1998; Fenig et al., 2001; Martín 
Rincón et al., 2002; Filipov et al., 2013; Kourinou et al., 2015). However, to the 
best of our knowledge, all previously reported radiation treatments applied to a 
pregnant patient were based on EBRT. No prior study has examined fetal doses for 
women receiving breast BT, although Venselaar et al. (1996) evaluated the 
absorbed dose at large distances from BT sources and proposed the application of 
his evaluations to estimate fetal doses. 
 In EBRT, the peripheral dose depends mainly on the distance from the field 
edge (it approximately falls exponentially with the distance (Stovall et al., 1995; 
Mutic et al., 1999; Podgorsak et al., 1999; ICRP, 2000; Josipovic et al., 2009)), but 
also on the field size and, in a minor contribution, on the depth in tissue (Antypas et 
al., 1998). The main sources of radiation outside the treatment area are head 
leakage radiation, radiation scattered in the collimators and the rest of the head of 
the accelerator, transmission through the collimators, and radiation scattered inside 
the patient (Antypas et al., 1998; Mutic et al., 1999). The use of physical wedges is 
ill-advised because of the higher amount of monitor units (MU) needed and the 
higher scatter component (Josipovic et al., 2009; Filipov et al., 2013). The use of 
high-energy photon beams (> 10 MV) should also be avoided as it leads to a higher 
proportion of the transmission and collimator scatter, as well as to generation of 
photoneutrons (Antypas et al., 1998). In order to reduce peripheral dose, a tertiary 
multileaf collimator (MLC) may be used, which reduces collimator scatter and 
transmission through the primary and secondary collimators (Mutic et al., 1999). 
Furthermore, shielding devices around the patient’s abdomen or the gantry are 
highly recommended to minimize exposure to the fetus from leakage and collimator 
radiation scatter (Ngu et al., 1992; Woo et al., 1992; Stovall et al., 1995; Nuyttens 
et al., 2002; Lliso et al., 2004; Josipovic et al., 2009; Filipov et al., 2013). The 
proposed lead thickness for EBRT is about 5 cm to 7 cm (Josipovic et al., 2009), 
which results in a massive custom device. 
Chapter 6 
_____________________________________________________________________________________________________________________________________________ 
100  
 Opposed to the traditional whole breast irradiation (WBI), accelerated partial 
breast irradiation (APBI) techniques have emerged in recent decades, either by 
interstitial or intracavitary BT, EBRT, or intraoperative radiation therapy (IORT). 
The American Society for Radiation Oncology (ASTRO) (Smith et al., 2009), the 
Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology 
and Oncology (GEC-ESTRO) (Polgar et al., 2010), and the American 
Brachytherapy Society (ABS) (Shah et al., 2013) have presented consensus 
statements for APBI. The rationale for APBI is that most of local relapses occur in 
proximity to the tumor bed (Polgar et al., 2005; Vicini et al., 2005). Thus, APBI 
may be another option to treat breast cancer in pregnant patients. 
 On the basis of the rapid dose fall off with distance (as a result of the inverse 
distance square law) from a BT implant, it is expected that this radiation technique 
reduces the dosage to organs at risk and the integral dose when compared to EBRT. 
This has been quantified for organs as the heart or lung (Patel et al., 2007; Weed et 
al., 2005). Also, in Chapter 2, based on MC simulations and patients with prostate 
cancer, a radiation protection advantage of BT over EBRT at large distances from 
the treatment volume was shown (Candela-Juan et al., 2013). This advantage could 
be applied to fetal dose reduction. Although there are no data to determine the 
optimal technique for APBI, interstitial BT has the highest follow up and is the 
technique of choice at our center for breast BT. This technique uses a HDR 
192
Ir 
source and an array of catheters inserted within the breast around the excision 
cavity. 
 The aim of the current study is to assess the radiation dose to the fetus when 
using interstitial breast HDR 
192
Ir BT. In addition, a new patient setup and lead 
shielding technique placed around the breast was designed to reduce the fetal dose. 
Absorbed doses were evaluated without and with this shielding. The variation of 
dose with distance to the implant as well as dose homogeneity within a 
representative slice of the fetal position were measured experimentally. A case 
report is also presented. 
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6.2 Materials and methods 
6.2.1 Case report 
 A 29-year-old woman in the 12
th
 week of gestation (see Figure 6-1) was 
submitted for postoperative irradiation of the right breast. An interstitial HDR 
192
Ir 
BT breast treatment was planned as described in section 6.2.2 because the fetal dose 
was estimated to be lower than the delivered by external radiotherapy (a 
comparison between both techniques can be found in the Discussion section of this 
chapter). Interstitial HDR 
192
Ir breast BT was also recommended because the 
patient satisfied the recommendations of ASTRO (Smith et al., 2009), GEC-
ESTRO (Polgar et al., 2010), and ABS (Shah et al., 2013), except for the age 
restriction, which is discussed later. From ultrasound measurements, it was 
estimated that the distance from the lower edge of the breast to the uterine fundus 
(the most proximal position of the uterus) 1 week before treatment was 20 cm, 
whereas the pubis was located an additional 10 cm caudally. The methodology 
described below was used to evaluate dose to the fetus. 
 According to the NCRP Report 174 (2013), the minimum acute lethal dose is 
estimated to be > 100 cGy for the fetus between the 8
th
 and the 15
th
 week of 
gestation. However, this is the most vulnerable period for irreversible whole-body 
growth retardation, with no-adverse effects observed between 25 cGy and 50 cGy. 
Nevertheless, given that a dose threshold of 5 cGy has been suggested in other 
studies (Kal et al., 2005), this conservative constraint was used in the current study 
to compare the treatment options. 
 
6.2.2 Treatment planning 
 The patient was seated in a chair with her right breast positioned over a table 
in such a way that the fetus was located beneath the table (see Figure 6-1). The 
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radiation dose to the fetus can then be reduced when the breast is shielded (see 
section 6.2.3). 
 An interstitial breast HDR 
192
Ir BT treatment was planned using Oncentra 
Brachy TPS v.4.3 (Elekta AB, Stockholm, Sweden). A total of 36 Gy in 8 fractions 
was prescribed at the 90% of the basal points, with two treatment fractions per day 
given in four consecutive days. Seven catheters were used, each of them having the 
HDR 
192
Ir source dwell positions for 9 cm of active length. The catheters were 
positioned in two coronal, parallel planes (three catheters in one plane and four 
catheters in the deeper-seated plane, both parallel to the thoracic wall, and defining 
equilateral triangles of side 1.6 cm) using a template (see Figure 6-2a). The 
minimum distance between the closest catheter and the thoracic wall was about 2 
cm. 
 
Figure 6-1. Simulation of the proposed patient set-up in the HDR brachytherapy 
treatment room. The patient is seated in a chair, placing the breast to be treated 
over the lead shielding, which has a hole in the lateral wall to allow connecting the 
transfer tubes to the catheters. With this position, the fetus is maximally located 
beneath the shielded table. 
Fetal dose reduction in pregnant patient with breast cancer 
_____________________________________________________________________________________________________________________________________________ 
 103 
6.2.3 Shielding design 
 Absorbed dose to the fetus is due to primary radiation from the 
192
Ir source 
and scattered radiation within the patient. The latter cannot be removed; however, 
the breast may be shielded to minimize dose contribution to the fetus from the 
primary component. 
 The shielding design consisted of a 3.5 cm thick layer of lead placed between 
the breast and the table. Thus, during the treatment, the breast rests over this lead 
shield. In addition, two lateral pieces of lead (3 cm thick each) were added (see 
Figure 6-2). The rationale for the use of this thickness was to attenuate most (over a 
factor of one-thousand, considering a tenth-value layer of 11 mm (Candela-Juan et 
al., 2014b)) of the primary radiation component of the absorbed dose to the fetus 
such that it just receives the scattered radiation from inside the mother. The lateral 
blocks allowed placing an extra piece of lead (2.5 cm thick) above the breast, 
parallel to the first layer (see Figure 6-2b). The aim of this last layer was to shield 
primary radiation to the thyroids and eye lenses given the seated position of the 
patient. Its thickness was chosen as a compromise between providing radiation 
attenuation and patient setup feasibility given its weight. 
 One of the lateral layers had a hole through which the transfer tubes were 
connected to the catheters (see Figure 6-1 and Figure 6-2b). In order to minimize 
the transit dose when the 
192
Ir source exits and returns to the remote afterloader, a 
hollow lead tube (0.4 cm thick) was made, which covered the transfer tubes (see 
Figure 6-2b). 
 It is important to note that lead shielding placed in contact with patient skin 
can considerably increase the surface dose due to backscattering and electron 
contamination. This problem was in Chapter 5 for surface and interstitial HDR 
192
Ir BT. From that study, it was concluded that the surface overdose may be 
removed in the current study by placing a 0.1 cm thick layer of water-equivalent 
material between the lead shielding and the patient skin. 
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a) b) 
Figure 6-2. Representation of the HDR 
192
Ir brachytherapy treatment set-up, 
showing a) the implant within the breast phantom, and b) the assembled lead 
shielding arrangement. 
 
6.2.4 Fetal dose evaluation 
6.2.4.1  Phantom measurements 
 Measurements of absorbed dose were made in a Rando phantom (Alderson 
Research Laboratories, Inc., Stanford, CT), which is sectioned into slices and is 
made of materials to radiologically mimic body tissues (see Figure 6-2). As a 
female-designed phantom was not available, the missing breast tissue was made of 
Roma Plastilina
TM
 (JOVI S.A., Rubí, Spain). While this material is denser than a 
female human breast, the differences in attenuation at the photon energies examined 
in the current study (originating from 
192
Ir) are expected to be negligible. 
 Because the patient was seated, her spine was oriented approximately 
vertically during treatment. Thus, it was decided to center the dosimeters at a 
position approximately representative of the center of the fetus, measuring the 
distance from the back of the patient. In this study, using data from Osei and 
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Faulkner (1999), it was estimated that the shortest distance between the fetus and 
the patient’s back was about 10 cm for a median pregnant woman, whereas the 
largest distance might be about 20 cm. Then, the position representing the fetus 
center was estimated to be at about 15 cm from the phantom’s back. Absorbed dose 
was measured at this central region, in several planes of the phantom, covering a 
distance dz between 5 cm and 35 cm from the lower edge of the treated breast (or 
the upper surface of the lead shield) (see Figure 6-3a). This way, dose was 
estimated as a function of distance from the breast, hence allowing the application 
of the results to a wide range of gestational ages. Furthermore, four extra 
measurements were made at distances of 10 cm and 20 cm from the lower edge of 
the breast in order to evaluate the uniformity of the dose distribution. The location 
of the dosimeters in these three planes is depicted in Figure 6-3b. 
 Additionally, measurements were made at the eye lenses and thyroid of the 
phantom. All dose measurements were made without and with the previously 
described shielding design. 
 
6.2.4.2 Radiochromic film dosimetry 
 The energy spectrum of radiation impinging the fetus is unknown, which 
may introduce a significant uncertainty in dosimeters with energy-dependent 
response. For this reason, in the current study, Gafchromic
TM
 EBT3 films (ISP, 
Wayne, NJ, USA) were used, whose energy response to monochromatic beams of 
35 keV has been shown to differ by at most 3% when compared to calibration with 
4 MV beams (Brown et al., 2012). This energy dependence was considered as an 
additional term of the uncertainty for derivation of dose.  
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a) b) 
Figure 6-3. a) Lateral view of the Rando phantom showing vertical distances dz 
from the caudal edge of the breast. b) Axial plane of the Rando phantom showing 
the location of the dosimeters and the distance between them. The location of each 
film is identified according to the notation: central C, anterior A, posterior P, right 
R and left L. 
 
 In order to obtain readings above a few cGy even for the farthest dosimeters, 
five complete treatments (with 8 fractions each) were irradiated consecutively when 
shielding was used. When shielding was not used, the films were subjected to 
irradiation from a single treatment (8 fractions). 
 The films were cut into 3.2 cm × 3.2 cm pieces. Additionally, a set of films 
belonging to the same lot were irradiated at known doses of 0, 10, 20, 50 and 200 
cGy, using a TrueBeam
TM
 linear accelerator (Varian Medical Systems, Palo Alto, 
CA, USA) with 6 MV beams. Together with the calibration films, the irradiated 
films were scanned 4 days after irradiation using a model 11000XL scanner (Epson 
Canada, Ltd., Markham, Ontario, Canada), employing a resolution of 100 dpi and 
16-bits per color. Scanned images were then analyzed using the Film QA Pro
TM
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software (Ashland Inc., Wayne, NJ, USA) with the multichannel film calibration 
method and protocol recommended in the literature by the film and software 
manufacturers (Micke et al., 2011; Lewis et al., 2012). The dose-response data was 
fitted by a rational function, as shown in Figure 6-4. The quality of the fitting curve 
indicates the adequacy of these films even in the low dose range. Regions of interest 
subtending 1.3 cm × 1.3 cm were defined at the center of the irradiated films and 
the average dose and its standard deviation were determined. 
 
Figure 6-4. Calibration data and calibration function for all three channels (R, G, 
B) of the Gafchromic EBT3 films used in this study to convert pixel values to 
absorbed dose. 
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6.3 Results 
6.3.1 Dose distribution in the central region 
 Table 6-1 shows absorbed doses measured with radiochromic film at central 
region C (see Figure 6-3b). The uncertainty of the measurements was obtained 
considering the standard deviation of the selected ROI, which increases with 
distance dz. Roughly, this uncertainty component is 3% at 5 cm and 45% at 25 cm. 
In addition, the uncertainty of the calibration curve at these low absorbed doses 
(roughly 3% according to the analysis software) was also considered as well as the 
uncertainties due to the variation of film sensitivity as a function of photon energy 
(3% according to Ref. (Brown et al., 2012)). Results are reported without and with 
shielding. Table 6-1 also shows the dose ratio for unshielded to shielded HDR-BT. 
The proposed shielding reduced the radiation exposure by a factor of two near the 
breast and more than an order of magnitude beyond 20 cm. The effect of shielding 
increased with increasing distance from the inferior edge of the breast. This was 
reasonable considering that at the closest axial planes there were still contributions 
from primary radiation that did not traverse the shielding to reach those regions 
within the patient. At farther distances, primary radiation was mostly attenuated and 
dose was mainly comprised of scattered radiation. For the experimental conditions, 
nearly constant attenuation factors of 15%/cm and 26%/cm (per unit dz) were 
observed without and with shielding, respectively. 
 Absorbed dose was also evaluated without and with shielding at positions in 
the phantom to estimate dose to the thyroid and the right eye lens. The upper lead 
shield had no effect on thyroid dose (40 cGy in both cases) as in this case it was not 
close enough to the thoracic wall to shield primary radiation. However, it shielded 
the ocular lenses and reduced absorbed dose by a factor of 20 (from 72.8 to 3.6 
cGy). 
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Table 6-1. Absorbed dose after a complete (36 Gy) brachytherapy treatment, 
measured with EBT3 radiochromic films placed between slices of the phantom, at 
15 cm from the phantom’s back. Distance dz was measured from the axial slice at 
the lower edge of the breast. Estimated uncertainties (with coverage factor 1k  ) 
are given in parentheses. 
 
 
Table 6-2. Relative difference between absorbed dose at a given point on the axial 
plane (see Figure 6-3b) and absorbed dose DC at the center C of the same axial 
plane (from Table 6-1), after a complete (36 Gy) brachytherapy treatment. 
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6.3.2 Dose homogeneity on an axial plane 
 Table 6-2 shows the measured relative difference between the dose at a 
given position (A (anterior), P (posterior), R (right) or L (left), as seen in Figure 
6-3b) of an axial plane and the dose in the center C of that same plane, for axial 
planes given by 10.0zd  cm and 20.0zd  cm. 
 The dose heterogeneity observed for HDR 
192
Ir interstitial breast BT (Table 
6-2) can be explained considering the inverse-distance square law and the 
contribution from primary and scattered radiation. The implant was in the right 
breast and in the anterior part of the phantom. When shielding is used, primary 
radiation to the anterior part of the abdomen is attenuated and there are 
contributions only from scattered radiation, which traveled a larger distance to 
reach the anterior part than the central part. Thus, shielding reduced dose to the 
anterior part of the phantom. The same argument applied to the left region of the 
patient abdomen. However, the distance that the scattered radiation has to traverse 
to reach the posterior part of the phantom is shorter than to the central region. When 
also accounting for contributions from primary radiation, dose to the posterior part 
commensurately increases. On the right side of the phantom, the dose variation is 
nearly negligible when compared to the dose at the center. Without shielding, the 
inverse-distance square law dominates and regions that are nearer the implant 
receive a higher dose. 
 
6.3.3 Case report 
 According to ultrasound measurements, the most proximal part of the fetus 
was 20 cm below the caudal edge of the breast one week before the planned 
treatment, with the pubis located at 30 cm. Considering a cranially growth of the 
fetus of 1 cm per week (Podgorsak et al., 1999) and that the fetus was still mainly in 
the central region, the highest absorbed dose to be received by the example fetus in 
this case report was estimated to be 2 cGy, whereas the estimated pubis dose was 
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less than 0.1 cGy. These values are notably below the 5 cGy constraint that was 
established for the current study. 
 
6.4 Discussion 
6.4.1 Clinical considerations 
 ASTRO, GEC-ESTRO and ABS have published recommendations for 
patient selection criteria for APBI (Smith et al., 2009; Polgar et al., 2010; Shah et 
al., 2013), and identify a high-risk group that should not be treated with APBI 
outside of clinical trials. This group, among other factors, includes patients younger 
than 40 to 50 years. These recommendations are based on the fact that young age 
has been documented to be a dominant adverse prognostic factor for local failure, 
and that the majority of studies with successful results for APBI included an age 
restriction for patient selection. However, the association of youth and local failure 
is based on data after WBI. There are retrospective analyses that do not find 
differences between the different ASTRO risk groups using APBI (Wilkinson et al., 
2013). Sensitive decisions, such as radiation therapy in a pregnant woman, should 
be made on an individual basis, and always assessing techniques that adequately 
reduce the fetal dose. 
 
6.4.2 Analysis of the dose as a function of depth 
 Based on the measured rate of dose falloff as a function of dz, for HDR 
192
Ir 
BT without and with shielding, for the experimental conditions of this study an 
uncertainty of 1 cm in measuring dz would result in a dose measurement uncertainty 
of 15% and 26%, respectively. For the measured values shown in Table 6-1, the 
magnitude of the measurement uncertainties without and with shielding exceeded 
the rate of dose falloff as a function of dz at approximately 24 cm. In retrospect, 
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perhaps the uncertainties at larger distances could have been diminished if extended 
detector irradiation times were utilized. 
 However, differences up to 50% compared with the central region are present 
for a given axial plane with HDR 
192
Ir BT, as examined in the current study. The 
exact location of the uterine fundus within a given axial plane is thus the largest 
contributor to the uncertainty of the evaluated fetal dose. Given the patient setup 
geometry and practical desire to minimize imaging of the fetus, a robust means of 
measuring the distance from the fetus to the implant, and the position of the uterine 
fundus is elusive to satisfy the dose constraint. Radiochromic films seem 
appropriate to provide quantitative, patient-specific dose measurements as long as 
adequate signal is generated (through delivery of multiple treatment fractions). 
 Based on this analysis, it seems reasonable to state that the estimated 
maximum fetal dose may be evaluated in HDR 
192
Ir BT with roughly a maximum 
conservative uncertainty of 50%. This magnitude is considered acceptable for 
radiation protection applications. If the measured doses with shielding were 
increased by this factor of 1.5, the maximum fetal dose would still be lower than the 
5 cGy constraint considered in this study for distances dz larger than about 17 cm. 
 
6.4.3 HDR 192Ir BT vs. EBRT 
 Other published studies on radiotherapy during pregnancy used EBRT 
techniques. In the current study, interstitial HDR 
192
Ir BT is proposed as a 
therapeutic option to treat breast cancer in pregnant patients, as previously argued. 
From an exposure perspective, differences exist between both radiotherapy 
techniques when applied to this malignancy. BT offers over EBRT the advantages 
of a smaller prescribed dose, a smaller number of treatment fractions, and a smaller 
overall treatment time, which facilitates maintaining the distance between the breast 
and the fetus as large as possible. However, BT delivers higher doses per fraction, 
which can increase the fetal toxicity, even though this has not been proven at low 
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radiation doses (< 10 cGy). On the other hand, peripheral dose in a given axial 
plane is nearly homogeneous in EBRT, whereas large dose heterogeneities have 
been observed in this study for the HDR-BT case. 
 It may be also interesting to compare accumulated fetal doses reported in 
other studies using EBRT with results obtained in the current study. Figure 6-5 
shows data from the current study (without and with shielding) in the central region 
(see Table 6-1) compared with peripheral doses measured by Martín Rincón et al. 
(2002) when using EBRT without wedges. The latter used tangential 6 MV photon 
beams, prescribing 50 Gy to the right breast. Figure 6-5 shows that peripheral dose 
decreases nearly exponentially in all cases (with an exponential fit provided for the 
different datasets). The slope of the depth-dose curve is steeper for the case of BT 
with shielding. When comparing this case with ‘EBRT – 6 MV’ (from Martín 
Rincón et al. (2002)), it is observed that shielded BT is advantageous from a 
radiation protection point of view beyond 10 cm from the caudal edge of the breast. 
It was the only examined treatment modality able to deliver less than 5 cGy as 
identified as the threshold for fetal toxicity. Differences with reported data by 
Martín Rincón et al. increase up to almost a factor of ten at 25 cm. 
 The treatment planning system only allows dose calculations near the source 
(up to roughly 10 cm) and so it cannot be used to validate results obtained in this 
study. MC simulations could have been performed to evaluate the photon energy 
spectrum at large distance, thus allowing the use of other detectors such as TLDs. 
Nevertheless, Venselaar et al. (1996) evaluated the peripheral dose rate at large 
distances from a 
192
Ir radioactive source, and adjusted the data to a fitting curve. For 
comparison purposes, this curve has been also represented in Figure 6-5 after 
converting the radial distances to dz distances, as used in the current study. The 
agreement between the dose values measured in the current study without shielding 
and those data by Venselaar et al. is good considering the uncertainties and the 
different geometrical conditions in both cases, which validates the results obtained 
in this study with radiochromic films.  
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Figure 6-5. Comparison of accumulated absorbed doses in the central region of a 
phantom after 50 Gy whole breast treatment using external-beam radiotherapy 
(EBRT) 6 MV X-rays without any wedges or shielding (from Martín Rincón et al. 
(2002)), and 36 Gy interstitial brachytherapy (BT) without and with shielding (from 
the current study). Dose values have been fitted by exponential curves. The curve by 
Venselaar et al. (1996) has also been plotted. The 5 cGy constraint presumed in this 
study is depicted with a red horizontal line. 
 
 Other authors have also reported the estimated fetal doses in pregnant 
patients with breast cancer using EBRT. Ngu et al. (1992) treated a woman in the 
late fetal stage using 6 MV photons and tangential wedged fields, covering the 
patient’s abdomen with 0.9 cm of lead shielding and using an additional lead block 
below the breast. A prescription dose of 50 Gy was prescribed and the maximum 
estimated fetal dose was estimated to be 14 cGy to 18 cGy. Van der Giessen (1997) 
evaluated the peripheral dose as a function of distance in breast radiotherapy for 
both, open and wedged beams, from photon energies covering 
60
Co gamma 
radiation and 6 to 25 MV X-rays. Fetal dose as a function of pregnancy stage was 
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reported from those measurements for a target dose of 50 Gy. The estimated 
maximum fetal doses were a factor 5 to 7 and 2 to 4 times higher than in the study 
by Martín Rincón et al. (2002) for the 
60
Co and 6 MV photon beams, respectively. 
Antypas et al. (1998) treated a 45-year-old woman at the second gestation week, 
using 6 MV X-ray beams and two opposing tangential fields, prescribing an overall 
absorbed dose of 46 Gy in 20 fractions. The distance between uterine fundus and 
the lower limit of the radiation fields was 29 cm, where the estimated absorbed dose 
was almost 4 cGy, a dose ten times higher than with the method proposed herein for 
the same distance. On the other hand, Filipov et al. (2013) evaluated fetal doses 
using a “pregnant” humanoid phantom irradiated with 6 MV photon beams and 
wedges. Measurements were done without and with a combination of 1.5 cm and 4 
cm-thick lead blocks, placed around the abdominal region. The minimum fetal 
doses were achieved when using the dynamic wedge and the lead shielding. In that 
case, the estimated dose to the uterine fundus was 13.8 cGy, whereas the pubis 
received 1.8 cGy, which is higher than obtained in the shielded BT approach 
proposed herein. Also, Kourinou et al. (2015) have recently evaluated the fetal dose 
for a breast treatment with 6 MV tangential beams, without wedges or shielding, 
performing measurements with an anthropomorphic phantom. The measured fetal 
doses ranged from 3.9 cGy at 60 cm from the isocenter to 24.8 cGy at 17.5 cm 
distance, also higher than in the shielded BT case. 
 While the use of abdominal shielding in EBRT has decreased the peripheral 
dose, delivery of absorbed dose is dependent on each particular case where dose 
reductions up to 60% have been achieved (Islam et al., 2001; Filipov et al., 2013). 
If this dose reduction is applied to the data in Figure 6-5, shielded BT would still be 
advantageous for dz > 12 cm. Therefore, interstitial breast HDR 
192
Ir BT with 
shielding has been demonstrated to be more advantageous for pregnant patients than 
EBRT, as long as the distance to the uterine fundus is more than 12 cm. 
 The prescription doses and radiobiological equivalence of the EBRT doses 
could be adjusted to match the HDR-BT circumstances. However, these alterations 
would not produce a more fair comparison since the documented prescription doses 
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represent those that are practically prescribed, and the magnitude of any 
radiobiological corrections at these low doses are governed by the uncertainties in 
their methodological assumptions. 
 Dose thresholds given in the literature do not specify if they should be 
related to a certain fetal volume, or if they should be considered as a maximum dose 
or a mean value. From a radiation protection perspective, the maximum dose value 
is typically used. If the maximum value would not be as important, but rather the 
mean or a certain dose volume, given the higher gradient of the BT peripheral dose, 
this BT shielding technique would be even more advantageous (recall that the 
estimated fetal dose at a distance of 30 cm from the caudal edge of the breast was 
below 0.1 cGy). 
 Besides the stated dosimetric advantage of HDR-BT over EBRT, there is 
another factor to consider, the shielding. The shielding mass proposed herein (over 
40 kg) is notably lower than needed for EBRT (over 200 kg (Stovall et al., 1995; 
Josipovic et al., 2009)) where the abdomen, larger than the breast needs to be 
shielded. This makes the BT shielding more manageable, with a lower likelihood of 
accident or couch damage. 
 The shielding described in the current study also allows protection of the 
ocular lenses and the healthy contralateral breast, as opposed to those generally 
used in EBRT, which only cover the abdomen region. The threshold dose above 
which the cataract formation could occur has been recently reduced to 50 cGy 
(Bouffler et al., 2012), although a linear relationship with no-threshold dose 
between probability of cataract formation and lens absorbed dose has not been 
discarded. 
 
6.4.4 Comparison of 192Ir with other HDR-BT sources 
 The technique described herein is based on an 
192
Ir source, the most popular 
radionuclide for HDR-BT. However, breast BT may be also performed nowadays 
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with 
60
Co sources or the 50 kV electronic brachytherapy (eBT) source (Xoft, Inc., 
Sunnyvale, CA, USA) (Rivard et al., 2006; Mille et al., 2010). Even though 
photons emitted by 
60
Co are more energetic than those emitted by 
192
Ir, up to a 
distance of about 25 cm from the source, the energy deposited by both 
radionuclides is nearly the same (
60
Co deposits a few percent smaller dose than 
192
Ir 
(Candela-Juan et al., 2013) in this depth range). Hence, 
60
Co sources may be also 
appropriate for this application, although a wider breast shielding might be required. 
 On the other hand, the eBT source emits photons of a considerably lower 
energy than 
192
Ir, and has been shown to give a smaller dose beyond a few 
centimeters. Through MC simulations, Mille et al. (2010) evaluated the absorbed 
dose to the normal uterus for a reference female phantom being treated to 34 Gy 
with balloon breast BT. Accumulated dose to the uterus was (11.20±0.03) cGy 
when using 
192
Ir and (0.153±0.002) cGy with the eBT sources, with a mean distance 
of 31.5 cm between the balloon center and uterus. Adjusting results of the current 
study to match the lower prescription dose and differing implant distances, HDR-
BT for the breast without and with shielding at the 34 Gy prescription dose and 
distance dz =25 cm provides 6.5 and 0.5 cGy, respectively. Consequently, eBT 
sources appear more favorable for breast BT than 
192
Ir for pregnant patients, even 
without addition of external shielding. 
 
6.4.5 Applicability of the current study to other setups 
 The treatment modality, patient setup geometry, and shielding proposed in 
the current study may be an important treatment method to consider, especially at 
the early gestational ages when the fetus is more sensitive to ionizing radiation and 
there is a higher probability to fetal death, malformations or mental retardations 
(NCRP, 2013). However, results presented herein are valid for the specific 
conditions reported in section 6.2.2 and for the shielding described in section 6.2.3, 
and so they should be carefully extrapolated to other conditions or systems. 
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 Considering treatment delivery, the geometrical setup used in the current 
study is based on a patient seated in a chair with the breast over a table and lead 
shielding surrounding the breast. An alternative setup could be the patient lying in 
the prone position, placing the breast to be treated inside a leaded box. This could 
distance the implant from the thoracic wall, thus achieving a higher attenuation of 
primary radiation. A lateral decubitus setup could be also considered, which may be 
more comfortable than the prone position, with the treated breast positioned closest 
to the shielding. Both of these two setup options should be evaluated from a 
dosimetric perspective before clinical use. 
 Finally, the treatment method described herein could also be applied to skin 
lesions of the extremities in which similar shielding could protect the fetus from 
primary radiation, thus achieving similar or even better dose reductions than in the 
current study. 
 
6.5 Conclusions 
 The optimized delivery of radiation therapy to pregnant patients with breast 
cancer is a demanding task in which the main aim should be tumor control while 
constraining dose delivered to the fetus beneath a fixed value. Previous studies 
evaluated the fetal dose delivered by EBRT. In the current study, HDR 
192
Ir BT has 
been proposed as an alternative method to reduce the fetal exposure. A specific 
patient setup and shielding design has been suggested. The peripheral dose has been 
evaluated as a function of the distance to the lower edge of the breast. Comparison 
with previously reported fetal doses from EBRT techniques showed a dosimetric 
advantage of shielded HDR-BT over EBRT beyond 10 cm. This option is thus an 
alternative method to be considered as long as the pathologic factors included in 
societal recommendations are satisfied, especially at the early gestational ages when 
the fetus is most sensitive to ionizing radiation and deterministic effects. 
 Chapter 7. GENERAL DISCUSSION 
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 From Chapter 2 to Chapter 6 we have presented five different studies 
related to the radiation protection of patients undergoing HDR brachytherapy. Each 
of these chapters has a specific discussion section and so the reader is referred to 
those sections for a deeper debate on each of the previous topics considered. In this 
section, a general discussion is presented relating the different studies of this 
dissertation. 
 Chapter 2 was the first study performed, and it was of relevance for the 
others. This chapter evaluated the peripheral dose for a patient undergoing HDR 
BT, either with 
60
Co or 
192
Ir sources. Because relative dosimetric differences around 
60
Co and 
192
Ir sources are less significant than prescription technique and the 
optimization parameters, no clinically significant differences exist between them. 
This means that, from a practical point of view where the goal is dose coverage of 
the lesion and dose minimization to healthy tissue, performing an HDR BT 
treatment with a 
60
Co source is equivalent to performing a treatment with a 
192
Ir 
source as long as their specific air-kerma strength or activity is considered. In other 
words, the same BT treatment plan (the same number of catheters and dwell 
positions) can be used for both sources with equivalent clinical results. Biological 
differences between them have been also stated to be negligible (Richter et al., 
2008; Strohmaier et al., 2011). This makes the comparison between these two 
sources independent on the technician and optimization parameters, which allows 
us to make a fair comparison between them, as presented in Chapter 2. MC 
simulations performed in this study showed that, from a patient radiation protection 
point of view, there is an advantage of 
60
Co over 
192
Ir up to ~25 cm, whereas 
192
Ir is 
increasingly advantageous beyond that distance. From the literature review 
performed in Chapter 3 it was found that most of the induced tumors appear within 
the high dose region. Thus, it might be expected from a theoretical point of view a 
slight increase of tumor induction with 
192
Ir than with 
60
Co, although the relative 
dose difference between these two sources is below 10% within this high dose 
region to healthy tissues and so in a practical point of view, this difference might 
result in negligible differences in the rate of cancer induction. Between 30 cm and 
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80 cm from the implant, organ equivalent doses are well below 0.1 Sv for common 
prescription doses, for which the probability to induce a tumor has been shown to 
be near the background level and with high uncertainties. Thus, even though at 
these large distances differences between the two sources for organ equivalent 
doses can be up to a factor of five, this is expected to result in negligible differences 
when considering the probability of cancer induction. 
 The second important point of discussion from Chapter 2 is the difference 
between different radiation techniques in terms of doses to healthy tissues. 
Equivalent doses here obtained were also compared with estimations made from 
EBRT with 3D-CRT, IMRT or proton therapy. As recently stated by a group of the 
GEC-ESTRO, second primary cancer risks must be also considered when deciding 
which patients should be irradiated and which techniques should be used (Murray et 
al., 2014). A recent study by Georg et al. (2014) has evaluated the dose to the 
nearest organs (bladder wall, rectal wall, femoral heads, urethra and pelvic tissue) 
of a prostate treatment, considering different treatment options: volumetric 
modulated arc therapy, intensity-modulated proton therapy, intensity-modulated 
carbon-ion therapy, LDR brachytherapy (with 
125
I sources) and HDR brachytherapy 
(with a 
192
Ir source). It was concluded that BT techniques were clearly superior in 
terms of rectal wall, bladder wall, and normal tissue sparing, with even lower values 
for HDR-BT. This study considered ten patients and it might not be generalizable 
since large differences exist among the literature and between different patients. In 
our study, similar organ doses were found between these different techniques for 
the nearest organs. Thus, it can be concluded that differences might be institution 
and patient dependent for the nearest organs. In our study, we also compared these 
techniques for large distances, and it is clear that BT is superior as the distance 
increases.  
 The fact that the studies by GEC-ESTRO (Murray et al., 2014) and Georg et 
al. (2014) are very recent denote the current importance and concern of the 
scientific and medical society about cancer risks and dose to healthy tissues 
resulting from different radiation techniques. In Chapter 2 and Chapter 3 we hope 
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to have been contributed to this aspect by comparing different sources and different 
radiation techniques in terms of second cancer risks, and to have been done an 
overview of the risks. Due to the large uncertainties in cancer risk estimates at low 
radiation doses, we do not advocate the use of MC simulations (highly time-
consuming) for individual patients.  
 Despite Chapter 2 was applied to a prostate carcinoma, results can be 
extended to other treatments such as the gynecological ones, which is the most 
extended application of HDR brachytherapy. The comparison between 
192
Ir and 
60
Co is also of application for any other treatment region. 
 Results from Chapter 3 concerning the current limitations of knowledge on 
tumor induction at low radiation doses motivated our interest in the study presented 
in Chapter 4. Epidemiologists and medical physicists from Sweden contacted us to 
perform MC simulations to characterize radium sources widely used during the first 
part of last century. As stated by the UNSCEAR committee in 2013, the extensive 
group of children treated with 
226
Ra sources may be very helpful to determine the 
relationship between a specific late hazard effect and the absorbed dose 
(UNSCEAR, 2013). Thus, while the topic might seem esoteric, the lack of accurate 
dosimetric data for the sources that were used in Sweden, and an evaluation of 
uncertainties, made it difficult to take the most profit of their extended data on 
patient follow-up. Therefore, it is expected that the dosimetric data presented in 
Chapter 4 are important for retrospective epidemiological studies. 
 Reducing the high absorbed doses to organs near the treatment volume is of 
importance to improve the treatment outcome in terms of toxicity. This was the aim 
of Chapter 5 when applied to the treatment of surface lesions. Typically moulds 
and flaps are used on superficial skin brachytherapy for treatment depths up to 
about 5 mm. The use of superficial skin shielding applicators is an efficient solution 
because these reduce significantly the absorbed dose to the surrounding healthy 
tissues. Currently there are radionuclide based HDR 
192
Ir applicators as well as 
electronic sources. All these applicators restrict the useful beam to cross-sectional 
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circular beams of some specific diameters. On the other hand, the use of moulds 
and flaps allows producing irregular dose distributions, which might be of more 
interest in some cases. In Chapter 5 we extended the advantage of shielding 
applicators to moulds and flaps by adding a lead shield above the implant. For 
example, shields might be placed on the nose surface to attenuate radiation to the 
eye lens from a nasal implant, or around the breast to protect the thyroid from direct 
radiation coming from a breast treatment. The study presented in Chapter 5 has 
allowed making this efficiently by evaluating the bolus thickness required to be 
placed between the implant and the lead shielding in order to avoid a large surface 
overdose due to electron contamination and backscattering in the lead shield. This 
study also allowed evaluating the dose reduction near the shielding. Thus, this study 
and the methodology proposed is easy, economical and effective to implement in 
clinical practice to allow irregular dose distributions in the surface while shielding 
some of the nearest organs, as achieved with specifically designed surface 
applicators. 
 The study presented in Chapter 6 concerning the reduction of the fetal dose 
in a pregnant patient with breast cancer was motivated by the experience and 
knowledge acquired from the other studies of this thesis. It was March 2013 when a 
pregnant patient with breast cancer was submitted to the radiotherapy oncology 
department of La Fe University and Polytechnic Hospital (Valencia, Spain). 
Besides the tumor control, the reduction of the fetal dose was a priority. To our 
knowledge, all previously reported cases of radiotherapy applied to pregnant 
patients were based on EBRT. However, Chapter 2 had revealed that BT was 
advantageous over EBRT at large distances. In addition, we had recently evaluated 
the influence of lead shielding, and knew how to avoid surface overdose. Chapter 5 
also allowed obtaining the thickness of the lead shielding required to absorb most of 
the primary beam that could contribute to increase notably the absorbed dose to the 
fetus, and this information was used to build the shielding presented in Chapter 6. 
The results with this setup and shielding were very promising when compared with 
previously reported data from EBRT, allowing the reduction of the fetal dose in 
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comparison with EBRT for distances between the caudal edge of the breast and the 
uterine fundus larger than 10 cm. Differences reach more than one order of 
magnitude at 30 cm distance. In 1983 it was estimated that 1 out of 1000 pregnant 
women were diagnosed with cancer (Donegan, 1983). This number is expected to 
increase as the age of pregnancy increases. Many of those patients need 
radiotherapy, and so the proposed setup and shielding can be of great benefit for 
them. 
 
 SUMMARY 
 The use of HDR 
192
Ir brachytherapy has increased substantially since the 
1990s and it is expected to grow even more in the near future (Guedea, 2014), thus 
becoming a fundamental therapeutic tool.  Compared to EBRT, BT has the 
advantages of a rapid fall off of dose around the sources and shorter overall 
treatment duration, herein reducing the risk of tumor repopulation. However, the 
dose distribution is not homogeneous and accuracy in source positioning is critical 
(Gerbaulet et al., 2002). 
 During radiation therapy not only the tumor volume absorbs dose, but also 
all the remaining tissues of the body. This may result in some cases in acute, sub-
acute and/or long-term side-effects, which depend on the location of the target 
volume, the amount of absorbed dose and dose rate, and the type of radiotherapy 
that is used. Reducing the absorbed dose to healthy tissues will surely improve the 
treatment success.  
 Due to improved long-term survival rates, long-term side-effects such as the 
induction of a second primary tumor related to the radiation treatment are becoming 
increasingly important. The scientific community tries to establish a relationship 
between organ equivalent doses and the probability that a specific tumor is induced. 
If the relationship were known, the secondary cancer induction from a typical 
brachytherapy treatment could be obtained and compared with the probability from 
other radiation techniques. The AAPM Task Group 158 and the NCRP Scientific 
Committee have excluded brachytherapy from their studies due to lack of data (Xu 
Summary 
_____________________________________________________________________________________________________________________________________________ 
126  
et al., 2008), which confirms the necessity to make a complete study regarding 
peripheral doses from HDR brachytherapy.  
 The goal of this thesis was threefold. Firstly, to evaluate the peripheral dose 
in a typical clinical scenario and discern which HDR radionuclide is more 
advantageous from a patient radiation protection point of view (see Chapter 2). 
Secondly, the risk of secondary malignancies induced by the BT treatment was 
reviewed (see Chapter 3). Concerning to this second point, because 
epidemiological data with higher dose estimation accuracy are needed, we provided 
a more accurate dosimetry based on the currently used formalism for old radium 
brachytherapy sources, for which a large and long patient follow-up exists (see 
Chapter 4). Thirdly, we aimed to reduce the peripheral dose received by organs 
and tissues near the implant using specifically designed implant shielding (see 
Chapter 5 and Chapter 6). Below is a summary of the information contained in 
each of the chapters of this dissertation.  
 In Chapter 1 a general introduction extending the information that has been 
summarized in the previous paragraphs was presented, along with the objectives of 
the thesis and an outline of it. 
 In Chapter 2 the peripheral dose to a patient undergoing HDR 
brachytherapy applied to a localized prostate carcinoma was obtained for both, 
60
Co 
and 
192
Ir sources. These are nowadays the only commercially-available 
radionuclides for HDR BT. MC simulations in GEANT4 were performed using a 
voxelized phantom described in ICRP Publication 110, which reproduces masses 
and shapes from an adult reference man defined in ICRP Publication 89. Point 
sources of 
60
Co or 
192
Ir with photon energy spectra corresponding to those exiting 
their capsules were placed in the center of the prostate, and equivalent doses per 
clinical absorbed dose in this target organ were obtained in several radiosensitive 
organs. Values were corrected to account for clinical circumstance with the source 
located at various positions with differing dwell times throughout the prostate. This 
methodology was repeated for a homogeneous water phantom. A database of organ 
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equivalent doses when applying HDR brachytherapy to the prostate with either 
60
Co 
or 
192
Ir was provided. 
 The results were that, for the nearest organs considered (bladder, rectum, 
testes, small intestine, and colon), equivalent doses given by a 
60
Co source were 
roughly 10% smaller than from 
192
Ir. However, as the distance increases, the more 
penetrating gamma rays produced by 
60
Co deliver higher equivalent doses. Thus, 
according to physical considerations, 
192
Ir is dosimetrically advantageous over 
60
Co 
sources at large distances, but not in the closest organs. The overall result is that 
effective dose per clinical absorbed dose from a 
60
Co source (11.1 mSv/Gy) is 
roughly 10% lower than from a 
192
Ir source.  
 Regarding the differences between calculations in a heterogeneous and a 
homogeneous water phantom, it was concluded that equivalent doses were the same 
for those soft tissues closer to the prostate than about 30 cm. As the distance 
increased, the differences of photoelectric effect in water and soft tissue, and 
appearance of other materials such as air, bone or lungs, produced variations 
between both phantoms which were at most 35% in the considered organ equivalent 
doses.  
 Finally, peripheral doses from HDR brachytherapy sources were compared 
with reported values from proton therapy and IMRT. Damage to distant healthy 
organs per clinical absorbed dose is lower with brachytherapy than with IMRT or 
protons, although the overall effective dose per Gy given to the prostate was very 
similar. Given that there are several possible fractionation schemes, which result in 
different total amounts of therapeutic absorbed dose, advantage of a radiation 
treatment (according to equivalent dose to healthy organs) is treatment and facility 
dependent, although BT is advantageous over EBRT for the furthest organs.  
 In Chapter 3, the current knowledge on cancer induction from ionizing 
radiation was reviewed. It was aimed to determine if a well established relationship 
between organ equivalent dose and probability of cancer induction was already 
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known, which could facilitate and improve the comparison between different 
radiation modalities performed in the previous chapter.  
 Graphically, three main areas can be identified in this dose–effect curve (Hall 
et al., 2004). In the central zone (between 0.1 Sv and 2.5 Sv) there appears to be a 
linear relationship in which, as the organ equivalent dose increases so does the 
probability of tumor induction.  
 At higher organ equivalent doses (> 2.5 Sv), radiation induced cell 
sterilization, cell repopulation, and proliferation may cause a deviation from a linear 
dose response (Nguyen et al., 2015). Phenomenological risk models based on fitting 
parameters have been applied to estimate the risk of inducing a tumor in organs 
inside the primary radiation field, i.e., at doses in excess of 2.5 Gy. In particular, 
recent studies have applied a model developed by Schneider (2009), which is based 
on the linear-quadratic formula, to estimate the outcome of different treatment 
modalities (Nguyen et al., 2015). Linear, linear-exponential, and plateau models 
have been also used (Abo-Madyan et al., 2014). A review study by Xu et al. (2008) 
showed that the cumulative risk for the development of second cancers has been 
estimated as ranging from 5% to 12% over a 25 year follow-up interval, although 
there exists a high dispersion of data. The model parameters have been determined 
with limited data and, therefore, uncertainties will limit the model predictions. 
Nguyen et al. (2015) have recently estimated that the uncertainties associated with 
model predictions are higher than 100%. This implies that, currently, it might not be 
feasible to reliably predict cancer risks based on treatment plan information and 
phenomenological risk models. 
 At low radiation doses (less than 0.1 Sv) also different models have been 
proposed based on observations. Because of its simplicity, reasonability, and 
conservative approach, international committees such as the ICRP and the NCRP 
recommended extrapolating the linear relationship to the lowest dose range. 
However, the available evidence for this has not been statistically significantly 
better for predicting cancer than other methods based on a threshold dose (Fletcher 
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et al., 2013) owing to high background incidence cases. Uncertainties in past 
epidemiological data of irradiation exposures within the diagnostic dose range did 
not rule out a possible threshold dose below which no excess cases of cancer 
appeared. This threshold dose might be within the range of 10 to 60 mSv (Xu et al., 
2008; Pauwels et al., 2011). Thus, the risks, if existent, are of the same order of 
magnitude than background levels.  
 From a deep literature review of studies concerning radiation therapy and 
cancer risks for organs receiving low radiation doses, Xu et al. (2008) concluded 
that many of the past dosimetry studies were based on inconsistent and sometimes 
confusing dose quantities, which reduces the possibility that they can be used to 
perform more sophisticated epidemiological studies. We thus conclude that 
retrospective risk assessments of ionizing radiation require more reliable dosimetric 
data and epidemiological studies, as well as an estimate of their uncertainty before 
general conclusions can be established.  
 During the first part of the 20th century, 
226
Ra was the most used 
radionuclide for brachytherapy. Thus, like survivors of the atomic bombs, data of 
children treated with 
226
Ra sources may be very helpful to determine the 
relationship between a specific late hazard effect and the absorbed dose.
 
As recently 
noted by the UNSCEAR committee, the latter is of current interest in the search for 
improved knowledge on dose-response relationships for cancer induction and other 
late effects due to exposure to ionizing radiation in early childhood (UNSCEAR, 
2013). Related to this, Sweden has long held a complete registry on cancer 
incidence coupled to unique citizen ID numbers. Together with detailed knowledge 
about the children that underwent 
226
Ra treatment, these data are of interest to use in 
research on late radiation effects. However, earlier dosimetric data for the sources 
that were used in Sweden were restricted. The aim of Chapter 4 was to 
dosimetrically characterize two 
226
Ra sources, commonly used in Sweden during 
the first half of the 20th century, for retrospective dose-effect studies, as requested 
by Swedish epidemiologists. 
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 An 8 mg 
226
Ra tube and a 10 mg 
226
Ra needle, used at Radiumhemmet 
(Karolinska University Hospital, Stockholm, Sweden) from 1925 to the 1960s, were 
modeled in two independent MC radiation transport codes: GEANT4 and MCNP5. 
Absorbed dose and collision kerma around the two sources were obtained, from 
which the TG-43 parameters that can be implemented in current planning systems 
were derived for the secular equilibrium state. Furthermore, results from this 
dosimetric formalism were compared with results from a realistic MC simulation 
with a superficial mould constituted by 5 needles inside a glass casing, placed over 
a water phantom, trying to mimic a typical clinical set-up. The aim of this 
comparison was to validate the use of dosimetric data in the format of TG-43 
parameters for surface treatments, where lack of backscattering at the water surface 
could give place to errors in the dose calculation. Furthermore, calculated absorbed 
doses using the TG-43 formalism were also compared with previously reported 
measurements and calculations based on the Sievert Integral. Finally, the dose rate 
at large distances from a 
226
Ra point-like-source placed in the center of 1 m radius 
water sphere was calculated with GEANT4, and data were fitted by an analytical 
function to allow estimation of absorbed dose at large distances from the sources. 
 From this study, TG-43 parameters (including gL(r), F(r,θ), Λ and sK) have 
been provided for epidemiological studies, and the fitting parameters of a 
mathematical curve that provides the dose rate between 10 cm and 60 cm from the 
source have been calculated. Results from TG-43 formalism are consistent within 
the treatment volume with those of a MC simulation of a typical surface clinical 
scenario. Comparisons with reported measurements made with TLDs show 
differences up to 13% along the transverse axis of the radium needle. It was 
estimated that the uncertainty associated to the absorbed dose within the treatment 
volume is 10% to 15%, whereas uncertainty of absorbed dose to distant organs is 
roughly 20% to 25%.  
 The results provided in Chapter 4 facilitate retrospective dosimetry studies 
of 
226
Ra using modern treatment planning systems, which may be used to improve 
knowledge on long term radiation effects. It is surely important for the 
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epidemiologic studies to be aware of the estimated uncertainty provided here before 
extracting their conclusions. 
 The following two chapters of this dissertation were aimed to reduce the 
peripheral dose received by organs and tissues near the implant using specifically 
designed implant shielding. In particular, in surface HDR brachytherapy with either 
60
Co, 
192
Ir, or 
169
Yb sources (the latter has potential as HDR source and might be 
available in the future), some radiosensitive organs near the surface may be exposed 
to high absorbed doses. This may be reduced by covering the implants with a lead 
shield on the body surface, which has two main dosimetric consequences. Firstly, 
backscattering produces a dose enhancement in the patient in the vicinity of the 
shielding. Secondly, photon absorption reduces dose above the shield, downstream 
from the distal surface of the barrier. Radiation transmission data had not been 
evaluated in surface or interstitial BT for a typical clinical scenario. Chapter 5 was 
aimed to evaluate the dosimetric perturbation produced by lead shields that are used 
in some surface HDR BT treatments.  
 Monte Carlo simulations in GEANT4 were performed for the three 
radionuclides placed at a single dwell position. Four different shield thicknesses (0, 
3, 6, and 10 mm) and three different source depths (0, 5, and 10 mm) in water were 
considered, with the lead shield placed at the phantom surface. From these 
simulations, backscatter dose enhancement and transmission data were obtained. 
Finally, results were corrected to account for a realistic clinical case with multiple 
dwell positions.  
 From this study it was concluded that the range of the high backscatter dose 
enhancement in water is 3 mm for 
60
Co and 1 mm for both 
192
Ir and 
169
Yb. Thus, as 
stated in Chapter 5, the backscatter overdose produced by the lead shield can be 
avoided just using a few millimeters of bolus, herein justifying the use of lead 
shields. On the other hand, transmission data for 
60
Co and 
192
Ir are smaller than 
those reported by Papagiannis et al. (2008) for brachytherapy facility shielding. For 
169
Yb, the difference is negligible. 
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 The previous study is of application in several clinical scenarios. For 
example, shields might be placed on the nose surface to attenuate radiation to the 
eye lenses from a nasal implant, or around the breast to protect the thyroid from 
direct radiation coming from a breast treatment. Another application of the previous 
approach is to minimize the fetal dose in a pregnant patient with breast cancer 
needing radiotherapy.  
 Chapter 6 aimed to assess the radiation dose to the fetus of a pregnant 
patient undergoing HDR 
192
Ir interstitial breast brachytherapy, and to design a new 
patient setup and lead shielding technique that minimizes the fetal dose. To do that, 
the pregnant woman was planned to be seated in a chair with the breast over a table 
and inside a leaded box specifically designed to protect the fetus. A total of 36 Gy 
in 8 fractions were prescribed. The shielding design consisted of a 3.5 cm thick 
layer of lead placed between the breast and the table. Thus, during the treatment, the 
breast rested over this lead shield. In addition, two lateral pieces of lead (3 cm thick 
each) were added. One of the lateral layers had a port through which the transfer 
tubes were connected to the catheters. The lateral blocks allowed placing an extra 
piece of lead (2.5 cm thick) above the breast, parallel to the first layer, aiming to 
reduce primary radiation to the thyroids and eye lenses. In addition, in order to 
minimize the transit dose when the 
192
Ir source exits and returns to the remote 
afterloader, a hollow lead tube was made, which covered the transfer tubes. Finally, 
a layer of water-equivalent material (1 mm thick) was placed between the lead 
shielding and the patient skin to minimize the backscattering and electron 
contamination coming from the shield, as had been determined in the previous 
chapter.  
 Dose measurements were done with radiochromic films that were placed 
between the slices of an anthropomorphic phantom modeling the patient. Dose 
variation as a function of distance from the implant volume as well as dose 
homogeneity within a representative slice of the fetal position was evaluated 
without and with shielding. Results with the previous setup were very promising. 
With shielding, the peripheral dose ranged from 50 cGy at 5 cm from the caudal 
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edge of the breast to < 0.1 cGy at 30 cm. The shielding reduces absorbed dose by a 
factor of two near the breast and more than an order of magnitude beyond 20 cm. 
The dose is heterogeneous within a given axial plane, with variations from the 
central region within 50%. From a literature analysis, it was also observed that 
interstitial HDR 
192
Ir brachytherapy with breast shielding can be more advantageous 
than EBRT from a radiation protection point of view, as long as the distance 
between the caudal edge of the breast and the uterine fundus is higher than about 10 
cm. At 30 cm distance, absorbed dose is more than a factor of ten smaller with 
shielded HDR brachytherapy than with EBRT. Furthermore, the weight of the 
shielding here proposed is notably lower than that needed in EBRT. Therefore, the 
shielded breast brachytherapy setup presented in Chapter 6 may benefit pregnant 
patients needing localized radiotherapy, especially during the early gestational ages 
when the fetus is more sensitive to ionizing radiation. 
 Finally, Chapter 7 presented a general discussion previous to this summary. 
 
 SUMMARY IN SPANISH / 
RESUMEN EN ESPAÑOL 
 La braquiterapia (BT) es una modalidad de tratamiento de radioterapia en la 
que se coloca una fuente radiactiva encapsulada cerca, en contacto o en el interior 
del volumen a tratar. La desintegración de esta fuente produce la emisión de 
energía, lo que puede dar lugar a la muerte celular. Una dosis absorbida muy 
elevada (la dosis absorbida se define como la energía absorbida por unidad de 
masa) se deposita en un corto período de tiempo y en un pequeño número de 
fracciones. Para poder realizar un tratamiento de BT se requiere que el volumen de 
tratamiento sea accesible y bien delimitado en tamaño y forma. La BT se utiliza 
comúnmente como una modalidad de tratamiento eficaz para el cáncer de cuello 
uterino, de próstata, de mama y de piel. También ha demostrado ser eficaz para 
tratar tumores de la región del cerebro, cabeza y cuello (por ejemplo, labios o 
lengua), ojo, la tráquea y los bronquios, el aparato digestivo y el tracto urinario (por 
ejemplo, la vejiga, el recto, el ano, la uretra o el pene), el tracto reproductor 
femenino (útero, vagina y vulva), y otros tejidos blandos (Gerbaulet et al., 2002).  
 En función de la tasa de dosis D alrededor de la fuente radiactiva empleada, 
la BT se clasifica en: BT de alta tasa de dosis (HDR) (D>12 Gy/h), BT de media 
tasa de dosis (MDR) (D=2-12 Gy/h)), BT de tasa de dosis pulsada (PDR) (pulsos 
cortos de radiación, generalmente una vez una hora) y BT de baja tasa de dosis 
(LDR) (D<2 Gy/h). En detrimento de la LDR, la HDR se está convirtiendo hoy en 
día en la modalidad más extendida en todo el mundo (Guedea, 2014). Las ventajas 
de la HDR sobre la terapia LDR incluyen la reducción de exposición del personal a 
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radiación ionizante, la reducción del tiempo de tratamiento global, la aplicación del 
tratamiento de forma remota, así como un ahorro económico (Bastin et al., 1993). 
Además, para el caso particular de la braquiterapia de próstata, se minimizan 
algunos de los problemas comunes relacionados con los implantes de semillas 
permanentes, tales como la incapacidad para corregir la posición de las semillas, 
incapacidad para optimizar la dosis absorbida una vez que las semillas están en su 
lugar, y la discrepancia entre la distribución de dosis planeada y la definitiva 
(Demanes et al., 2014). Por contra, se ha estimado que con la BT HDR existe un 
mayor riesgo de efectos secundarios (Dale, 1985). Por todas estas razones, la terapia 
de HDR es la técnica de BT considerada en este estudio que trata la protección 
radiológica del paciente. 
 El uso de la BT HDR se ha incrementado sustancialmente desde la década de 
1990 y se espera que crezca aún más en un futuro próximo (Guedea, 2014), 
convirtiéndose así en una herramienta terapéutica fundamental. En comparación 
con la radioterapia externa (EBRT), la BT tiene la ventaja de una rápida caída de la 
dosis con la distancia a la fuente y una duración del tratamiento total menor, siendo 
así un tratamiento más localizado y que reduce el riesgo de repoblación tumoral. 
Sin embargo, la distribución de dosis no es homogénea y la precisión en el 
posicionamiento de la fuente radiactiva es crítica (Gerbaulet et al., 2002). 
 Durante un tratamiento de radioterapia no sólo el volumen del tumor absorbe 
dosis, sino también todos los tejidos restantes del cuerpo, en mayor o menor 
medida. Órganos cercanos o en contacto con el tejido a irradiar pueden recibir 
también altas dosis de radiación, mientras que el tejido más alejado se expone a 
dosis de radiación bajas. Esto puede resultar en algunos casos en efectos 
secundarios agudos, sub-agudos y/o efectos de largo plazo. La aparición de estos 
efectos depende de la ubicación del volumen a tratar, de la cantidad de dosis 
prescriba, de la tasa de dosis, y del tipo de radioterapia que se utiliza. Es seguro que 
la reducción de la dosis absorbida por los tejidos sanos mejora el éxito del 
tratamiento en relación a las secuelas. 
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 Debido al incremento de la tasa de supervivencia a largo plazo, los efectos 
secundarios tales como la inducción de un tumor secundario están convirtiéndose 
cada vez más importantes. La comunidad científica intenta establecer una relación 
entre dosis equivalentes a órganos y la probabilidad de que se induzca un tumor. Si 
se conociera dicha relación, se podría obtener cuál es la probabilidad de inducir un 
tumor tras un tratamiento típico de braquiterapia, comparándola con la probabilidad 
derivada de otras técnicas de tratamiento con radiaciones. El Grupo de Trabajo 158 
de la Sociedad Americana de Físicos Médicso (AAPM) y el Comité Científico del 
Consejo Nacional Americano de Protección y Medición de Radiación (NCRP) han 
excluido la braquiterapia de sus estudios de tumores radio inducidos debido a la 
falta de datos (Xu et al., 2008), lo que confirma la necesidad de realizar un estudio 
completo con respecto a las dosis periféricas en braquiterapia HDR. 
 Tres son los objetivos principales de esta tesis. En primer lugar, evaluar la 
dosis periférica en un escenario clínico típico de BT HDR y discernir qué fuente 
radiactiva de HDR es más ventajosa desde el punto de la protección radiológica del 
paciente (véase el Capítulo 2). En segundo lugar, se pretende realizar una revisión 
bibliográfica sobre el riesgo de inducir un tumor secundario tras un tratamiento de 
BT (véase el Capítulo 3). Con respecto a este segundo punto, ya que se necesitan 
más datos epidemiológicos con mayor precisión en la estimación de la dosis, 
llevamos a cabo una caracterización dosimétrica precisa de antiguas fuentes de 
226
Ra para las cuales existe un extenso y completo seguimiento, basada en el 
formalismo utilizado actualmente para fuentes de BT (véase el Capítulo 4). En 
tercer lugar se tiene como objetivo reducir la dosis periférica recibida por los 
órganos y los tejidos cercanos al implante de BT HDR, utilizando para ello 
blindajes que hemos diseñado especialmente para este objetivo (véase el Capítulo 5 
y el Capítulo 6). 
 A continuación se muestra un resumen de la información contenida en cada 
uno de los capítulos de esta tesis. 
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 En el Capítulo 1 se presentó una introducción general que extiende la 
información que se ha resumido en los párrafos anteriores. Además, se introdujeron 
los objetivos de la tesis y un esbozo de lo contenido en cada uno de ellos. 
 En el Capítulo 2 se obtuvo la dosis periférica en un paciente sometido a BT 
HDR aplicada a un carcinoma de próstata localizado tanta con fuentes de 
60
Co 
como de 
192
Ir. Estos dos radionúclidos son hoy en día los únicos comercialmente 
disponibles para HDR BT. Para llevar a cabo el objetivo de este estudio se 
realizaron simulaciones MC con GEANT4, utilizando un maniquí voxelized 
proporcionado por la Publicación 110 de la Comisión Internacional de Protección 
Radiológica (ICRP). Este maniquí reproduce las masas y formas de todos los 
órganos del hombre adulto considerado de referencia. Las fuentes puntuales de 
60
Co 
o 
192
Ir se colocaron en el centro de la próstata y se simuló la emisión de fotones con 
un espectro de energía igual al que sale de las fuentes reales. A partir de estas 
simulaciones se obtuvo la dosis equivalente en todos los órganos del cuerpo, 
normalizado por la dosis absorbida por la próstata. Los valores fueron corregidos 
para tener en cuenta la circunstancia clínica según la cual la fuente no se lleva a una 
única posición en el centro de la próstata, sino que se sitúa en varias posiciones a lo 
largo de toda la próstata, con diferentes tiempos de permanencia en cada una de 
estas posiciones. Esta metodología se repitió para un maniquí igual que el anterior, 
pero en el que la composición de todos los vóxeles se sustituyó por agua. Esto 
último tenía por objetivo comparar los resultados dosimétricos en un maniquí 
realista respecto a cuándo se considera todo el cuerpo hecho de agua, que es la 
situación actual en la planificación de tratamientos de braquiterapia. 
 Este estudio proporcionó una base de datos de dosis equivalentes a órganos 
tras aplicar braquiterapia HDR a la próstata, ya sea con fuentes de 
60
Co o de 
192
Ir. 
Lo que se observó fue que en los órganos cercanos considerados (vejiga, recto, 
testículos, intestino delgado y colon), las dosis equivalentes dadas por la fuente de 
60
Co son aproximadamente un 10% inferiores a las derivadas de un tratamiento con 
192
Ir. Sin embargo, a largas distancias (más de 30 cm aproximadamente), el 
60
Co 
proporciona dosis equivalentes superiores debido a una mayor energía media de los 
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fotones que emite. Así, de acuerdo a las consideraciones físicas, el 
192
Ir es 
dosimétricamente ventajoso sobre el 
60
Co a grandes distancias, pero no en los 
órganos cercanos. El resultado global es que la dosis efectiva por dosis clínica 
absorbida en la próstata es 11.1 mSv/Gy cuando se hace uso de una fuente de 
60
Co, 
y un 10% aproximadamente inferior cuando se hace uso de una fuente de 
192
Ir. 
 En cuanto a las diferencias entre los cálculos en un maniquí heterogéneo y un 
maniquí homogéneo de agua, se concluyó que las dosis equivalentes eran iguales 
para los tejidos blandos que estaban a un máximo de unos 30 cm de la próstata, es 
decir, cerca del implante. A medida que aumentaba la distancia, las diferencias de 
efecto fotoeléctrico en el agua y los tejidos blandos, y la aparición de otros 
materiales tales como aire, hueso o pulmones, producen variaciones entre ambos 
maniquíes, alcanzado las diferencias entre la dosis equivalente a órganos un 35% en 
el peor de los casos. 
 Finalmente, las dosis periféricas derivadas de tratamientos con fuentes de BT 
HDR se compararon con los valores reportados en la literatura para tratamientos 
con protones y radioterapia externa de intensidad modulada (IMRT). Se vio que el 
daño a los órganos sanos distantes es menor con braquiterapia que con IMRT o 
protones, aunque la dosis efectiva total por Gy a la próstata es muy similar en los 
tres casos. Dado que hay varios posibles esquemas de fraccionamiento, que resultan 
en diferentes cantidades totales de dosis absorbida terapéutica, la ventaja de un tipo 
de tratamiento de radioterapia frente a otro (según dosis equivalente a órganos 
sanos) es dependiente del propio tratamiento y del fraccionamiento utilizado en la 
instalación, aunque en cualquier caso la BT es ventajosa sobre la EBRT y los 
protones para los órganos más alejados. 
 En el Capítulo 3 se revisa el conocimiento actual sobre la inducción de 
cáncer debido a las radiaciones ionizantes. El objetivo fue determinar si existía una 
relación bien establecida entre la dosis equivalente a órganos y la probabilidad de 
inducción de cáncer, lo que podría facilitar y mejorar la comparación entre 
diferentes modalidades de tratamiento de radiación realizada en el capítulo anterior. 
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 Se pueden identificar tres regiones diferentes en el gráfico que relaciona la 
dosis equivalente a órgano con la probabilidad de inducir un tumor (Hall et al., 
2004). En la zona central (entre 0.1 y 2.5 Sv) hay una relación lineal según la cual, 
un aumento de la dosis absorbida incrementa proporcionalmente la probabilidad de 
inducir un tumor. 
 A mayores dosis equivalentes a órganos (> 2.5 Sv), los efectos de 
esterilización celular debida a la radiación, la repoblación de células y la 
proliferación pueden causar una desviación en la respuesta lineal (Nguyen et al., 
2015). Para realizar estimaciones en los órganos que se encuentran dentro del 
campo de radiación y que, por lo tanto, reciben más de 2.5 Sv, los investigadores 
han aplicado modelos de riesgo fenomenológicos basados en diversos parámetros 
de ajuste. En particular, estudios recientes han aplicado un modelo desarrollado por 
Schneider (2009) que se basa en la fórmula lineal-cuadrática para estimar el 
resultado de diferentes modalidades de tratamiento (Nguyen et al., 2015). Otros 
modelos como el de meseta-lineal y lineal-exponencial también han sido utilizados 
para hacer estimaciones (Abo-Madian et al., 2014). Un estudio de revisión 
realizado por Xu et al. (2008) mostró que el riesgo acumulado para el desarrollo de 
tumores secundarios se ha estimado que va desde el 5% al 12% tras un intervalo de 
seguimiento de 25 años, aunque existe una alta dispersión en los datos. Los 
parámetros del modelo se han determinado con datos limitados y, por tanto, las 
incertidumbres limitarán las predicciones realizadas. Nguyen et al. (2015) han 
estimado recientemente que las incertidumbres asociadas con las predicciones de 
estos modelos son superiores al 100%. Esto implica que, en la actualidad, podría no 
ser factible predecir de forma fiable los riesgos de cáncer basándonos en la 
información del plan de tratamiento y modelos de riesgo fenomenológicas. 
 En dosis bajas de radiación (menos de 0.1 Sv) también existen diferentes 
modelos, algunos basados en la teoría y otros en observaciones. Debido a su 
simplicidad, razonabilidad, y el enfoque conservador, los comités internacionales 
como la ICRP y la NCRP recomiendan extrapolar la relación lineal a este rango de 
dosis bajas. Sin embargo, la evidencia disponible no es estadísticamente más 
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significativa para predecir el cáncer inducido que la de otros modelos basados en 
una dosis umbral (Fletcher et al., 2013), lo cual es debido a los altos valores de 
fondo. Las incertidumbres en los datos epidemiológicos no descartan una posible 
dosis umbral por debajo de la cual no hay un exceso de casos de cáncer. Por lo 
tanto, los riesgos derivados de bajas dosis de radiación, en el caso de que existan, 
son del mismo orden de magnitud que los niveles de fondo. 
 A partir de una revisión bibliográfica llevada a cabo por Xu et al. (2008), la 
cual se centraba en las pequeñas dosis de radiación derivadas de tratamientos de 
radioterapia, se llegó a la conclusión que muchos de los estudios dosimetría 
realizados hasta la fecha se basaron en cantidades de dosis inconsistentes y, a veces, 
confusas, lo que reduce la posibilidad de que puedan ser utilizados para llevar a 
cabo estudios epidemiológicos más sofisticados. Por lo tanto, concluimos que las 
evaluaciones de riesgo retrospectivas de las radiaciones ionizantes requieren datos 
dosimétricos más fiables, así como una estimación de su incertidumbre antes que se 
puedan extraer conclusiones más generales. 
 Durante la primera parte del siglo 20, el 
226
Ra fue el radionúclido más usado 
en braquiterapia. Por lo tanto, al igual que los sobrevivientes de las bombas 
atómicas, los datos de los niños tratados con fuentes de 
226
Ra pueden ser muy útiles 
para determinar la relación entre un determinado efecto radioinducido y la dosis 
absorbida. Como señaló recientemente el Comité Científico de las Naciones Unidas 
en el Efecto de las Radiaciones Atómicas (UNSCEAR, 2013), este último grupo es 
de interés actual en la búsqueda de un mejor conocimiento sobre las relaciones 
dosis-efecto. En relación con esto, Suecia ha mantenido durante mucho tiempo un 
registro completo de la incidencia de cáncer en todos los pacientes tratados. Junto 
con un conocimiento detallado acerca de los niños que se sometieron al tratamiento 
de 
226
Ra, estos datos son de interés para su uso en la investigación sobre los efectos 
tardíos de la radiación. Sin embargo, los datos dosimétricos hasta la fecha utilizados 
para las fuentes que se utilizaron en Suecia son escasos y de presentan dudas.  
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 A petición de epidemiólogos suecos, el objetivo del Capítulo 4 fue 
caracterizar dosimétricamente dos fuentes de 
226
Ra comúnmente utilizadas en 
Suecia durante la primera mitad del siglo 20 con el fin de llevar a cabo estudios 
retrospectivos. Para ello, un tubo de 8 mg de 
226
Ra y una aguja de 10 mg de 
226
Ra, 
utilizados en Radiumhemmet (Hospital Universitario Karolinska, Estocolmo, 
Suecia) desde 1925 hasta la década de 1960, fueron reproducidos en dos códigos 
MC que simulan el transporte de radiaciones y su interacción con la materia. Los 
códigos independientes utilizados fueron GEANT4 y MCNP5. Con ellos se 
obtuvieron las distribuciones de dosis absorbida y kerma de colisión alrededor de 
las dos fuentes, a partir de las cuales se derivaron los parámetros del TG-43 que se 
pueden implementar en los sistemas actuales de planificación. Además, los 
resultados de este formalismo dosimétrico se compararon con los resultados de una 
simulación realista también hecha con MC con un molde superficial constituido por 
5 agujas dentro de una funda de vidrio. Ésta se colocó sobre un maniquí de agua 
que simulaba el paciente, tratando de imitar un típico caso clínico de tratamiento de 
piel. El objetivo de esta comparación fue validar el uso de los datos dosimétricos 
proporcionados en el formalismo del TG-43 para tratamientos superficiales, 
teniendo en cuenta que el TG-43 considera un medio infinito de agua mientras que 
en un tratamiento de piel hay una falta de retrodispersión en la superficie del agua, 
que podría dar lugar a errores en el cálculo de la dosis. Además, las dosis 
absorbidas calculadas utilizando el formalismo del TG-43 también se compararon 
con las mediciones y cálculos previamente reportados en la literatura que se 
basaban en el antiguo formalismo de la Integral de Sievert. Por último, la tasa de 
dosis a grandes distancias de un una fuente de 
226
Ra colocada en el centro de una 
esfera de agua de 1 m de radio se calculó con GEANT4, y la tasa de dosis en 
función de la distancia se ajustó con una función analítica para permitir la 
estimación de la dosis absorbida a largas distancias de la fuentes (entre 10 y 60 cm 
de la fuente). 
 Los resultados del formalismo del TG-43 son coherentes dentro del volumen 
de tratamiento con los de una simulación MC de un escenario clínico. Por otro lado, 
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las comparaciones con medidas realizadas en 1994 con dosímetros 
termolunimiscentes muestran diferencias de hasta un 13% a lo largo del eje 
transversal de la aguja. La incertidumbre estimada para la dosis absorbida en el 
volumen de tratamiento está entre el 10% y el 15%, mientras que la incertidumbre 
de la dosis absorbida a órganos distantes es aproximadamente un 20% a un 25%. 
 Se espera que los resultados presentados en el Capítulo 4 permitan facilitar 
estudios de dosimetría retrospectiva con fuentes 
226
Ra, usando sistemas de 
planificación de tratamientos modernos, que pueden ser utilizados para mejorar el 
conocimiento sobre los efectos de la radiación a largo plazo. Sin duda, es 
importante que los estudios epidemiológicos sean conscientes de la incertidumbre 
estimada aquí antes de extraer sus conclusiones. 
 Los siguientes dos capítulos de esta tesis se orientaron a reducir la dosis 
periférica recibida por los órganos y los tejidos cercanos al implante, utilizando para 
ello blindajes diseñados específicamente para este propósito. En particular, en 
tratamientos superficiales con fuentes HDR de BT, ya sea con 
60
Co, 
192
Ir, o 
169
Yb 
(éste último tiene potencial como fuente HDR y puede estar disponible en el 
futuro), algunos órganos radiosensibles cerca de la superficie pueden estar 
expuestos a altas dosis absorbidas. Esto puede reducirse cubriendo los implantes 
con un blindaje de plomo situado en la superficie del cuerpo. Este blindaje tiene 
principalmente dos repercusiones dosimétricas. En primer lugar, la retrodispersión 
producida en el plomo puede generar una sobredosificación importante en la 
superficie del paciente, la cual no es deseada. En segundo lugar, el blindaje reduce 
la dosis al otro lado del mismo. Antes de realizar este estudio no existían datos de 
transmisión de radiación a través de barreras de plomo de distintos espesores 
utilizados en braquiterapia superficial e intersticial. El Capítulo 5 está dirigido a 
evaluar la perturbación dosimétrica producida por estos blindajes de plomo que se 
utilizan en algunos tratamientos superficiales de BT HDR. 
 Para llevar a cabo este estudio se realizaron simulaciones MC con GEANT4, 
simulando los tres radionúclidos previamente citados. Se consideraron cuatro 
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espesores diferentes de plomo (0, 3, 6 y 10 mm) y tres profundidades de 
localización de las fuentes diferentes (0, 5 y 10 mm) en agua, estando el blindaje 
colocado en la superficie del maniquí. A partir de estas simulaciones, se obtuvieron 
las componentes de retrodispersión y transmisión. Los resultados fueron corregidos 
para tener en cuenta un caso clínico realista con múltiples posiciones de 
permanencia de las fuentes. 
 De este estudio se concluyó que el rango de la sobredosificación en piel 
debida a la retrodispersión es de 3 mm para 
60
Co y 1 mm tanto para fuentes de 
192
Ir 
como de 
169
Yb. Por lo tanto, como se dijo en el Capítulo 5, se concluye que la 
retrodispersión producida por el blindaje de plomo se puede evitar simplemente 
usando unos pocos milímetros de bolus colocado entre el blindaje y la superficie del 
paciente. Este simple montaje justifica el uso de blindajes de plomo. Por otro lado, 
se observó que los datos de transmisión para 
60
Co e 
192
Ir son más pequeños que los 
reportados por Papagiannis et al. (2008) para los blindajes de una instalación de 
braquiterapia. En cambio, para el 
169
Yb la diferencia era insignificante. 
 El estudio anterior es de aplicación a varias situaciones clínicas. Por ejemplo, 
los blindajes pueden ser colocados sobre la superficie de la nariz para atenuar la alta 
dosis de radiación a la que se ven expuestos los cristalinos en un implante nasal, o 
alrededor de la mama para proteger la tiroides de la radiación directa procedente de 
un tratamiento de mama. Otra aplicación podría ser la reducción de la dosis fetal en 
una paciente embarazada con cáncer de mama que necesite radioterapia. 
 El Capítulo 6 tuvo como objetivo evaluar la dosis de radiación al feto de una 
paciente embarazada que se somete a un tratamiento de BT intersticial con una 
fuente HDR de 
192
Ir, así como diseñar una nueva posición de tratamiento y un 
blindaje específico que minimice al máximo esa dosis fetal. Para ello, se planeó 
sentar a la paciente, colocando el pecho a tratar sobre una mesa, en el interior de 
una caja de plomo específicamente diseñado para proteger al feto. La dosis prescrita 
al volumen a irradiar fue de 36 Gy en 8 fracciones. El diseño del blindaje consistió 
en una gruesa capa de 3.5 cm de plomo colocada entre el pecho y la mesa. Por lo 
Summary in Spanish 
_____________________________________________________________________________________________________________________________________________ 
144  
tanto, durante el tratamiento, la mama descansaba sobre este blindaje de plomo, 
atenuando así la radiación directa al feto. Además, se añadieron dos piezas laterales 
de plomo (3 cm de espesor cada una). Una de las capas laterales tenía un agujero a 
través del cual los tubos de transferencia por los cuales se transporta la fuente de 
forma remota se conectaron a los catéteres que se introducen dentro de la mama. 
Los bloques laterales permiten la colocación de una pieza extra de plomo (2.5 cm 
de espesor) por encima de la mama, paralelo a la primera capa, con el objetivo de 
reducir la radiación primaria al tiroides y los cristalinos. Además, con el fin de 
minimizar la dosis de tránsito debido a los movimientos de salida y entrada de la 
fuente de 
192
Ir, se hizo un tubo de plomo hueco, que cubría los tubos de 
transferencia. Por último, una capa de material equivalente agua (con 1 mm de 
espesor) se colocó entre el blindaje de plomo y la piel del paciente para minimizar 
la retrodispersión de electrones, tal y como se había determinado en el capítulo 
anterior. 
 Las medidas de la dosis fetal se hicieron con películas radiocrómicas 
colocadas entre las rodajas de un maniquí antropomórfico que simulaba al paciente. 
Así se obtuvo la variación de la dosis en función de la distancia desde el volumen 
del implante, así como la homogeneidad dentro de un corte representativo de la 
posición fetal. Las medidas dosimétricas se realizaron tanto con blindaje como sin 
blindaje, para evaluar su eficiencia. Los resultados con la configuración anterior 
fueron muy prometedores. Con el blindaje, la dosis periférica varió de 50 cGy a 5 
cm del borde caudal de la mama a menos de 0.1 cGy a los 30 cm de distancia. El 
blindaje redujo la dosis absorbida en un factor dos cerca de la mama y en más de un 
orden de magnitud más allá de los 20 cm. La dosis es heterogénea dentro de un 
corte axial dado, con variaciones respecto a la zona central del paciente de hasta un 
50%. De un análisis de la literatura, también se observó que la braquiterapia 
intersticial de HDR con fuentes de 
192
Ir y con el blindaje aquí desarrollado es más 
ventajoso que la EBRT desde un punto de vista de la reducción de la dosis al feto, 
siempre y cuando la distancia entre el extremo caudal de la mama y el fondo uterino 
sea mayor a 10 cm. A 30 cm de distancia, la dosis fetal es más de un factor 10 
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inferior con braquiterapia de HDR y el blindaje aquí diseñado que con EBRT. 
Además, el peso del blindaje aquí propuesto es notablemente inferior al 
recomendado en EBRT. Por lo tanto, la braquiterapia intersticial de mama con el 
blindaje presentado en el Capítulo 6 puede beneficiar a pacientes embarazadas que 
necesiten radioterapia localizada, especialmente durante las primeras edades de 
gestación, cuando el feto es más sensible a la radiación ionizante. 
 Por último, el Capítulo 7 ha presenta una discusión general que ha precedido 
a este resumen. 
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